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Abstract
M atrilysin (M M P-7, EC 3.4.24.23) is the smallest m em ber o f the matrix m etalloproteinase 
(M M P) family and has been shown to be overexpressed in various tumours including breast and 
colon cancers. M atrilysin has also been shown to play an im portant role in several aspects o f 
tum our biology including growth, progression, invasion and metastasis. W ith respect to colon 
cancer, m atrilysin is unique in that it is the only M M P expressed exclusively by the malignant 
epithelia o f  colonic adenocarcinomas. These facts com bine to make matrilysin a promising 
therapeutic target. However, in order to develop drugs which specifically inhibit matrilysin it is 
important to understand how m atrilysin gene expression is controlled, something which to date 
remains poorly understood.
W e have examined a panel o f  human colon tum our cell lines and have shown that 
m atrilysin expression can be upregulated by a num ber o f cytokines including EGF, IL-6 and bFGF. 
Analysis o f  the m atrilysin prom oter revealed the presence o f a number o f  potential transcription 
factor binding sites including three ETS sites. We have shown that EGF treatm ent increased 
matrilysin gene expression by activation o f PEA3 transcription factors using artificial promoter, 
western blot and EM SA analysis. ‘Supershift’ EM SA analysis showed that other PEA3 subfamily 
members such as ERM  and ER81 may also be involved which is in agreem ent with other studies. 
In addition, we have found that EGF increased cellular levels o f  [3-catenin through destabilisation 
o f the E-cadherin/catenin com plex which resulted in increased binding to the T cf site within the 
m atrilysin promoter.
W e also exam ined the expression and regulation o f matrilysin in the K562 and HL-60 
myeloid leukaemia cell lines. Results showed that only the K562 cell line expressed m atrilysin and 
in vitro  invasion assays showed that the K562 cells were up to 4 times more invasive than the HL- 
60 cell line. M atrilysin antibody blocking experiments showed a significant decrease in invasion in 
the K562 cell line suggesting a role for matrilysin in leukaemia invasion. The MMP and TIMP 
profiles o f these cell lines were also examined.
Our data suggests that EGF plays an important role in the regulation of matrilysin gene expression 
via a number of new mechanisms. Furthermore, we have shown that matrilysin plays an important role in 
leukaemia cell line invasion. These findings have identified possible new drug targets that will inhibit 
matrilysin expression which in turn should lead to decreased tumourigenesis and invasion and metastasis.
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Chapter 1
Introduction to the Matrix Metalloproteinases
1. Introduction
1.1 The extracellular matrix
The extracellular matrix (ECM) is a complex and dynamic meshwork that is 
assembled outside cells from the specialised glycoproteins and proteoglycans secreted by 
them. As well as providing structural support in the form of bone, cartilage and tendon 
the ECM also plays an important role in many biological processes such as cell adhesion 
and migration, tissue morphogenesis, as well as cell proliferation and differentiation. The 
ECM can generally be divided into two categories: the basement membrane and the 
interstitial connective tissue (Boudreau and Jones, 1999).
The basement membranes are extracellular structures that usually separate cells 
from underlying connective tissue. They are found for example between endothelial and 
epithelial cells and underlying the connective tissue around muscle and adipose tissue. 
The major components of the basement membranes are type IV and V collagens, laminin, 
entactin and several glycoproteins which interact noncovalently to form a dense network. 
In the adult the basement membrane usually forms a barrier to most cell types and thus 
serves to compartmentalise tissues and organs. However, in some cases the basement 
membrane can be selectively penetrated, for example, during white blood cell diapedesis 
into surrounding tissue. The basement membrane in the kidney also serves as a biological 
filter whereby molecules are allowed to pass through on the basis of a certain molecular 
weight (Lukashev and Werb, 1998, Kawai et al., 1999, De Arcangelis and Georges- 
Labouesse, 2000).
Included among the interstitial connective tissues are heterogenous regions such 
as the dermis and stroma, as well as more specialised tissues such as bone and cartilage. 
These tissues contain several cell types in addition to those responsible for producing the 
bulk of the ECM, i.e. fibroblasts in connective tissue and osteoblasts in bone. These 
additional cell types include macrophages, lymphocytes, granulocytes, melanocytes, fat, 
endothelial, muscle and nerve cells. The major protein of the connective tissue matrix is
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collagen. Collagens type I and III are found in most connective tissues while types II and 
IX collagens are present in cartilage. Collagens type VI, VII, VIII, IX, X and XII have 
also been described in specific tissues. In addition to the collagens, interstitial connective 
tissue also contains fibronectin, elastin, chondroitin sulphate proteoglycans, heparin 
sulphate proteoglycans, tenascin and hyaluronic acid. Laminin and entactin are also found 
in interstitial connective tissues and are not exclusively basement membrane components.
The ECM plays an important role in cell signaling during proliferation, migration 
and differentiation and this is primarily achieved through the interaction of the cell with 
the ECM via the use o f cell adhesion molecules (CAMs). There are four main members 
o f the CAM family which are the cadherins, integrins, selectins and immunoglobulin like 
adhesion molecules. The interaction between the cells and the ECM is essential for 
several biological processes such as cell proliferation whereby cell adhesion to the ECM 
modulates the expression and functional state of several cell cycle regulators including 
cyclin dependent kinases, cyclins and cyclin dependent inhibitors (Lukashev and Werb, 
1998). Several cytokines are also incorporated into the ECM such as, basic fibroblast 
(bFGF) and epidermal growth factor (EGF), which when released also provide the cell 
with valuable external stimuli which inform the cell of the surrounding environment 
(Aharoni et al., 1997, Kaiura et al., 2000).
From the description above it is clear that both the basement membranes and 
interstitial connective tissue are important structural features of embryonic and adult 
tissues and defects in their synthesis and assembly can have profound effects on normal 
biological processes. When considering the possible ways in which defects in the ECM 
may be generated it is important to remember that the quality and quantity of the matrix 
depends not only on the structural components such as collagen, laminin and 
proteoglycan, but also on the regulated expression of ECM degrading proteinases and 
their inhibitors. These proteinases and their inhibitors have, for the most part, been 
studied in the context o f their possible role in tumour invasion and metastasis (McCawley 
and Matrisian, 2000). The degradation of ECM proteins can be effected by a variety of 
enzymatic activities o f which there are four main classes (Shi et al., 1993): i) serine 
proteinases e.g. plasminogen activators; ii) cysteine proteinases e.g. cathepsins B and L;
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iii) aspartyl proteinases e.g. cathepsin D and iv) matrix metalloproteinases (MMPs) e.g. 
matrilysin (MMP-7).
The MMPs are believed to be the primary contributors to ECM degradation as a 
result of several key characteristics: they are secreted into the extracellular space and 
function under normal physiological conditions, they are highly regulated and frequently 
induced in areas o f active matrix remodeling and the members o f this family are the only 
enzymes capable of degrading fibrillar collagens. The condition of the ECM is influenced 
by the balance between the levels of structural proteins and matrix degrading proteinases, 
their inhibitors and activators.
1.2 The matrix metalloproteinase family
The MMPs are a family of highly conserved zinc dependent endopeptidases 
which collectively are capable of degrading the components of the basement membrane 
and interstitial ECM. They are a continually growing family of enzymes which currently 
consist o f at least 23 well defined members. The MMPs can be defined by the following 
characteristics: i) they share common amino acid sequences; ii) their proteolytic activity 
can be inhibited by tissue inhibitors of metalloproteinases (TIMPs) ; iii) they are either 
secreted or exist as transmembrane pro-enzymes that require activation to exert their 
matrix degrading activity; iv) the active site contains a zinc ion and requires a second 
metal cofactor such as calcium and v) enzyme activity is optimal in the physiological pH 
range (Nagase and Woessner, 1999). The properties o f the human MMPs which have 
been cloned to date are summarised in table 1 .1 .
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Table 1.1 Properties ofthe human matrix metalloproteinase family.
MMI* Domain Enzym e Name M W  kDa 
(latent)
MW kDn 
(active)
Substrates Activation o f  other 
M M P)
M IN IM AL
M M P-7 M atrilysin, Pump-1. 28 19 Proteoglycans, laminin, fibronectin, 
gelatins, collagen IV, elastin, entactin, 
tenascin.
M M P-1, M MP-2, 
M MP-9
H EM OPEXIN
MMP-1 Interstitial coilagenase 55 45 Fibrillar collagens (types I,II,III,VII,X), 
gelatin, proteoglycans.
Unknown
M M P-8 Neutrophil coilagenase 75 58 Collagens I, II, III. U nknown
M MP-13 Collagenase-3 65 55 Collagen I, II, III, IV Unknown
M M P-12 M etalloelastase 53 45/22 Elastin, fibronectin, collagen IV M M P-2, M MP-12
M MP-3 Stromelysin-I 57 45 Proteoglycans, laminin, fibronectin, 
collagen III,IV, V, X, gelatins.
M M P-1, MMP-8, 
M MP-9
M M P-10 Stromelysin-2 57 44 Proteoglycans, fibronectin, collagen III, 
IV, V, gelatins.
M MP-8
M M P -11 Stromelysin-3 51 44 Laminin, fibronectin (very weakly), Unknown
FIBR O N ECTIN
M M P-2 G elatinase A 72 66 Gelatins, collagens IV, V, VII, X, 
elastin, fibronectin.
Unknown
M M P-9 G elatinase B 92 86 Gelatins, collagens IV, V, elastin. Unknown
TR AN SM EM BR A NE
M M P-14 M T1-M M P 63 CD44 M MP-2
M M P-15 M T2-M M P 72 Unknown Unknown
M M P-16 M T3-M M P 64 U nknown MMP-2
M M P-17 M T4-M M P 70 Unknown Unknown
M MP-24 M T5-M M P 60 Proteoglycan ECM  com ponents. Unknown
M MP-25 M T6-M M P 62 Unknown M MP-2
M ISCELLA N EO U S
M MP-19 RASI-1 - - Gelatins, A ggrecan, cartilage. Unknown
M M P-2 0 Enamelysin 54 • A m elogenin, A ggrecan, cartilage. U nknown
M M P -21 Recently cloned M M P - - Unknown U nknown
M M P-22 Recently cloned M M P - - Unknown Unknown
M M P-2 3 Recently cloned M M P 28 - Unknown Unknown
M M P-26 Endom etase/matri lysin-2 28 IS Collagen type IV, Fibronectin, Fibrin, 
Gelatin.
MMP-9
M MP-27 Epilysin 59 * Casein Unknown
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Previously, the MMPs were divided into subclasses with respect to their substrate 
specificity but this classification system became redundant as the family grew and new 
substrates were identified for individual members. MMPs are now classified according to 
their protein domain structure and on this basis the MMP family can be loosely divided 
into classes which contain the following domains; i) the minimal domain which is 
comprised o f a pre, pro and catalytic region, ii) the hemopexin domain, iii) the fibronectin 
domain and iv) the trans-membrane domain. (See figure 1.1).
1.2.1 The classification and structure of MMPs
Figure 1.1 Domain structure of various MMP family members. [H = Hinge domain ; F = fiirin consensus 
site ; FN = Fibronectin-like domain ; C = collagen-like domain ; TM = transmembrane-like domain].
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1.2.1.1 The minimal domain of MMPs
The minimal domain is comprised of the pre, pro and catalytic domain. The pre 
domain can be found at the amino terminus of all MMPs and is involved in directing the 
protein for cellular export. The pre domain is rapidly removed prior to secretion (Wilhelm 
et al., 1987).
The pro domain, which can be up to 100 amino acids long, contains a highly 
conserved sequence of eight amino acids, PRCGVPDV (Nagase et al., 1990). The pro­
domain must be removed through cleavage in order to activate the enzyme. This region is 
involved in maintaining the enzyme in a latent state since mutations in this area results in 
an enzyme which no longer requires proteolytic activation. In vitro, this activation can be 
achieved by a variety o f agents including oraganomercurials, oxidants, sulphydryl 
alkylating agents and, in some cases, proteolytic cleavage by trypsin or plasmin (Nagase 
et al. 1990). This spectrum of activators suggests that a conformational change is required 
for activation and that a thiol bond is involved. Activation of MMPs involves a process 
whereby the N-terminal part of the molecule is folded around the latent enzyme so that the 
cysteine residue in the conserved PRCGVPDV region complexes with a zinc molecule in 
the active site. The activation results when a conformation change dissociates the cysteine 
from the zinc atom and replaces it with water. This has been referred to by Van Wart and 
colleagues as the ‘cysteine switch’ mechanism (See figure 1.2). The activated MMP is 
then capable of auto proteolysis. In vitro, other enzymes such as cathepsin G and 
neutrophil elastase have shown to activate stromelysin-1 and gelatinase A (VanWart et al., 
1990).
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Figure 1.2 Cysteine switch mechanism for MMP activation. The pro domain of the latent molecule is 
folded around so that the cysteine residue can form a complex with the zinc molecule in the active site. An 
initial cleavage then causes a conformation change in the molecule that disrupts the cysteine-zinc interaction 
and frees the zinc to participate in the proteolytic cleavage. Thus when the cysteine is ‘on’ the zinc, the 
activity of the enzyme is ‘o ff , hence referred to as the ‘cysteine switch mechanism’ (Van Wart et al., 1990).
The catalytic site is another element of the minimal domain and contains the 
conserved sequence HEXGHXXGXXHS. The active site holds a zinc ion by coordinate 
bonding to three histidines. Studies have also shown that some MMPs contain a second 
zinc binding site which plays an important role in stabilising tertiary structure (Yuan et 
al., 1994). Two calcium ions are also present in the catalytic domain but these however, 
are not essential for enzymatic activity but may be important in inhibitor binding (Yuan, et 
al., 1994). Matrilysin (MMP-7) and MMP-26, also known as matrilysin-2, are the 
smallest members of the MMP family. They are comprised of just these three essential 
minimal domains which may imply that MMP-7 and MMP-26 were the first MMP-family 
members to evolve.
The type IV collagenases, MMP-2 and MMP-9, have three repeats of fibronectin- 
type domain inserted into the catalytic domain which have been shown to be required for 
gelatinase/collagenase activity (Steffensen et al., 1995). MMP-9 is the only MMP to
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contain a small region similar to the 012 chain of type V collagen in the hinge region but 
the functional significance of this insertion remains unclear.
1.2.1.2 The MMP hemopexin terminal domain
The fourth domain, the C-terminal, of MMPs is involved in the recognition of 
macromolecular substrates and has been implicated in determining the distinct substrate 
specificities o f the MMPs (Borkakoti, 1998). Matrilysin, until the recent cloning of 
MMP-26 (endometase/matrilysin-2), was the only family member which did not contain a 
COOH-terminal domain that has homology to a heme binding protein (hemopexin) and 
the ECM component vitronectin, known as the hemopexin domain. Although matrilysin 
does not contain this domain it still retains an ability to degrade a wide variety of 
substrates. The hemopexin domain is linked to the catalytic domain via a short but 
variable hinge region which is proline rich and is thought to be involved in substrate 
interaction (Nagase and Woessner, 1999). The presence of the hemopexin domain in 
MMP-1, MMP- 8  and MMP-13 allows them to cleave fibrillar type I collagen (Hirose et 
al., 1993).
1.2.1.3 The MMP transmembrane domain
The most recently described members of the MMP family contain a 
transmembrane domain near their carboxyl termini which localises the enzymes to the 
plasma membrane and thus, they are referred to as membrane type matrix 
metalloproteinases (MT-MMPs) (Polette and Birembaut, 1998). While these MMPs have 
a common domain structure with pre-, pro- catalytic and hemopexin-like domains, they 
have also three unique insertions. First there is an insertion of 11 amino acids between the 
pro peptide and catalytic domains. This sequence is also present in MMP-11. The 
sequence is recognised by furin, a pro-protein convertase, present in the Golgi apparatus 
which is able to activate recombinant MT1-MMP (Sato et al., 1996). Furin can cleave 
MT1-MMP which subsequently results in MMP-2 activation although other reports have 
shown that MT1-MMP activity is not a pre-requisite for MMP-2 activation as plasmin has 
also been shown to activate MMP-2 extracellularly. The MT-MMPs have a second
insertion o f 8 amino acids within the catalytic enzyme domain whose function remains 
undefined. The third insertion at the C-terminus contains a hydrophobic amino acid 
sequence which acts as a transmembrane domain. The MT-MMPs cannot apparently be 
activated by agents such as organomecurials (Pei and Weiss, 1995) but require proteolytic 
activation by molecules such as furin. It has also been shown that MT1-MMP and MMP- 
11 have a unique similarity in that neither enzyme can efficiently degrade ECM proteins. 
This observation suggests the possibility that there may be other functions associated with 
MMPs other than the degradation of ECM proteins.
1.2.2 Substrate Specificities of the MMPs
The degradation of the ECM is a multi-step process in which members of the 
MMP family are inextricably linked. Each MMP has a unique yet slightly overlapping 
substrate specificity. Prior to the classification of MMPs with respect to their protein 
domain characteristics, the MMPs were classified according to their substrate specificity. 
Broadly speaking the MMPs were divided into three subclasses: i) the type I collagenases; 
ii) the type IV collagenases and iii) the stromelysins (see table 1.1 for additional 
information on molecular weights and substrates). However, with the discovery of so 
many new MMP family members it has become more efficient to classify the substrate 
specificities of the MMPs according to their domain structure.
1.2.2.1 Substrate specificities of the minimal domain sub-class of MMPs
Matrilysin (MMP-7) has thus far been the only MMP family member to be 
classified under this heading although further studies involving MMP-26/matrilysin-2 
should also place it in the minimal domain category. Matrilysin is the smallest member of 
the MMP family with the inactive form having a molecular weight o f 28 kDa and the 
active form having a molecular weight o f 19 kDa. Interestingly, matrilysin has the 
broadest substrate activity of all the MMPs with an ability to degrade collagens, 
proteoglycans and glycoproteins (Fingleton et al., 1999). Matrilysin has been shown to 
play an important role in many normal biological process but has also been shown to play 
an active part in the progression and invasion of many tumour types including colon,
9
breast and prostate cancers (McDonnell et ah, 1991, Newell et al., 1994 and Sundareshan 
et ah, 1999). The role of matrilysin in these processes will be discussed in more detail in 
chapter 3.
1.2.2.2 Substrates specificities of the hemopexin domain sub-class of MMPs.
The hemopexin domain sub-class is comprised of several members which are 
characterised by the presence o f four hemopexin-like repeats in their C-terminal region. 
Hemopexin domain sub-class members include MMP-1, MMP-8 , MMP-13, MMP-12, 
MMP-3, MMP-10 and MMP-11. MMP-1, MMP- 8  and MMP-13 which are capable of 
degrading fibrillar collagens that include type I, II, III, VII, X, gelatin and proteoglycans. 
Interstitial collagenase (MMP-1) and neutrophil collagenase (MMP-8 ) have been well 
characterised and both these enzymes operate by cleaving the alpha chains of types I, II 
and III collagen at a single site. This results in an ‘unwinding’ of the helical structure 
which subsequently exposes the collagen to other proteolytic agents. The gene encoding 
interstitial collagenase was isolated from a human lambda (X) phage cDNA library 
(Collier et al., 1988a). Neutrophil collagenase was identified and sequenced from a 
cDNA library derived from peripheral leukocytes of a patient with chronic granulocytic 
leukaemia (Hasty et ah 1990) and its expression has been found to be restricted to cells of 
a neutrophil and chondrocyte lineage. MMP-13 also known as collagenase-3 was cloned 
from a cDNA library derived from breast tissue (Freije et ah, 1994). Increased expression 
of MMP-13 in breast carcinoma and the absence of detectable levels in normal tissues has 
been shown and therefore a possible link to tumourigenesis has been proposed. Analysis 
o f MMP-13 substrate specificity has shown that collagen type II is preferentially 
hydrolysed by MMP-13 (Knauper et ah 1996).
The stromelysin subclass, containing stromelysin-1, -2, -3 (MMPs -3 , -10 -11 
respectively) and metalloelastase (MMP-12) are capable of cleaving many ECM 
components (with the exception of MMP-11) including proteoglycans, fibronectin, 
collagens and gelatins but have no proteolytic activity for native collagen type I, with the 
exception o f stromelysin-3 which is a weak proteinase in comparison to other members of 
this subclass but has been shown to cleave laminin and fibronectin (Murphy et al. 1993).
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Stromelysin-1 was identified in 1985 as a secreted MMP (Chin et al., 1985). The 
molecule was originally cloned by virtue of its inducibility by oncogenes and growth 
factors and was referred to as transin (Matrisian et al., 1985). Transin was later shown to 
be the rat homolog of human stromelysin-1 (Muller et al., 1988). Stromelysin-2 (MMP- 
1 0 ) has been identified in both rat and human tissues and has a similar amino acid 
sequence (75-80% homology) and substrate specificity to stromelysin-1 (Nicholson et al., 
1989). However, the two genes are regulated differently by growth factors due to 
differences in transcription factor binding sites within each promoter. Stromelysin-3 
(MMP-11) was initially isolated from stromal cells surrounding breast carcinomas and its 
expression has been associated with the invasion and metastasis of breast cancer (Bassett 
et al., 1990). The stromelysins have been shown to be over expressed in several cancer 
types including colon, breast and prostrate cancer (McDonnell et al., 1991, Pacheco et al., 
1998 and Sundareshan et al., 1999).
The final member o f the stromelysin subclass is metalloelastase (MMP-12). 
Metalloelastase is a macrophage specific member of the MMP family and was initially 
identified in the lung as a 22 kDa protein with elastinolytic activity (Feinberg et al., 2000). 
MMP-12 degrades a number of proteins that not only includes elastin but also collagen 
type IV, fibronectin, vitronectin and laminin. Human and mouse M M P-12 have been 
shown to undergo auto-proteolytic processing and recombinant M MP-12 has also been 
shown to play an important role in the MMP activation cascade and is capable of 
activating MMP-2 and MMP-3. MMP-12 expression has also been shown to play an 
important role in arteriosclerosis, arthritis and emphysema (Shapiro, 1998 and Johnson et 
al., 1998).
1.2.2.3 Substrate specificities of the fibronectin domain sub-class
The fibronectin domain sub-class currently contains two members, MMP-2 and 
MMP-9 or gelatinase A and gelatinase B respectively. MMP-2 and MMP-9 degrade 
denatured collagens (gelatins) and are specific for the degradation of type IV basement 
membrane collagen. MMP-2 was cloned by Collier et al. (1988b) from a human lambda 
(k) phage cDNA library. It is secreted as a 72 kDa proenzyme and when activated cleaves
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the following substrates in order of preference: gelatin, collagens type IV, V, VII and 
fibronectin. The expression of MMP-2 is widespread and is frequently elevated in 
malignant tumours. MMP-9 was traditionally thought o f as a macrophage specific 
gelatinase but its expression has been described in malignant cells, neutrophils 
cytotrophoblasts and keratinocytes (Collier et al., 1988 and Wilhelm et al., 1989). MMP- 
9 was cloned from SV-40 transformed human lung fibroblasts (Willhelm el al., 1989). It 
is secreted as a 92 kDa proenzyme and when activated degrades gelatins, collagens type 
IV and V and elastin.
1.2.3 The membrane type matrix metalloproteinases (MT-MMPs)
Using domain contents to classify the MMPs has resulted in the grouping 
together of various sub-families such as the MT-MMPs. The membrane type matrix 
metalloproteinases are comprised o f 6  family members. The first member of the MT- 
MMP family (MT1-MMP) was isolated by Sato et al. (1994) who cloned a cDNA 
encoding a MMP of 63 kDa with a transmembrane domain. Expression o f the gene 
product of this MT-MMP induced specific activation of MMP-2 on the cell surface in 
vitro and enhanced cellular invasion of reconstituted basement membrane. Following this 
discovery o f MT1-MMP (MMP-14), five other MT-MMPs have been identified; MT2- 
MMP (MMP-15) which has a molecular weight of 72 kDa (Takino et al., 1995), MT3- 
MMP (MMP-16) which has a molecular weight 64 kDa (Matsumoto et al., 1997) and 
MT4-MMP (MMP-17) which has a molecular weight of 70 kDa (Puente et al., 1996), 
MT5-MMP which has a molecular weight of ~ 60 kDa (Wang et al., 1999) and MT6 - 
MMP (MMP-25) which has a molecular weight of ~62 kDa (Kojima et al., 2000. MT1- 
MMP has also been reported to act as a receptor for pro-MMP-2 (Will et al., 1996). MT1- 
MMP has also been shown to be involved in the activation of pro collagenase-3 (MMP- 
13). The substrate characteristics o f the MT-MMP group remain unclear.
1.2.4 Recently cloned MMPs
Several new and novel members of the MMP family have recently been 
discovered including MMP-18, MMP-19, MMP-20, MMP-21, MMP-22, MMP-23, MMP-
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26 and MMP-27. MMP-18 is a novel eollagenase isolated from metamorphosing 
Xenopus laevis tadpoles and has essentially identical enzymatic activity to human 
interstitial collagense (Stolow et al., 1996).
MMP-19 and MMP-20 exhibit previously described MMP characteristics but 
lack a series of structural features distinctive of the diverse MMP subclasses and have 
been proposed to be the first members of a new MMP subfamily (Pendas et al., 1997 and 
Stracke et al., 2000). MMP-19 may play a role in arthritis since serum anti-MMP-19 
autoantibodies are frequently detected in rheumatoid arthritis patients (Sedlacek et al., 
1998). MMP-19 is mainly expressed in the lung, placenta, pancreas, ovary, spleen, and 
intestine suggesting that it may have specialised role in these tissues. MMP-20, also 
known as enamelysin was cloned from odontoblastic cells which are involved in matrix 
remodeling during enamel maturation, and the enzyme was shown to cleave the major 
component of teeth ECM, amelogenin (Llano et al., 1997). MMP-20 expression is 
restricted to the enamel organ (Stracke et al., 2000). MMP-19 has also been recently 
shown to cleave aggrecan, a proteoglycan of the cartilage ECM, and cartilage oligomeric 
matrix protein (COMP) which again may implicate MMP-19 in arthritic disease.
The gene for MMP-21 was identified together with the gene for MMP-22 in the 
Cdc2Ll-2 locus at the end of the short arm of human chromosome 1, lp36.3, which is 
deleted frequently in a number of tumours. The catalytic domains o f MMP-21 and MMP- 
22 are related most closely to MMP-11 (stromelysin-3). These proteins do not contain 
highly conserved cysteine residues in the proenzyme domain and have been shown to be 
involved in the autocatalytic activation of other metalloproteinases. Multiple MMP-21 
and MMP-22 mRNAs, some of which are derived by alternative splicing, are expressed in 
a tissue-specific manner (Gururajan et al., 1998). MMP-23 was originally cloned from an 
ovarian cDNA library (Velasco et al., 1999). This protein exhibits sequence similarity 
with MMPs, but displays a different domain structure in that MMP-23 lacks a 
recognizable signal sequence and has a short prodomain, although it contains a single 
cysteine residue that can be part of the cysteine-switch mechanism operating for 
maintaining enzyme latency. The C-terminal domain is considerably shortened and shows 
no sequence similarity to hemopexin, whereas all human MMPs, with the exception of
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matrilysin and MMP-26, contain four hemopexin-like repeats. Furthermore, MMP-23 is 
devoid o f structural features distinctive of the diverse MMP subclasses, including the 
specific residues located close to the zinc-binding site in collagenases, the transmembrane 
domain of membrane-type MMPs, or the fibronectin-like domain of gelatinases (Velasco 
et al., 1999). MMP-23 is predominantly expressed in ovary, testis, and prostate, 
suggesting that this new MMP may play a specialized role in reproductive processes. The 
protein has a molecular weight of approximately 28 kDa.
MMP-26, also known as endometase and matrilysin-2, was isolated from human 
endometrial tumours and human placenta (Park et al., 2000 and Uria and Lopez-Otin, 
2000). The enzyme is similar to matrilysin in that it contains only three functional 
domains but has a low sequence homology to matrilysin and is specifically expressed in 
the human uterus. MMP-26 has a molecular weight o f 28 kDa and is capable of cleaving 
a diverse spectrum of substrates including collagen type IV, fibronectin and gelatin and 
has also been shown to be expressed in malignant tumours. MMP-27, also known as 
epilysin, was cloned from kidney and testis cDNA libraries. MMP-27 has a molecular 
weight o f 59 kDa and has been shown to degrade casein. The protein contains a signal 
sequence, a prodomain, a zinc-binding catalytic domain, and a hemopexin-like domain. 
In addition, epilysin has a furin activation sequence but has no transmembrane sequence. 
MMP-27 has a broad substrate specificity and is expressed in a number o f tissues 
including testis, lungs, heart colon and brain (Lohi et al., 2001).
1.2.5 Additional M M P substrates
In addition to ECM components, MMPs can cleave precursor forms of other 
MMPs, urokinase-type plasminogen activator (uPA) and proteinase inhibitor a-1- 
antitrypsin (see Chambers and Matrisian, 1997 for review). MMPs have also been 
implicated in the activation of growth factors, e.g. tumour necrosis factor alpha (TNF-a) 
and growth factor receptors such as interleukin- 6  receptor (IL-6 r), (Gearing et al., 1994 
and Chambers and Matrisian, 1997). A recent report also describes the ability of 
matrilysin and MMP-9 to inhibit angiogenesis via the hydrolysis o f plasminogen to 
produce angiostatin fragments (Patterson and Sang, 1997). Novel functions attributed to
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the MMPs such as those outlined above have helped to redefine the matrix 
metalloproteinases as important factors in not only ECM remodeling but in numerous 
biological processes including cell proliferation, migration and angiogenesis.
1.3 The ADAMs family
The ADAMs family (a disintegrin and metalloproteinase) are transmembrane 
proteins that contain a disintegrin and metalloproteinase domain and therefore, potentially 
have both cell adhesion and proteinase activities. The ADAMs are a rapidly growing 
family and thus far, 29 members have been characterized, although the function of many 
of these members has yet to be determined. An ADAM is a multi-domain protein ~ 750 
amino acids long and includes : the pro-domain, the metalloproteinase, disintegrin, 
cysteine rich, EGF-like transmembrane domains and the cytoplasmic tail domain (see 
Primakoff and Myles, 2000 for review). Among the 29 known ADAMSs, 17 have been 
shown to have a metalloproteinase active site with the correct amino acid sequence 
(deduced from the cDNA) and therefore are thought to be functional proteinases. The 
other 12 ADAMs have one or more residues in the active site which are incompatible to 
those with metalloproteinase activity and are therefore thought to lack metalloproteinase 
activity. It is possible however, that although they may be poor proteinases they may still 
retain the ability to dock with substrates and present them to more suitable proteinases. 
Many members of the ADAMs family, 14 in all, are expressed in a wide variety o f tissues 
while 15 are found exclusively in the testis which suggests that these ADAMs play an 
important role in the processes o f spermatogenesis and fertilisation. Several of the 
ADAMs have been shown to act as sheddases and perhaps the best studied of these is 
Tumour Necrosis Factor (TNF)-a converting enzyme (TACE) or ADAM-17. TNF-a, 
which is involved in the inflammatory response is synthesised as a 26 kDa membrane 
anchored protein which is cleaved by TACE to give the active 17 kDa ligand. The 
generation o f a TACE knockout mouse causes embryonic lethality as a result of the 
inability to shed TN F-a and transforming growth factor-a (TGF-a) (Black and White,
1998). These mice were also unable to shed the TNF receptor, L-selectin (an adhesion 
molecule) or amyloid protein precursor (APP) which suggests that TACE is a sheddase 
with multiple substrates (Peschon et ah, 1998 and Buxbaum et al., 1998). Recently
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another ADAMs family member, Kuzbanian (ADAM-10) has been shown to release Delta 
which is a Notch ligand (Qi et al., 1999). Notch is a surface receptor that regulates cell 
fate determination in various aspects of development, such as neurogenesis. New data has 
also shown that Kuzbanian can mediate the transactivation of the EGF receptor by G- 
protein coupled receptors and via the cleavage of heparin bound EGF (HB-EGF) (Yubing 
Yan, personal communication).
Recently it has been made clear that ADAM proteins with a thrombospondin 
repeat m otif (ADAMTS) represent an important and separate class of proteinases. 
ADAMTS which have been well charaterised include gon-1 (involved in gonad formation 
in C. elegans), ADAMTS-4 (aggrecanase-1) and ADAMTS-11 (aggrecanase-2) (see Tang 
and Hong, 1999 for review). The fundamental difference between ADAMs and 
ADAMTS proteins stem from their different locations in tissues. ADAMs are 
transmembrane proteinases, the known substrates of which are other transmembrane 
proteins. ADAMTS proteins are soluble extracellular matrix proteins that consist of a 
pro-domain, and metalloproteinase and disintegrin domains, but lack the ADAMs’ 
cysteine rich, EGF-like transmembrane and cytoplasmic domains. The thrombospondin 
motifs present on the C-terminal side of the disintegrin domain o f ADAMTS may function 
along with the disintegrin domain to maintain these proteins in an appropriate location in 
the ECM architecture.
1.4 Regulation of the MMPs
The constitutive level o f expression o f MMP genes is normally low, the enzymes 
being induced under various physiological circumstances when ECM remodeling is 
required, for example during embryogenesis, wound repair and bone remodeling. MMP 
expression is tightly regulated which indicates the biological importance o f these 
enzymes. In addition, individual members of the MMP family are separately regulated 
and their expression is highly tissue specific. The regulation of MMPs is complex and 
occurs at a number of different levels including; i) the transcriptional level; ii) at the 
protein level via processing of the latent precursor to an active enzyme; and iii) by
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modulating proteinase activity via the tissue inhibitor o f metalloproteinases (TIMPs), (see 
section 1.5).
1.4.1 Transcriptional regulation of MMP genes
Several studies have shown that MMPs are regulated both positively and 
negatively at the transcriptional level by a variety o f  growth factors, cytokines, oncogenes, 
phorbol esters and adhesion molecules (Fingleton and McDonnell, 1993, Birkedal-Hansen 
et al., 1993 and Crawford and Matrisian, 1996). In order for genes to be transcribed a 
number o f  elements o f  the cells transcriptional machinery need to be in place on the 
promoter o f the gene. Within the promoter there are short sequences of DNA known as 
transcription factor binding elements to which transcription factors can bind (see figure 
1.3). Although there is a clear demarkation in the patterns o f MMP expression, the MMP 
gene promoters show remarkable similarities with respect to transcription factor binding 
sites (see figure 1.3). For example the majority of the promoters o f the human MMP 
genes with the notable exception o f gelatinase A (MMP-2) and stromelysin-3 (MMP-11) 
contain an activating protein-1 (AP-1) element which binds the Fos/Jun AP-1 protein 
complex (Crawford and Matrisian, 1996). Another notable element which is found 
throughout the MMP promoters is the polyoma enhancing activator-3 (PEA3) element.
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Figure 1.3 Transcription factor binding elements within various MMP promoters. Note that the figure is not 
drawn to scale.
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1.4.2 Transcription factor binding elements within the MMP promoters
A single AP-1 element is normally present at approximately -70  base pairs (bp) 
upstream in the promoter region of each inducible MMP gene. The AP-1 site has been the 
subject of much recent research and it is now known to be essential for the basal 
transcription o f MMP-1 (Curran and Murray, 2000). Molecules that inhibit the expression 
of inducible MMP genes also appear to act via the AP-1 site. The AP-1 site is necessary 
for the transcriptional response to a variety of signals, for example, interleukin- 1 (IL-1), 
tumour necrosis factor-a (TNF-a), interferon-p (INF-P) and 12-O-tetradecanoylphorbol 
13-acetate (TPA) (Curran and Murray, 2000). Other agents that modulate the expression 
o f MMPs, such as glucocorticoids, retinoids and transforming growth factor-P (TGF-P) 
also require the AP-1 site to exert their function. Many studies have looked at the effects 
of these molecules on MMP-expression in isolation which is not typically the case in vivo 
as several agents may be required to initiate the transcription of MMP genes. In many 
cases it is possible that the effects may not be direct and the initiation of MMP 
transcription may be a downstream response. Other cw-acting elements are also necessary 
for both basal transcription and trans-activation by phorbol esters, cytokines and growth 
factors (Vincenti et al., 1996, Benbow and Brinckerhoff, 1997). AP-1 transcription 
factors are protein complexes, composed o f Jun and Fos subunits. These subunits form 
heterodimeric leucine zipper proteins that bind to a consensus DNA sequence, typically 
TGAGTCA, which is the AP-1 element within the MMP promoters. In normal cells, Jun 
and Fos proteins are transiently expressed following a mitogenic stimulus to the cell. The 
cellular concentration o f these subunits is normally controlled by the stability of their 
mRNA (i.e. post transcriptional regulation), as well as by the rate o f gene transcription. 
Binding o f the Jun/Fos complexes to the AP-1 site is associated with transcriptional 
activation of the MMP genes, but some members of the Fos and Jun families act as 
transcriptional repressors. Fos/Jun complexes that are weak activators of AP-1 interact 
with this site, thereby blocking interaction with more potent activators. For example, Jun 
B has been shown to inhibit Jun induced MMP-1 gene expression (Westermarck et al, 
1997). Expression of Jun B is associated with differentiated cells, which may contribute 
to the less aggressive biological behaviour observed in more differentiated tumours
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(Curran and Murray 2000). A second activating protein complex (AP-2) has also been 
described and has been shown to play a significant role in the regulation of MMP-2 
whereby it was found to be necessary for constitutive expression of MMP-2 (Qin et al.,
1999). The AP-2 transcription factor family is comprised of three members, AP-2a, AP- 
2(3 and AP-2 y which bind to a site distinct to that of AP-1 (GCCN3GGC for AP-2 versus 
TGAGTCA for AP-1) (Hilger-Eversheim et al., 2000).
Most of the promoters of MMP inducible genes also contain a polyoma 
enhancing activator-3 (PEA3) site which binds members o f the ETS (E-twenty six) family 
of oncoproteins. The combination of AP-1 and PEA3 binding sites has been referred to as 
an ‘oncogene responsive unit’ and it appears to be a recurring motif, found in the 
promoter regions o f other genes (Gutman and Wasylyk, 1991). The AP-1 and PEA3 sites 
display functional cooperation and there is evidence of synergism between these sites 
(Crawford and Matrisian, 1996). Thus, inhibition or modulation of these two sites may 
represent a therapeutic approach to downregulate synthesis o f MMPs.
Several compounds are also capable of inhibiting the synthesis of MMPs 
including retinoids, thyroid hormones, glucocorticoids, progesterone and androgens. All 
these agents bind to members of the nuclear receptor subfamily which control gene 
transcription via a number of different mechanisms. Firstly, nuclear receptors act on the 
promoter regions of MMP genes. To date, few hormone response elements (HRE) have 
been found within the MMP promoters and they appear to inhibit transcription by forming 
complexes with the DNA through interactions with AP-1 proteins. Glucocorticoids and 
retinoids also inhibit AP-1 activation by complexing with the site or by sequestering Fos 
and Jun proteins (Schroen and Brinckerhoff, 1996). Studies have also shown that TGF-(3 
inhibits the EGF induction of stromelysin gene expression through an upstream element 
referred to as the TGF-(3 inhibitory element (TIE). Interestingly, Fos protein is present in 
the complex that recognises the TIE element (Kerr et al., 1988). Thus it appears that 
proto-oncogene induction by growth factors can be involved in both positive and negative 
regulation of MMP gene expression.
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1.4.3 Post Transcriptional Regulation of MMP Activity
Although sophisticated transcriptional control mechanisms play an important role 
in the modulation o f MMP synthesis, post-transcriptional control mechanisms are central 
to the control o f MMP activity as all the soluble MMPs are secreted as inactive zymogens 
requiring activation by cleavage of the N-terminal pro-domain. It has been suggested that 
the endogenous activator of MMPs is plasmin, produced from the plasminogen precursor 
by the action of plasminogen activators, (He et al., 1989). Plasmin can convert both 
proMMP-1 and proMMP-3 to their active forms. MMP-7, MMP-3, MMP-10 and the 
MT1-MMP can also activate other MMPs by proteolytic cleavage. Pro-MMP-2 has been 
shown to be a substrate for MX 1-MMP (Sato et al., 1996). Interestingly, MT1-MMP also 
binds to TIMP-2 and it has been proposed that the MT1-MMP/TIMP complex acts as a 
receptor for pro-MMP-2. Once pro-MMP-2 has bound, other M Tl-M M Ps in proximity to 
the complex clip the pro domain resulting in active pro-MMP-2. Plasmin has also been 
implicated in the activation of pro-MMP-2 when it is bound to the MT1-MMP complex. 
(Mazzieri et al., 1997). These proteolytic events are tightly regulated in a cascade style 
system and this system serves as a controlled but powerful mechanism to coordinate 
complete degradation of the multiple components of the ECM (see figure 1.4).
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complex at the cell surface
Figure 1.4 Matrix metalloproteinase activation cascades. Cell surface associated plasmin, generated by the 
activity o f receptor bound urokinase-like plasminogen activator on cell bound plaminogen, is a key initiator 
of MMP activation, notably MMP-3, MMP-2 and MMP-9. Active surface MT1-MMP acts as a second focus 
of activation, cleaving proMMP-2 which subsequently acts in other cleavage reactions. MT1-MMP may 
also activate MMP-13 directly. A more likely event, is activation of MMP-13 by MMP-2. Both MMP-2, 
MMP-3 and MMP-13 can activate MMP-9. MMP-13 may also be activated by MMP-3.
1.5 Tissue Inhibitors of Metalloproteinases (TIMPs).
Serum proteinases, such as a-2-macroglobulin and other non specific proteinase 
inhibitors such as a t proteinase inhibitor are ubiquitously present in extracellular spaces 
and play an important role in controlling the overall proteolytic activity in tissues 
(Kennedy, 1998). In addition, the proteolytic activity of MMPs is specifically inhibited 
by the tissue inhibitor o f metalloproteinases (TEMPs) family o f  proteins (Brew et ah, 
2000). The TIMP family is comprised o f at least 4 distinct members which are produced 
by a variety o f cell types including fibroblasts, keratinocytes, endothelial cells and
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osteoblasts. TIMP-1, TIMP-2 and TIMP-4 are secreted in soluble form while TIMP-3 is 
bound to the ECM (Carmichael et ah, 1986, Stetler-Stevenson et ah, 1989, Leco et al., 
1994 and Greene et al., 1996). TIMPs mediate MMP inhibition by binding non- 
covalently to active MMPs in a 1:1 stoichiometric manner. TIMPs show a 30-40% 
homology at the amino acid sequence level and share several structural features; they 
possess 12 cysteine residues which are necessary for the formation of 6  loops; the N 
terminal domain is necessary for MMP inhibition and all TIMPs contain the consensus 
sequence VIRAK in this domain; the TIMPs also contain a 29 amino acid leader sequence 
which when cleaved gives the mature protein (DeClerck et al., 1993 and Gomez et ah, 
1997); the C terminal domain has enzyme binding sites which by interaction with the 
MMPs increases the rate o f enzyme inhibition (Wojtowicz-Praga et al., 1997).
1.5.1 TIMP-1
TIMP-1 is an extensively glycosylated protein with a molecular weight of 28 
kDa. Human TIMP-1 is secreted by a variety of cell types and has a wide tissue 
distribution (Carmichael et ah, 1986). TIMP-1 has been shown to inhibit multiple MMPs 
with the exception o f MT1-MMP but has been found to be most effective against MMP-9. 
In addition, TIMP-1 binds to the C-terminal hemopexin domain of proMMP-9 and slows 
its activation (Gomez et ah, 1997). The gene encoding TIMP-1 has been cloned and 
sequenced (Mahtani and Willard, 1988). The secreted protein has 184 amino acids and 
six intramolecular disulphide bonds. In the early mouse embryo, tissue localisation data 
showed that high levels o f TIMP-1 mRNA transcripts were found at the sites o f active 
matrix remodeling such as developing bone, where its expression overlapped significantly 
with that of members o f the TGF-P family (Flenniken and Williams, 1990). TIMP-1 has 
also been shown in several studies to have many diverse biological functions including 
roles in gonadal steroidogenesis, ovulation, tissue remodeling during tumour progression, 
growth factor activity, including erythroid potentiating activity (EPA) and inhibition of 
angiogenesis in vitro (Gomez et ah, 1997). Recently it has been found to suppress 
apoptosis in B-cells (Guedez et ah, 1998) and accumulate in the nucleus of fibroblast cells 
during the S phase of the cell cycle (Zhao et al., 1998). Expression of TIMP-1 is 
regulated at the level of transcription by various growth factors, cytokines and hormones.
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Some studies have shown it to be coordinately regulated with MMPs while others have 
shown it to be reciprocally regulated. Phorbol esters and IL-1 stimulate both MMP and 
TIMP-1 expression (Overall, 1994) whereas MMP expression is decreased and TIMP-1 
expression increased by TGF-P and retinoic acid (Gomez et al., 1997). TIMP-1 
expression is also stimulated by IL-6 , EGF, oncostatin M and glucocorticoids (Kahari and 
Saarialho-Kere, 1999). TNF-a has also been shown to stimulate TIMP-1 at low 
concentrations while inhibiting expression at high levels (Iato et al., 1990). The TIMP-1 
promoter contains several transcription factor binding sites including AP-1, AP-2, Spl and 
PEA3 but does not contain a TATA box. The AP-1 site at -92  bp upstream of the 
initiation site is essential for basal activity (Clark et al., 1997).
1.5.2 TIMP-2
TIMP-2 is a 21 kDa unglycosylated protein which was originally co-purified with 
MMP-2 from the supernatants of human melanoma cells. It consists of 192 amino acids 
residues with a 41% homology to TIMP-1 at the amino acid level (Stetler-Stevenson et 
al., 1989). TIMP-2 forms a complex with proMMP-2 and has a complex role in the 
regulation of MMP-2 (Golberg et al., 1989) (see figure 1.4). At low concentrations 
TIMP-2 promotes a ternary complex formation with proMMP-2 and MT1-MMP. Once 
the complex has formed a second TIMP-2 free MT1-MMP proteinase activates MMP-2 
(Strongin et al., 1995). When extracellular levels of TIMP-2 are high the activation of 
MMP-2 is prevented due to the inhibition of MT1-MMP activity by excess TIMP-2. 
Although a key element in MMP regulation, TIMP-2 has also been shown to play 
important roles in other biological processes, for example, in the protection of melanoma 
cells from apoptosis (Baker et al., 1998, and Valente et al., 1998). TIMP-2 tends to be 
constitutively expressed by many cell types in culture, although in cases where TIMP-2 
expression can be modulated, the response is typically the opposite to that of TIMP-1 
(Stetler-Stevenson et a l,  1990 and Overall, 1994). The TIMP-2 promoter has a number of 
potential transcription factor binding sites including several Sp-1 sites and an AP-1 site. 
However, in contrast to the TIMP-1 promoter, it is unresponsive to TPA and various 
cytokines (DeClerck et al., 1994).
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1.5.3 TIMP-3
Unlike other members of the TIMP family, TIMP-3 has poor solubility and is 
specifically localised to the ECM. The secreted mature protein contains 188 amino acids 
and shares 30% homology with TIMP-2. The unglycosylated protein has a relative 
molecular weight o f 21 kDa, although a higher molecular weight form due to 
glycosylation has been reported (Anand-Apte et al., 1996 and Baker et al., 1998). The 
protein contains an N-linked glycosylation site suggesting that the natural protein may 
exist in a glycosylated form, although the functional consequences of glycosylation 
remain unclear (Anand-Apte et al., 1996). TIMP-3 was first isolated as a transiently 
expressed protein in the ECM of transforming chick fibroblast cultures (Blenis and 
Hawkes, 1984) and was subsequently identified as a member of the TIMP family (Pavloff 
et al., 1992). TIMP-3 inhibits a wide range o f MMPs including MMP-1, MMP-2, MMP- 
3, MMP-9 and MMP-13 and has also been shown to inhibit the activity of TNF-a 
converting enzyme (TACE). TIMP-3 is expressed in a number o f tissues including 
cartilage, muscle and kidney (Leco et al., 1994). The TIMP-3 promoter lacks a TATA 
box and contains several AP-1 sites (Kim et al., 1997). TIMP-3 expression has been 
shown to be stimulated by a number of agents including EGF, TGF-P, platelet derived 
growth factor (PDGF), phorbol esters, dexamethasone, and IL-1 (3. TIMP-3, unlike TIMP- 
1 and TIMP-2, does not appear to have any growth potentiating activity but it has been 
reported to be involved in suppressing cell growth and inducing apoptosis (Ahonen et al., 
1998 and Baker et al., 1998).
1.5.4 TIM P-4
TIMP-4 contains 195 amino acids and the protein has a molecular weight of 23 
kDa (Greene et al., 1996, Liu et al., 1997). TIMP-4 shares a 37% sequence homology 
with TIMP-1 and a 51% homology to TIMP-2 and TIMP-3. In comparison to other TIMP 
family members TIMP-4 expression is restricted and is normally localised in the adult 
human heart and at lower levels in kidney, colon, placenta and kidney (Greene et al.,
1996). TIMP-4 has been shown to inhibit the activities of MMP-1, MMP-3, MMP-7,
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MMP-9 and in particular has been shown to be a potent inhibitor of MMP-2 (Liu et al.,
1997).
The TIMP family of metalloproteinase inhibitors represent an important 
mechanism in the regulation of MMP activity which is essential in the maintenance of 
ECM homeostasis. Recent reports have shown that TIMPs, aside from MMP inhibition, 
have several other important biological functions the mechanisms of which have yet to be 
elucidated.
1.6 MMPs in cancer invasion and metastasis
MMPs have been implicated in a number of pathological conditions including 
rheumatoid arthritis (Cawston et al., 1999) and atherosclerosis (Thompson and Parks, 
1996) but it is their role in tumour invasion and metastasis which has been extensively 
studied (Parsons et al., 1997).
1.6.1 Metastasis
Metastasis is the spread of cancer from a primary tumour to distant sites of the 
body and is the most lethal aspect of cancer (Chambers and Matrisian, 1997). In order to 
spread to these distant sites, invading tumour cells must overcome the barrier o f the 
surrounding ECM. As MMPs are involved in the proteolytic cascade which is responsible 
for ECM degradation, many studies have investigated the links between tumour invasion 
and metastasis and MMP expression and in general it has been concluded that MMPs are 
inextricably linked to this process. Metastasis is regarded as a multi-step process 
separated into sequential steps which are as follows; the escape of cells from the primary 
tumour, intravasation (entry of cells into the lymphatic or blood circulation), survival and 
transport in the circulation, arrest in different organs, extravasation (escape of cells from 
the circulation) and growth of cells to form secondary tumours in the new organ 
environment. Angiogenesis, the formation of new blood vessels, is essential for the 
secondary tumour to grow beyond minimal size and the cell must escape immune 
destruction during each of the metastatic steps (see figure 1.5).
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Figure 1.5 The role of MMPs in tumourigenesis and cancer metastasis. MMPs were traditionally thought of 
as being involved in tumour invasion and metastasis due to their ECM degrading capabilities (bold legend) 
but recent evidence has suggested that MMPs are implicated in several stages of primaiy and secondary 
tumourigenesis (adapted from Chambers and Matrisian, 1996).
MMPs have been associated with the malignant phenotype for many years 
(Chambers and Matrisian, 1997) and early work concentrated on collagen type IV 
destruction (Liotta et aL, 1980). Collagen type IV is a major component of the basement 
membrane and it has been demonstrated that MMP-2 and MMP-9 play a major part in its 
degradation. Subsequent studies demonstrated the association o f MMP family members 
with tumour progression. Several generalisations can be made, i) the number o f MMP 
family members that can be detected tends to increase with tumour progression, ii) the 
relative levels o f any MMP family member tend to increase with increasing tumour stage 
and iii) the MMPs can be produced by tumour cells or by the surrounding host tissue. 
These generalisations are evident in several tumour types including, colon, breast and 
pancreatic cancer.
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Numerous studies have investigated the expression of MMPs in various cancers 
with many showing that the level o f MMP expression can be used as a prognostic marker 
for how aggressive a particular tumour is. For example, MMP-1 has been shown to be 
associated with poor prognosis in colorectal cancer whereby tumour sections were 
examined for the presence of MMP-1 (Murray et al., 1996). Results showed that the 
presence of MMP-1 could be prognostic of tumour aggressiveness and that the prognostic 
value was independent o f Duke’s stage (the classification system used to define colon 
tumour aggressiveness). Matrilysin (MMP-7) has been shown to involved in the invasion 
and metastasis of several tumours, in particular, those of colon and breast origin and 
reports have shown that increased levels of matrilysin correlate well with increased 
invasion and metastasis. Matrilysin has also been recently shown to play an important 
role in early breast and colon tumourigenesis. The studies which identified matrilysin as 
being an important factor in colon and breast tumour progression will be discussed in 
more detail in chapter 3. In experiments examining patient biopsies, MMP-2 and MMP-9 
levels were assessed and it was found that high levels o f these enzymes were prognostic 
for a poor overall survival of patients (Sier et al., 1996, Ogura et al., 1997 and Baker et al.
2000). MMP-2 has been found to play an important role in breast cancer and has been 
detected very early in breast carcinoma but not in normal, resting breast tissue (Poulsom et 
al., 1993). Once again MMP-2 expression has been found to increase with increasing 
tumour aggressiveness (Polette et al., 1994). The protein has been localized in tumour 
cells (Daidone et al., 1991, Hoyhtya et al., 1990) and also stromal cells (Okada et al., 
1995) in breast carcinoma by immunohistochemistry. An association between MMP-9 
positive cells and either invasive carcinoma cells or lymph node metastasis has also been 
found in breast carcinoma, although expression of the enzyme is not strictly confined to 
the neoplastic cell. Stromelysin-3 has also been shown to be expressed in breast 
carcinomas (Basset et al., 1990) and it was found that the stromelysin-3 mRNA 
expression was restricted to the stromal cells immediately surrounding the islands of the 
malignant tumour epithelial cells. Many other MMPs have been detected in these tissues 
but it is beyond the scope of this study to examine them in detail.
Recent evidence suggests that MMPs play a much broader role in metastasis than 
previously believed, and that the action of MMPs at steps both before and after the
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breakdown of the apparent physical barriers to metastasis may in fact be of greater 
importance (see figure 1.5). MMPs and their inhibitors appear to be important regulators 
in the growth of tumours, both at the primary site and at métastasés. How MMPs mediate 
this growth regulation is not yet fully understood, but a number o f mechanisms are 
possible. Firstly, MMPs appear to contribute to the initiation o f growth, at both primary 
and secondary sites. One can speculate that this may involve regulation of the growth 
environment by, for example, regulating access to growth factors, such as EGF (Ravanti 
and Kahari, 2000), from the extracellular matrix surrounding the growing tumour, either 
directly or via a proteolytic cascade. Insulin like growth factor binding proteins (IGFBPs) 
are cleaved by a number of serine proteinases that are initially activated by MMPs such as 
MMP-2 and MMP-9 (Clemmons, 1998). Similarly, MMPs and their inhibitors appear to 
regulate the sustained growth of tumours. Beyond the maintenance of an appropriate 
growth environment, the role o f MMPs in angiogenesis is likely to be important at this 
stage. Angiogenesis is required for growth of both primary and metastatic tumours and 
MMPs play a contributory role in regulation of angiogenesis.
1.6.2 The anti-tumour effect of TIMPs
There are several mechanisms that support the anti-tumour effect of TIMPs. 
Firstly, TIMPs have anti-angiogenic activity either by a direct effect on endothelial cell 
proliferation or by their ability to downregulate the activities of MMPs required for 
endothelial cell migration and invasion (Blavier et al., 1999). As a second mechanism it 
has been recently recognised that MMPs can degrade proteins other than structural MMP 
proteins such as IGFBPs. Some of these proteins form complexes with growth factors and 
control their bioavailability. By preventing the degradation of IGFBP by MMPs, TIMPs 
can therefore play an important role in preventing the bioavailability of this potent growth 
factor. A third mechanism that supports the anti-tumour effect of TIMPs is based on the 
increasingly recognisable fact that the ECM can control essential cellular functions such 
as growth, differentiation and apoptosis. Thus by maintaining the integrity of the ECM 
via MMP inhibition, TIMPs can maintain an indirect control over malignant cell 
proliferation. TIMPs on the other hand have also been shown to have a tumour promoting 
effect. For example, in colon cancer, higher levels of TIMP-1 have been observed in
I
association with more invasive stages and in non-Hodgkin’s lymphoma, TIMP-1 
expression is a positive index of malignant expression. In bladder and breast cancers, 
elevated levels of TIMP-2 in tumour tissues predict an unfavorable rather than a favorable 
prognosis. The mechanisms supporting the paradoxically positive effect o f TIMPs in 
tumour progression are not fully understood but are the focus o f intensive investigations. 
It may be possible that the tumour cells increase the amount of TIMPs in response to 
increased levels of MMPs in order to halt ECM degradation and tumour progression. The 
role of TIMP-2 as a docking molecule for MMP-2 activation has also been well 
documented and therefore increased levels of MMP-2 may also result in increased levels 
o f TIMP-2. TIMP-1 has also been shown to bind to the EPA receptor thus stimulating the 
growth of erythroid cells (Murate et ah, 1993).
Details o f the mechanisms by which MMPs and their inhibitors contribute to 
creating an environment that favours the initiation and continued growth of primary and 
metastatic tumours remain to be elucidated, but are of key importance in cancer therapy. 
An understanding of the molecular role of MMPs at each of the sequential steps required 
to produce clinically evident metastases will be important in the design and appropriate 
use of novel therapeutics designed to combat metastasis.
1.7 Physiological roles of MMPs
The expression of MMPs by a variety of cell and tissue types has been 
extensively studied. Although the majority of the MMPs were first isolated and cloned 
from tumour-associated tissues, their roles in normal tissue formation and remodeling has 
been less frequently studied. Initial reports point to complex and highly individualised 
patterns o f expression for the various family members. The complexity of expression 
patterns in normal tissues is demonstrated by examples of cell type and tissue specific 
regulation, inducible and constitutive expression and discrepancies between in vitro and in 
vivo studies. The best defined correlations o f MMP expression with normal functions are 
found during trophoblast invasion (Cross et ah, 1994) development (Matrisian and Hogan 
1990), endometrial remodeling (Salamonsen, 1994) ovulation (Russell and Findlay, 1995) 
and angiogenesis. (Fisher et ah, 1994).
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1.7.1 MMPs and reproduction
Development of the human foetus depends primarily on the embryo rapidly 
gaining access to the maternal circulation and the embryo achieves this by using 
specialised cells referred to as trophoblasts. In contrast to tumour cell invasion, 
trophoblast invasion is precisely regulated (Cross et al., 1994). A number of investigators 
have shown that trophoblast cells employ a number of MMPs during their invasion of the 
uterus and in particular, MMP-2 and MMP-9 have been shown to play an important role 
in this respect (Librach et al., 1991 and Fisher et al., 1994).
Perhaps the most dramatic expression of MMPs in normal tissue is observed in 
the human cycling endometrium. The uterine endometrium is regularly shed throughout 
the human reproductive life which implies active remodeling. During the menstrual phase 
several MMPs including, MMP-1, MMP-3, MMP-10, MMP-11, MMP-2 and MMP-9 are 
all expressed (Rodgers et al., 1994) which implicates the importance of MMPs in the 
breakdown and release of endometrial tissue during menstruation.
1.7.2 The role of MMPs in angiogenesis
MMPs, as stated earlier, have been shown to play an important role in 
angiogenesis during tumour development but are also involved in angiogenesis in normal 
conditions such as embryonic development, ovulation, bone formation, inflammation and 
wound repair. In order to form a new capillary in response to an angiogenic stimulus the 
ECM must first be degraded in order to make space for the advancing endothelial cells. 
The penetration o f local ECM barriers by endothelial cells requires the strict control and 
regulation of a variety o f proteinases including the MMPs. Angiogenic stimuli include 
fibroblast growth factor (FGF), angiotropin, angiogenin and EGF (Fisher et al., 1994). 
Cultured endothelial cells have been shown to secrete a number of MMPs such as, MMP- 
1, MMP-2, MMP-3 and MMP-9 in response to different stimuli (Moscatelli and Rifkin, 
1988, Mignatti et al., 1989 and Fisher et al., 1994). Other evidence also suggests that 
MMPs may negatively regulate angiogenesis. Recently matrilysin and MMP-9 have been
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shown to cleave plasminogen thus giving rise to angiostatin which is a potent inhibitor of 
angiogenesis (Patterson and Sang, 1997). This would therefore imply that MMPs can play 
a direct role in the regulation of angiogenesis. Perhaps this may also explain why MMP 
inhibitors such as Agouron have been found to perform worse than placebo in recent 
phase III clinical trials (see section 1.8) whereby the inhibition of the MMPs may assist in 
the vascularisation of the tumour.
1.7.3 MMPs and apoptosis
The nature of the ECM can influence the apoptotic programme in mammalian 
cells, thus leading to the association o f MMPs with apoptosis. It is hypothesised that the 
basement membrane is a survival factor for epithelial cells and that loss of contact with 
the basement membrane results in initiation of the apoptotic cascade (see Wiesen and 
Werb, 2000 for review). Several investigators have shown this to be the case. For 
example in the breast, a basement membrane rich in laminin is required for normal 
mammary development and when mammary epithelial cells are placed in culture without 
essential basement membrane components, the cells undergo apoptosis. MMPs may also 
be involved in processing factors which induce apoptosis such as Fas which when it 
interacts with its ligands induces apoptosis in T lymphocyte cells. Fas is a member of the 
TNF/nerve growth factor receptor family and MMPs have the ability to convert proTNF-a 
and Fas ligand to active, soluble forms which induce apoptosis. Recently, Powell et al 
(1999) have found that Fas ligand is a substrate for matrilysin and plays an important role 
in the apoptotic cascade in breast cancer cell lines.
1.8 MMPs as therapeutic targets
As the role of MMPs in tumour development and progression became apparent, 
many potential inhibitors o f these enzymes (matrix metalloproteinase inhibitors, 
(MMPIs)) were assessed for anticancer properties. TIMPs, in general, were unsuitable for 
therapeutic use due to the proteins short half-life and large size. Therefore a number of 
synthetic inhibitors have been designed.
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1.8.1 Batimistat/Marimistat MMP inhibition
Batimistat (British Biotech Inc., Oxford, UK), a potent broad spectrum inhibitor 
of MMPs, is a synthetic hydroxamate derivative, whose structure imitates the MMP 
binding site of collagen. Batimistat functions by chelating the zinc ion present at the 
active site of each MMP enzyme. The drug proved successful in animal trials but its 
major drawback was its extreme insolubility. Recent in vitro studies have shown that 
Batimistat inhibits angiogenesis and this may be the basis o f its anti tumour effects 
(Curran and Murray, 2000).
Marimistat is a second generation MMP inhibitor and phase I and II trials have 
shown the inhibitor, which is orally administered, to be effective against colon, ovarian, 
prostate, lung and pancreatic cancer. It can also be safely used in association with other 
chemotherapeutic agents. Potential drawbacks for both Batimistat and Marimistat are the 
dose limiting side effects which include inflammation of the joints and tendons which are 
reversible on discontinuation of the treatment (Tierney et ah, 1999). The drugs are also 
broad spectrum inhibitors which may have other undesirable side-effects as the exact 
functions of MMPs have not yet been fully elucidated. Thus the development of specific 
MMP-inhibitors may prevent cancer spread while having minimal interference in other 
normal biological processes involving MMPs. Recently phase three clinical trials 
involving marimastat were halted as it was found to be performing worse than the 
placebo. Thus further chemical modifications of these drugs are required in order to 
improve specificity and reduce cytotxicity.
1.8.2 Other Bryostatin MMP inhibitiors
The bryostatins are a group of naturally occurring macrocyclic lactones which 
inhibit MMP activity in a different manner to that of Batimistat and Marimistat. Although 
the exact mode of action remains unclear, it is thought that bryostatin downregulates the 
PKC pathway. Several genes including MMP-1, MMP-3, MMP-9 and MMP-11 are 
downstream targets of the PKC pathway and therefore bryostatin may prevent the 
transcriptional activation of these genes. Recently a number of companies including
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Bayer and Agouron began testing byrostatin compounds for their effectiveness as 
tumouristatic agents. BAY 12-9566 (Bayer) was shown in pre clinical trials to be 
effective as an MMP inhibitor but unfortunately it was withdrawn from all clinical trials in 
1999 when it was found to be less effective than the placebo. However, another bryostatin 
compound, AG3340/prinomostat developed by Agouron has proved to be more 
successful. Studies have shown prinomostat to inhibit the proliferation and invasion of 
glioma cells in vitro (Price el al., 1999). Prinomostat is a selective MMP inhibitor and 
inhibits the activity of MMP-2, MMP-9, M MP-13 and MT1-MMP (Shalinsky el al.,
1999). In early 2001, Agouron halted phase III clinical trials which were examining the 
effects o f prinomostat on prostate and lung cancers. Phase II trials involving patients with 
earlier stages o f the disease, however, are set to continue. Redevelopment o f these drugs 
by Bayer and Agouron using new chemistry techniques such as ‘combinatorial’ chemistry 
may lead to the discovery of new potent MMP inhibitors which have minimal side effects.
1.8.3 Indirect inhibition of MMPs by tyrosine kinase directed inhibitors
A number of other drugs are available which may inhibit MMP activity indirectly 
such as tyrosine kinase receptor (TK-r) inhibitors. Initially these drugs inhibited tyrosine 
kinase receptors in a non-specific manner which resulted in unwanted side effects. 
Chemical alteration o f initial lead compounds has resulted in several new drugs being 
developed which specifically target various receptors. A recent example of this is the 
Her2/Neu anti-body based drug, Herceptin released by Genentech. Her2/neu is a tyrosine 
kinase receptor which was been found to be amplified in a majority o f breast cancers and 
this drug has been shown in clinical trials to prevent tumour growth and to have no 
deleterious side effects (Cornez and Picart, 2000). Tyrosine kinase receptors, once bound 
to a ligand, mediate their response via a number of pathways including the mitogen 
activated kinase pathway (MAPK) and the extracellular response kinase (ERK) pathway. 
The endpoint o f these interlinked pathways are transcription factors which carry out the 
desired effect by binding to the promoter of target genes. One o f the transcription factors 
targeted by these pathways is the AP-1 complex proteins Jun and Fos. As shown earlier 
many o f the inducible MMP genes have AP-1 transcription factor binding elements within
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their promoter and therefore inhibition of the tyrosine kinase receptors may not only lead 
to the cessation of cell growth but also to the indirect inhibition of MMPs.
1.8.4 Novel approaches to MMP Inhibition
Another rapidly expanding area of cancer therapeutic research is the design of 
specific transcription factor inhibitors in order to prevent the transcription of target genes. 
This can be achieved in a number of ways including conventional drug design procedures 
and also by the development of triple helix oligonucleotide inhibitors. The triple helix 
oligonucleotide inhibitors act by binding to transcription factor DNA sequences within the 
target genes promoter thus preventing the binding of the transcription factor protein.
The construction of antisense nucleotides has also been shown to be a successful 
method in the inhibition of MMPs. Antisense oligonucleotides to matrilysin have been 
tested on two human colon cancer cell lines, CaR-1 and WiDR. The antisense 
oligonucleotide inhibited both the secretion of matrilysin and also inhibited in vitro 
metastasis (Miyazaki et al., 1999).
Ribozyme technology has also been investigated as a possible MMP inhibitor and 
recently an MMP-9 ribozyme has been evaluated in an experimental model. The 
ribozyme works on the basis of cleaving MMP-9 mRNA transcripts thus preventing the 
translation of MMP-9 mRNA into protein (Peng et al., 1997).
1.8.5 Drug delivery mechanisms
Although many new drugs have been shown to be potent inhibitors of MMP 
synthesis and enzymatic activity in vitro, their effects in vivo require more in depth 
analysis. One of the main barriers o f successful in vivo treatment is the method of drug 
delivery. MMPs, as have been shown, are not only involved in matrix remodeling but 
also have a host of other functions in normal biological processes and thus it is essential 
that drugs which inhibit their synthesis or activity be delivered to the areas in which the 
tumours are developing. Most novel drug-delivery systems have stemmed from work on
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new polymers, lipid vesicles, cyclodextrins, pro-drugs, and viral vectors. For example, 
some polymer systems can be rendered "smart", i.e. sensitive to a tissue environment. 
Thus, a drug-polymer complex can be designed to undergo a conformational change or 
enzymatic breakdown that results in release of the active drug only under certain 
conditions. The liposome is another construct that serves as an envelope for active drug 
particles and can, like polymers, deliver high concentrations o f drugs to infected or 
neoplastic tissue. Once these technologies have become more refined, they can perhaps 
be tailor made for the delivery o f MMP inhibitors to tumour sites within the body thus 
reducing the risk of undesirable side effects.
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1.9 Summary
The MMP family continues to expand with the recent cloning of new MT-MMP 
family members, MMP-26 (matrilysin-2/endometase) and MMP-27 (epilysin). Although 
the enzymatic properties of the MMPs are becoming clearer the complex regulation of this 
large and multifunctional group of endopeptidases in vivo is poorly understood. An 
understanding of how the MMPs are regulated at the transcriptional and protein level is 
essential for predicting what happens during tumourigenesis. To date, individual MMPs 
have been shown to be of prognostic significance in several tumour types. Precise 
information on which MMPs are critical in invasion and knowledge o f their regulatory 
mechanisms may help in the development o f more effective MMP inhibitors. In the case 
of matrilysin, several reports have shown that this MMP is involved in the tumourigenesis 
and progression o f many cancer types, in particular, in breast and colon cancers and it has 
also been shown to be involved in the early stages of tumour development. Therefore, 
matrilysin presents itself as an excellent therapeutic target and inhibitors directed against 
its transcription or proteolytic activity may serve as potent anti-tumourigenic/anti- 
metastatic agents.
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1.10 Thesis Overview
The research presented in this thesis examines the regulation of matrilysin 
(MMP-7) in colon cancer and leukaemia and has been divided into three main chapters.
• Chapter 3:
A panel of human colon cell lines was used to examine the effects of several cytokines 
on matrilysin expression at the transcriptional and protein levels. Matrilysin 
expression was analysed via reverse transcription polymerase chain reaction (RT- 
PCR) and western blot analysis. Human matrilysin promoter (2.3 kbp and 335 bp) 
luciferase reporter constructs were also employed. The presence o f silencers and 
enhancers within the murine matrilysin gene was also examined.
• Chapter 4:
A thorough investigation into the mechanisms of EGF mediated matrilysin 
upregulation was carried out. The effects of EGF treatment on PEA3 transcription 
factors was analysed using artificial promoter constructs, immunoblot analysis and 
elctrophoretic mobility assays (EMSA). The effect of EGF on E-cadherin and p- 
catenin on PEA3 transcription factor and matrilysin levels was also examined.
• Chapter 5:
The expression and regulation of matrilysin in leukaemia was investigated and the 
potential role of matrilysin in leukaemia invasion and metastasis was also addressed. 
The levels of MMP-2, MMP-9, TIMP-1, TIMP-2 and TIMP-3 were investigated with 
respect to their importance in leukaemia invasion.
In order to provide clarity this thesis has been divided into seven chapters. 
Chapter 1 serves as a general introduction to the MMP family. There is a common 
materials and methods section (Chapter 2) and bibliography (Chapter 8 ). Chapters 3, 4 
and 5 each have their own introduction, results and discussion sections while chapter 6  
provides an overall summary of the thesis.
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Chapter 2 
M aterials and Methods
2.1 Materials
All general purpose chemicals and reagents used in experimental work were of analytical grade 
and were purchased from Sigma-Aldrich Chemical Company; Dublin, Ireland, BDH 
Chemicals Ltd., Poole, Dorset, England and Riedal De Haen AG, Seelze, Hannover, Germany.
Cell culture medium and transfection reagents (Lipofectamine, Cellfectin and Superfect) were 
obtained from Sigma-Aldrich, Dublin, Ireland, Gibco BRL, Paisley, Scotland and Qiagen, 
Crawley, West Sussex, England.
Foetal calf serum was supplied by Sigma-Aldrich, Dublin, Ireland.
Disposable plastics for animal cell and microbiological culture, and 96-well plates were 
obtained from Sarstedt, Sinnottstown Lane, Drinagh, Co. Wexford, Ireland.
Human matrilysin promoter constructs, artificial promoter constructs and the matrilysin anti­
body were kindly donated by Prof. Lynn Matrisian, Vanderbilt University, Nashville, TN, 
USA.
HCA7 human adenocarcinoma colon cell line was a gift from Dr. Susan Kirkland, University 
of London, England.
BHK cells transfected with the human MMP-9 cDNA (BHK 92) were obtained from Prof. 
Dylan Edwards, University of East Anglia, Norwich, England.
All other cell lines used in this study were obtained from the European Collection of Animal 
Cell Cultures (ECACC), Porton Down, Salisbury, Wiltshire, England.
TIMP primers were obtained from Hugh McGlynn Ph.D., University of Ulster at Coleraine, 
Northern Ireland.
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PBS tablets were purchased from Oxoid Ltd., Basingstoke, Hampshire, England.
Taq polymerase and other components of RT-PCR reactions were purchased from Sigma 
Aldrich, Dublin, Ireland and Promega Corp., Southampton, Hampshire, England.
Anti-MMP-9, MMP-2 and TIMP antibodies were purchased from Chemicon, Temecula, 
California, USA and Calbiochem, Beston, Nottingham, England.
X-ray film, film developer and fixative were purchased from Sigma-Aldrich, Dublin, Ireland.
L-glutamine, trypsin, penicillin/streptomycin were purchased from Sigma-Aldrich, Dublin, 
Ireland.
The BCA reagent for protein determination and Supersignal West ECL detection kit were 
obtained from Pierce Chemicals, Rockford, Illinois, USA.
Cytokines were obtained from, Promega, Southampton, England, Sigma Aldrich, Dublin, 
Ireland and Roche-Boehringer Mannheim, Lewes, East Sussex, England.
Biocoat Matrigel invasion chambers were obtained from Collaborative Biomedical Products, 
Becton Dickinson Labware, 2 Oak Park, Bedford, MA 01730, USA.
RNA ISOLATOR was obtained from Genosys Biotechnologies, Cambridge, England.
Specific primers for PCR were made to order by MWG-Biotech, Ebersberg, Germany,
Qiagen kit for preparation of DNA purchased from Qiagen, Crawley, West Sussex, England.
Equipment used is outlined in the relevant methods section.
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2.2 Methods
2.2.1 Cell culture methods
All cell culture techniques were performed in a sterile environment using a Holten 
HB255 laminar air flow cabinet. Cells were visualised with an Olympus CK2 inverted phase 
contrast microscope.
2.2.1.1 Culture of adherent cell lines
SW480 (ATCC Cat# CCL-228), SW620 (ATCC Cat# CCL-227), HCT116 (ATCC 
Cat# CCL-247), LoVo (ATCC Cat# CCL-229), WiDR (ATCC Cat# CCL-218), HT1080 
(ATCC Cat# CCL-121 ), HCA7 and BHK92 cell lines were maintained in Dublecco’s 
modification of Eagles medium (DMEM) supplemented with 5% (v/v) [DMEM S5] foetal 
bovine serum (FBS), 2 mM L-glutamine, 1 mM N-[2-Hydroxyethl]piperazine-N’-[2- 
ethanesulfonic acid] (HEPES) and 1 unit/ml penicillin and l|jg/ml streptomycin (see table 2.1 
for colon cell line characteristics). All cells were cultured in 25cm2 or 75 cm2 tissue culture 
flasks. As these were all strongly adherent cell lines, trypsinisation was required for harvesting 
cells prior to subculturing. For trypsinisation, the growth medium was aspirated and the flask 
rinsed with 3 ml of phosphate buffered saline (PBS) to remove any residual FBS which 
contains a trypsin-inhibitor (a 2-macroglobulin). 2  ml of fresh trypsin ethylenediamine 
tetracetic acid (EDTA) (0.025% (w/v) trypsin with 0.02% (w/v) EDTA in 0.15 M PBS, pH 
7.4) was then placed in each flask and the flask incubated at 37°C for 5-10 min or until all the 
cells had detached from the surface. The cell suspension was removed to a sterile universal 
container containing 5 ml growth medium and centrifuged at 2000 rpm for 5 min. Cells were
5 6 ' • 2resuspended in culture medium at 2 x 1 0  - 1 x 1 0  cells/ml, using 20 ml of medium per 75cm 
culture flask and 10 ml per 25cm2 flask. All cell lines were incubated in a humid, 5% (v/v) 
CO2 atmosphere at 37°C in a Heraeus cell culture incubator.
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Cell line Ras myc p53 fos ros src Comments
SW480 + + + + Established from a primary 
adenocarcinoma in the colon. Male 
patient, 50 years, classified as Dukes’ B
SW620 + + + + The cell line was derived from the 
metastasis (lymph node) of the same 
tumour from which SW480 was derived. 
Male patient, 51 years, classified as 
Dukes’ C
WiDr + + + + Cell line is derived from the HT-29. 
Female patient, 78 years old
LoVo + + + + LoVo was initiated in 1971 from the 
fragment of a metastatic tumour nodule in 
the left supra clavicular region of a 56 year 
old Caucasian male patient with a 
histologically proven diagnosis of 
adenocarcinoma of the colon
HCT116 + + + + + + Colorectal carcinoma isolated from a male 
patient
Table 2.1 Colon cancer cell lines used in the study. Positive expression of oncogene products in the cell is 
denoted by the + sign while expression of oncogene products not detected in the cell lines are denoted by a -
2.2.1.2 Culture of cells in suspension
K562 (ATCC Cat# CCL-243) and HL-60 ( ATCC Cat # CCL-240) leukaemia cell 
lines were maintained in DMEM supplemented with 10% (v/v) FBS, 1 mM HEPES, 2 mM L- 
glutamine, 1 unit/ml penicillin and l(j.g/ml streptomycin (see table 2.2). Cultures were 
maintained at densities o f 2.5 x 105 cells/ml, in 75 cm2 flasks. Cultures were passaged by
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diluting the cells with media. The cells were incubated in a humid 5% CO2  atmosphere at 
37°C.
Characteristics K562 HL-60
Tissue Chronic Myeloid Leukaemia (CML) 
: Bone marrow
Acute Promyelocytic Leukaemia 
(AML) : Peripheral blood : 
Promyeloblast
Morphology Lymphoblast Myeloblastic
Tumouri genic Yes, in nude mice Yes, form colonies in semi solid 
media and produce subcutaneous 
myeloid tumours in mice
Oncogene N/A Myc +
Comments The K562 cell line was established 
from the plueral effusion of a of a 53 
year old caucasian female with 
chronic myelogenous leukaemia in 
terminal blast crises. The cell 
population has been characterised as 
highly undifferentiated and of a 
granulocytic series. K562 blasts are 
multipotential, haematopoietic cells 
that spontaneously differentiate
HL-60 is a promyelocytic cell line 
from peripheral blood leukocytes. 
HL-60 cells spontaneously 
differentiate and differentiation 
can be induced by a number of 
compounds including TPA, 
DMSO, actinomycin D and 
retinoic acid. The cells exhibit 
phagocytic activity and 
responsiveness to chemotactic 
stimuli
Table 2.2 Characterisation of the K562 and HL-60 human leukaemia cell lines 
2.2.1.3 Cell counts
Cell counts were performed using a Neubauer haemocytometer slide. Trypan blue 
exclusion dye was routinely used to determine cell viabilities. 2 0 jal trypan blue was added to
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100(il cell suspension, and the mixture left to incubate for 2 min. A sample of this mixture was 
added to the counting chamber of the haemocytometer and the cells visualised by light 
microscopy. Viable cells excluded the dye and remained clear while dead cells stained blue. 
The number of cells was calculated as follows (Average number of viable cells) x 1.2 (dilution 
factor) x l x l 0 4 = viable cells/ml.
2.2.1.4 Recovery and storage of cells
Long term storage of cells was achieved by storing the cells in liquid nitrogen and 
maintaining them in a cryofreezer (supplied and serviced by Cooper Cryoservice Ltd, Dublin, 
Ireland). Cells to be stored were centrifuged and the resulting cell pellet resuspended at a 
concentration of 1 x 106 cells/ml in FBS containing the cryopreservative dimethylsulphoxide 
(DMSO) at a final concentration of 10 % (v/v). 1 ml aliquots were transferred to sterile 
cryotubes, and frozen first at -20°C for 30 min, then overnight at -80°C and then immersed in 
the liquid nitrogen. Cells were recovered from liquid nitrogen by thawing rapidly at 37°C and 
transferring to a sterile universal tube containing 5 ml growth media. The cells were 
centrifuged at 2000 rpm for 5 min, resuspended in fresh medium, transferred to culture flasks 
and incubated at 37°C in 5% CO2.
2.2.1.5 Cytokine and TPA treatment of cells in culture
Cells were routinely cultured for at least 2 passages prior to cytokine and/or 12-0- 
tetradecanoyl-phorbol-13-acetate (TPA) treatment. For these experiments, adherent cells were 
grown until approximately 70% confluent after which the growth medium was decanted and 
the cells rinsed with sterile PBS. 8  ml of fresh serum free medium was then added to each 
75cm2 flask. Suspension cells were washed 3 times in PBS and seeded at lxlO6 cells/ml in 8 
ml of serum free media in a 75cm2 flask. Both adherent and suspension cells were left in 
serum free media overnight at 37°C. The following day, fresh serum free medium was added 
and the flasks were supplemented with one of the following cytokines or TPA (final 
concentrations in brackets): insulin like growth factor I and II (IGF-I and IGF-II) (100 ng/ml),
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epidermal growth factor (EGF) (50 ng/ml), interleukin 6  (IL-6 ) (100 units/ml), basic fibroblast 
growth factor (bFGF) (50ng/ml) and TPA (100 ng/ml). The cells were then returned to the 
incubator for 8  hours. 2, 4, 6 ,12  and 24 hour time points were also examined and 8  hours was 
found to be the optimal time period for RNA. The cells were harvested for total ribonucleic 
acid (RNA), or for 24-72 hr after which the conditioned medium was collected and 
MMP/TIMP expression analysed.
2.2.2 RNA isolation
RNA is easily degraded by the ubiquitous RNase enzymes. These enzymes are 
resistant to autoclaving but they can be inactivated by treatment with the chemical 
diethylpyrocarbonate (DEPC) when it is added to solutions at a final concentration of 0.1 %. 
Solutions containing amines such as Tris cannot be DEPC-treated directly as the DEPC is 
inactivated by these chemicals. These solutions were prepared in DEPC-treated water. All 
other solutions for RNA work were DEPC-treated, and gloves and disposable sterile plastics 
used at all times. Any glassware used was baked overnight at 200°C. The procedures must be 
carried out quickly and on ice to help prevent degradation of RNA by endogenous RNases.
2.2.2.1 RNA extraction from cultured cells
Total RNA was isolated from equal numbers of cells using RNA ISOLATOR 
(Genosys/Sigma Aldrich, Dublin Ireland), which is a modified version of the single step 
method by acid guanidinium thiocyanate-phenol-chloroform extraction. The cultured cells 
were lysed directly in the culture flask by adding 2 ml of reagent per 75 cm2 flask and 
incubating for 5 min at RT to permit the complete dissociation of nucleoprotein complexes. 
Phase separation was then achieved by adding 0.2 ml of chloroform per 1 ml of reagent, 
shaking for 15 s and incubating at RT for 2-15 min. The resulting mixture was centrifuged at 
12,000 rpm for 15 min. Following centrifugation, the mixture separates into a lower red, 
phenol-chloroform phase, an interphase, and a colour-less upper aqueous phase. RNA remains 
exclusively in the aqueous phase whereas DNA and proteins partition to the interphase and
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organic phase respectively. The aqueous phase was transferred to a fresh tube and the RNA 
precipitated by adding 0.5 ml of isopropanol per ml of reagent used. Samples were incubated 
at RT for 10 min and centrifuged at 12,000 rpm for 10 min. The RNA pellet was then washed 
once with 75% ethanol, allowed to air dry and dissolved in sterile Tris-EDTA (TE), pH 8.0 (10 
mM Tris-HCl; 1 mM EDTA). RNA samples were stored at -80°C.
2 2 2 .2  RNA analysis by gel electrophoresis
To check that the RNA isolated was intact and had not been degraded, samples were 
run on 1% agarose gels. The gels were prepared by boiling the agarose in IX Tris Borate 
EDTA (TBE) (0.08 M Tris-HCl pH 8.0: 0.04 M boric acid; 1 mM EDTA). Once cooled to 
hand-hot, the gel was cast into the Hybaid Horizontal Gel Electrophoresis system. The RNA 
samples (5 (0,1) were prepared for electrophoresis by mixing with 15(il sample buffer (50% (v/v) 
formamide; 8.3 % (v/v) formaldehyde; 0.027 M 3-[N-Morpholino]propanesulfonic acid 
(MOPS), pH 7; 6.7 mM sodium acetate; 0.67 mM EDTA) and 3(j,l loading buffer (50 % (v/v) 
glycerol; 1 mM EDTA; 0.4 % (w/v) bromophenol blue; 1 f-ig/(-il ethidium bromide) and the 
sample heated for 10 min at 65°C prior to loading on the gel. The gel was run at 100V in IX 
TBE. As ethidium bromide was included in the loading buffer, there was no need for further 
staining and the gel could be visualised directly on a UV transilluminator. The presence of 2 
strongly staining bands, representing the 28 S and 18 S ribosomal subunits, signified intact 
RNA. Degradation could be seen as a smear running down the length of the gel.
2.2.3 Reverse transcription polymerase chain reaction (RT-PCR)
The PCR reaction has emerged as a powerful tool for amplifying small quantities of 
deoxyribonucleic (DNA) for analysis. RT-PCR is a modification of the technique which 
allows analysis of small quantities of specific messenger RNA (mRNA). Total RNA is primed 
with oligo dT’s and then converted to complementary DNA (cDNA) using reverse 
transcriptase. cDNAs of interest are then amplified in the PCR by inclusion of the appropriate 
primers. Details of the primers used are shown in table 2.3. The PCR used was semi-
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quantitative as a constitutively expressed gene, (3-actin, was also amplified from the same RNA 
sample along with the MMP or TIMP target. This acted as an internal control and, by 
calculating the ratio of MMP to (3-actin, relative amounts of the targets could be determined 
and compared to different reactions.
2.2.3.1 Reverse transcription
lpg of total RNA (prepared as outlined in section 2.2.2.1) was mixed with 0.5pg 
oligo dT primers and the mixture brought to a final volume of 5 fil with sterile water. This 
priming reaction was incubated at 70°C for 10 min. To this was added 4jj,1 5X transcription 
buffer (supplied with the reverse transcription enzyme by the manufacturer), 2f.il 100 mM 
dithiothretiol, lp l RNasin, lf.il of a mix of dATP, dCTP, dGTP and dTTP each at a 
concentration of lOmM, 6 (il sterile water, and lp l of Moloney murine leukaemia virus reverse 
transcriptase (MMLV-RT). The reaction mixture was incubated at 37°C for 1 hr before being 
heated to 95°C for 2 min to inactivate the enzyme. The resulting cDNA was stored at 4°C until 
required for PCR.
2.2.3.2 Polymerase Chain Reaction
A 45 fil PCR mix was prepared by adding 5 fil of 10X reaction buffer (supplied with 
the Taq polymerase enzyme), 1 pi each of dATP, dCTP, dGTP, and dTTP, each at a 
concentration of lOmM, lp l of the forward and reverse primers required in the reaction, 0.5 f-il 
Taq DNA polymerase and sterile water to bring the volume to 45 jj!  into a reaction tube. To 
this reaction mixture was added 5 pi of cDNA prepared as in section 2.2.3.1 and the mixture 
overlaid with 50 pi mineral oil. The tube was placed on a Hybaid thermocycling machine 
programmed with an initial incubation of 93 °C for 3 min, followed by 30 cycles consisting of 
the following sequential steps : 93°C for 90 s, annealing temperature as in Table 2.3 for 90 s 
and 72°C for 3 min. The PCR products were then removed from under the oil and placed in 
fresh tubes. 15pl amounts were run on 2 % agarose gels as described in section 2 .2 .3.3 below.
46
Target Primer sequence Product
size
Temp
r o
Reference
MMP-2 5’ TGA CAT CAA GGG CAT TTC AGG AGC3’ 
3’ GTC CGC CAA ATG AAC GGT CCT TG 5’
180bp 53 Shimonovitz 
et al., 1994
MMP-7 5’ TGT ATC CAA CCT ATG GAA ATG 3’ 
3’CAT TTA TTG ACA TCT ACG CGC 5’
341 bp 47 Witty et al., 
1994
MMP-9 5 ’GGT CCC CCC ACT GCT GGC CCT TCT ACG GCC 3’ 
3’ GTC CTC AGG GCA CTG CAG GAT GTC ATA GGT 5’
640bp 54 Onisto et al., 
1993
TIMP-1 5’TGC ACC TGT GTC CCA CCC CAC CCA CAG ACG 3’ 
3’GGC TAT CTG GGA CCG CAG GGA CTG CCA GGT 5’
551 bp 53 Onisto et al., 
1993
TIMP-2 5’TGC AAT GCA GAT GTA GTG ATC AGG G 3’ 
3’TGC TTA TGG GTC CTC GAT GTC GAG A 5’
552bp 60 Stetler- 
Stevenson et 
al., 1990
TIMP-3 5’CTG TGC AAC TTC GTG GAG 3’ 
3’ TCG GTA CCA GCT GCA GTA 5’
250bp 55 Apte et al., 
1994
p- actin 5’ TCA GGA GGA GCA ATG ATC TTG A 3’
3’ GAA ATC GTG CGT GAC ATT A AG GAG A AG CT 5’
3 83bp 47-55 Nakajima- 
Iijima et al., 
1985
Table 2.3 Details of the primers used for RT-PCR experiments. The primers were chosen so that they amplified 
sequences specific to the particular gene and did not cross react with any other MMPs or TIMPs. 'Hie primers were 
chosen to span an intron within the gene which meant that any amplification of genomic DNA rather than cDNA 
would result in larger sized products than those expected.
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2.2.3.3 Agarose gel electrophoresis
An agarose gel was prepared by boiling the appropriate quantity of agarose in 100 ml 
of IX TBE buffer, pH 8.2 (0.08 M Tris; 0.04 M boric acid; 1 mM EDTA). The percentage gel 
used depended on the sizes of the DNA being visualised with a lower percentage gels (0.6 - 
1.2%, w/v) being used for visualising large sized DNA fragments (e.g. over 2Kb) and higher 
percentage gels (2-3%, w/v) reserved for small DNA fragments (e.g. 200-500bp). Once cooled 
to hand-hot, 1 |il of 1 0 mg/ml ethidium bromide solution was added to the gel which was then 
cast into the Hybaid Horizontal Gel Electrophoresis system.
Samples for electrophoresis were prepared by mixing with a suitable quantity of 6 X 
gel loading buffer (40% w/v sucrose; 0.25% w/v bromophenol blue). Typically 1 2 .5 (0,1 of the 
sample was mixed with 3 (d of loading buffer and the samples loaded into the wells of the gel. 
The gel was run at 100V in IX TBE. Electrophoresis was completed when the blue loading 
dye had run to within 0.5cm of the bottom of the gel. The gel was visualised by placing on a 
UV transilluminator. The images of the gels were saved on disc using a Pharmacia Gel 
Documentation System.
2.2.4 Bicinchoninic acid (BCA) protein microassay
In this assay, C u11 reacts with the protein under alkaline conditions to give Cu+, which 
in turn reacts with BCA to give a coloured product. Two separate reagents were supplied in 
the commercially available assay kit (Pierce Chemicals): A, an alkaline bicarbonate solution 
and B, a copper sulphate solution. Working solution was prepared by mixing 1 part reagent B 
with 50 parts reagent A. 200jil of this solution was added to 10)il test sample or protein 
standard in wells of a microtitre plate. The plate was incubated at 37°C for 30 min. The 
absorbance of each well was read at 560 nm using a microtitre plate reader (Rosys Anthos 
2010). Protein concentrations were determined from a bovine serum albumin (BSA) standard 
curve in the 0 - 1  mg/ml range.
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2.2.5 Protein electrophoresis
2.2.5.1 SDS Polyacrylamide Gel Electrophoresis (PAGE)
SDS- PAGE was performed using the discontinuous system described by Laemmli 
(1970) using 10% or 15% (w/v) polacrylamide gels as necessary. The 10% [volumes for 15% 
gel in brackets] resolving gels and 3% stacking gels were prepared as follows :
Resolving G el: 3.3 ml [5 ml] 30%(w/v) acrylamide containing 0.8%(w/v)
bisacrylamide
4 ml [2.3 ml] distilled water
2.5 ml [2.5 ml] 1.5M Tris, pH 8 .8  containing 0.4% (w/v) SDS 
0.1 ml [0.1 ml] 10% (w/v) SDS
0 .1  ml [0 .1  ml] 1 0 % (w/v) ammonium persulphate (freshly prepared) 
0.005 ml [0.005 ml] TEMED
Stacking G e l: 0.33 ml 30% acrylamide solution
1.4 ml distilled water
0.25 ml 0.5M Tris, pH 6 .8  containing 0.4% (w/v) SDS,
0.02 ml 10% SDS
0 . 0 2  ml 1 0 % ammonium persulphate (freshly prepared)
0.002 ml TEMED
Samples were mixed with sample buffer (2% (w/v) SDS; 0.08M Tris, pH 6 .8 ; 10% 
(w/v) glycerol; 0.2% (w/v) Coomassie Brilliant Blue). For western blot analysis a similar 
sample buffer was used with the exception that p-mercaptoethanol at a final concentration of 
1M was used. The gel was electrophoresed in running buffer, pH 8.3 containing 0.025M Tris, 
0.192M glycine and 0.1% (w/v) SDS at 20 milli amps (mA) per gel using an Atto vertical 
mini-electrophoresis system until the blue dye front reached the bottom of the gel.
49
2.2.S.2 Staining with Coomassie Brilliant Blue
Gels were stained for 2 hr in 0.5% (w/v) Coomassie Brilliant Blue in acetic acid : 
isopropanol: H2O ( 1 : 3 : 6 ,  v/v/v), and destained overnight in the same solvent system.
2.2.6 Western Blotting
Samples were boiled for 10 mins prior to electrophoresis in sample buffer (0.5M Tris, 
pH 6 .8 , 0.4% SDS, 30% glycerol, 10 % SDS 0.12 mg/ml bromophenol blue and 1M P- 
mercaptoethanol). Following electrophoresis as outlined in section 2.2.5.1, the gel was soaked 
for 30 min in cold transfer buffer (0.025 M Tris, pH 8.3; 0.192 M glycine; 20% (v/v) 
methanol). Nitrocellulose and eight sheets of Whatman filter paper were cut to the same size 
as the gel and soaked in transfer buffer. The proteins were transferred from the gel to the 
nitrocellulose for 1 hr at 100 V. After transfer, the blot was blocked for 1 hr in blocking 
solution [5% (w/v) dried milk dissolved in Tris Buffered Saline plus Tween [TBST] (10 mM 
Tris pH 8.0; 150mM NaCl; 0.05% (v/v) Tween 20)] and then incubated overnight at 4°C with 
primary antibody diluted, according to manufacturers instructions in blocking solution. The 
following day, blots were washed three times for 10 min each with TBST and then incubated 
for 3 hr gently shaking at room temperature (RT) with a suitable biotinylated secondary 
antibody diluted according to the manufacturers recommendations in TBST. After incubation 
the blots were washed again three times in TBST for 10 min and a suitable streptavidin horse 
radish peroxidase (HRP) labelled tertiaiy antibody, diluted to the manufacturers instructions, 
was added and the blots which were then incubated for 1.5 hr at RT. Bands were identified 
using enhanced chemiluminescence (ECL) which involved covering the blots in a luminol 
containing substrate. Light emitted from bands present on the blots was detected using 
photographic film (Kodak BioMAX). In some cases (MMP-2 and MMP-9) the bands were 
detected colourimetrically. This procedure typically employed a secondary antibody linked to 
HRP. The substrate for HRP used in this procedure, diaminobenzidine (DAB), was prepared 
by dissolving one 5 mg tablet in 15 ml TBS, filtering and adding fresh hydrogen peroxide 
(H2O2) to a final concentration of 0.024 % (v/v). This was poured directly onto the blots and 
the colour precipitate was allowed to develop.
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2.2.7 DNA preparation methods
2.2.7.1 Preparation of competent cells
Using a sterile loop, Escherischia coli DH5a were scraped from a frozen stock and 
inoculated into 5 ml of sterile IX medium (1% (w/v) tryptone; 0.5% (w/v) yeast extract; 1% 
(w/v) NaCl; lOmM MgCh; lOmM MgSC^). This culture was grown overnight with shaking 
(200 rpm) at 37°C. The following day, 1 ml of the DH5a culture was inoculated into 100 ml 
of fresh, sterile IX medium and the culture grown at 37°C at 200 rpm until the O.D. at 550nm 
had reached 0.6 (approximately 2-3 hr). The culture was then centrifuged at 2,500 rpm for 12 
min at 4°C. The pellet was resuspended in 33 ml o f frozen storage buffer (FSB), pH 6.4 
(lOmM CH3COOK, lOOmM KC1,45mM MnCl2 .4H20 , lOmM CaCl2 .2H20 , 3 mM HAC0 CI3, 
10% (v/v) glycerol). The resuspended pellet was left on ice for 10 min and then centrifuged at 
2500 rpm for 10 min at 4°C. The pellet was resuspended in 8 ml of cold FSB. DMSO was 
then added drop wise until it reached a final concentration of 3.5% (v/v). The mixture was left 
for 10 min at 4°C after which the same quantity of DMSO was again added. The cells were 
quickly aliquoted into 2 0 0  |il amounts in pre-chilled eppendorfs and flash-frozen in liquid 
nitrogen prior to storage at -80°C.
2.2 .7 .2  Transformation of competent cells
10 ng of the required DNA was placed in a sterile microfuge tube. To this was added 
lOOul of the competent cells which had been briefly thawed between the fingers. The tube was 
swirled gently and placed on ice for 30 min. The cells were then heat-shocked by placing the 
tube in a waterbath at 42°C for 90 s after which they were returned to ice for 2 min. 1 ml of 
sterile Luria-Bertrani (LB) medium, pH 7.5 (1% (w/v) tryptone; 0.5 % (w/v) yeast extract; 1% 
(w/v) NaCl ) was added to the tube and the cells incubated at 37°C for 1 hr with gentle 
agitation (200 rpm). The cells were centrifuged at 6,000 rpm for 1 min in a Hereaus Microfuge 
and the supernatant removed. The pellet was gently resuspended in 0.2 ml LB medium and 
then plated out on LB agar plus ampicillin (LB medium containing 1.5% (w/v) agar and 35 
|ig/ml ampicillin) plates which were incubated overnight at 37°C in an inverted position. Two
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plates were used for each transformation, 90% of the transformation (i.e. 180 fil) was spread on 
one, while 1 0 % (i.e. 2 0  jal) was spread on the second, to ensure single colonies were obtained. 
Two controls were included in every transformation experiment : (1) A mock transformation 
reaction that received no DNA, and (2) A transformation reaction that received a known 
amount of a standard preparation of plasmid DNA.
2.2.7.3 Minipreparation of plasmid DNA
Single colonies of bacteria from the transformed cells grown on the LB ampicillin 
plates were selected and each placed into sterile universal containers containing 5ml LB broth 
supplemented with 35(ig/ml ampicillin. These minicultures were grown overnight at 37°C and 
150 rpm. The following day, 1.5 ml of each of the cultures were transferred to sterile 
microfuge tubes and centrifuged at 1 0 , 0 0 0  rpm for 1 min after which the supernatants were 
aspirated. The pellets were resuspended in 100 fil of solution 1 (50 mM glucose; 25 mM Tris- 
HC1, pH 8.0; lOmM EDTA, pH 8.0) and vortexed. 200j_tl of solution 2 (0.2 M NaOH; 1% 
(w/v) SDS) was added to each tube and the tubes mixed by gentle inversion after which 150fil 
cold solution 3 (3M potassium acetate, pH 4.8) was added and the tubes were placed on ice for 
5 min. The tubes were then centrifuged for 5 min at 10,000 rpm after which the supernatants 
were carefully transferred to fresh tubes and the pellets discarded. 450 jal of phenol : 
chloroform : 2 M Trizma ( 1 : 1 : 1 ,  v/v/v) was then added to each tube and the mixtures 
vortexed and then centrifuged at 12,000 rpm for 10 min. The resultant aqueous phase was 
carefully removed to a fresh tube. 500 (_il of 100% ethanol was added and the mixtures let sit at 
RT for 10 min prior to being centrifuged at 10,000 rpm for 10 min. The supernatants were 
removed and the pellets washed twice with 70% (v/v) ethanol and then dried at 37°C before 
being resuspended in 25|_tl TE, pH 8  and stored at 4°C until ready to digest.
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2.2.1 A  Restriction digests
DNA was digested with restriction endonucleases for identification purposes or for 
linearization of plasmid. For minipreparation DNA, the digest mixture contained 5|il DNA,
2.5 |_d of 10X reaction buffer (supplied with each enzyme, by the manufacturer), 16.5 jul of a 
25 jug/ml solution of RNase A and 1 ul (15-20 units, approximately) of the appropriate 
restriction enzyme (details of plasmids and restriction enzyme used will be outlined in chapter 
3). For maxipreparation DNA, l|ig  of DNA was prepared in a reaction solution containing 
10X reaction buffer and lfil restriction enzyme. The digests were incubated at the appropriate 
temperature for the enzyme (usually 37°C) in a water bath for 3 hr.
2.2.7.5 Maxipreparation of plasmid DNA (Qiagen-tip 500 method)
A small aliqout of transformed bacteria glycerol stock containing the desired plasmid 
was inoculated into a starter culture of 5 ml LB medium containing 35|ig/ml ampicillin, grown 
for 8  hr with shaking at 37°C. The starter culture was diluted 1/500 into 500 ml LB medium 
containing 35ug/ml ampicillin and grown at 37°C overnight at 250 rpm. Next day the bacterial 
cells were harvested by centrifugation at 6,000 rpm for 15 min at 4°C. The pellet was 
resuspended in 10 ml of Buffer PI (50 mM Tris-HCl, pH 8.0; lOmM EDTA; 100fjg/ml RNase 
A) and 10 ml of Buffer P2 (200 mM NaOH; 1% SDS) added and mixed thoroughly by 
inverting the tube. After incubation at RT for 5 min 10 ml of chilled Buffer P3 (3 M potassium 
acetate, pH 5.5) was added, mixed by inversion and incubated on ice for 20 min. The samples 
then became quite viscous with a large amount of white protein precipitate. In order to remove 
as much of the precipitate as possible the samples were centrifuged twice (the sample was 
centrifuged at 13,000 rpm for 30 min at 4°C and the supernatant re-centrifuged at 13,000 rpm 
for 15 min at 4°C). Once the protein precipitate was removed the supernatant was applied to an 
equilibrated Qiagen tip-500 [add 10 ml Buffer QBT (750 mM NaCl, 50 mM MOPS, pH 7.0; 
15% isopropanol; 0.15% Triton X-100) and allow the column to empty by gravity flow], and 
allowed to enter the resin by gravity flow. The Qiagen tip was then washed with 2 x 30 ml 
Buffer QC (1 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol). The DNA was eluted with
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15 ml of Buffer QF (1.25M NaCl; 50 mM Tris-HCl, pH 8.5; 15% isopropanol) and 
precipitated by adding 0.7 volumes of RT isopropanol. The sample was centrifuged at 11,000 
rpm for 30 min at 4°C. The DNA pellet was washed with 5 ml of 70% ethanol at RT and 
centrifuged at 11,000 rpm for 10 min. The pellet was allowed to air dry and dissolved in 500|_d 
sterile TE.
2.2 .7 .6  Spectrophotometric analysis of nucleic acids
DNA or RNA concentration was determined by measuring the absorbance at 260 nm, 
the wavelength at which nucleic acids absorb light maximally A 50jig/ml preparation
of pure DNA has an absorbance of 1 unit at 260nm while a 40 fag/ml of pure RNA also has an 
absorbance reading of 1 at this wavelength. In order to calculate the concentration of DNA in 
samples the following calculation was used, ABS260nm x 50 x 100 (dilution factor, 5(il sample 
in 495 (il of H2O) = fjg/ml of DNA. To determine the concentration of RNA a similar formula 
was used, ABS260nm x 40 x 100 (dilution factor, 5fJ.l sample in 495 (il of H20 ) = fig/ml of RNA. 
The purity of an RNA or DNA preparation was determined by reading absorbances at 260 nm 
and at 280nm, the A,max for proteins and obtaining the ratio of these absorbances. Pure DNA 
with no protein contamination should have an ABS26o/ABS28o ratio of 1.8  while for pure RNA, 
the ratio is 2.0. Lower ratios indicate the presence of protein while higher ratios often indicate 
residues of organic reagents.
2.2.8 Transient transfection of human colon cell lines
2.2.8.1 Superfect (Qiagen) mediated transient transfections
The day prior to transfection the cells were seeded at lx l 05 cells/ml in 1 ml of growth 
medium in a 24 well plate and incubated overnight in a humidified incubator at 37°C with 5% 
CO2 . 1 j-ig of total DNA, including 10 ng of normalising plasmid DNA (pCHllO and 
pRenilla), was diluted in 150 (d of cell culture media containing no serum, proteins or
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antibiotics. The solution was mixed for 30 s and briefly spun in order to collect the contents to 
the bottom of the tube. 10 fil of Superfect was added to the tube and the contents vortexed for 
10 s. The samples were then incubated at room temperature for 30 min in order to allow DNA- 
liposome complex formation. While complex formation was taking place the media covering 
the cells was removed and the cells were washed once in 0.5 ml of PBS. After 30 min 1 ml of 
normal growth containing media was added to the reaction tube containing the transfection 
complexes and the contents were mixed by pipetting up and down twice. The contents of the 
tube were then added into three wells of a 24 well plate ( -  333 p,l each). The cells were then 
incubated with the complexes for approximately 6  hr. Afterwards the media containing the 
complexes was removed and the cells were then fed with 500 jal of fresh serum containing 
media and allowed to recover overnight. The following day the cells were serum starved for at 
least 12 hr prior to cytokine treatment. Subsequently the cells were treated with cytokines of 
interest (concentrations outlined in section 2 .2 .1.5) for 2 - 8  hr (depending on plasmid used) 
before being lysed for luciferase analysis (see section 2.2.8 .3/4/5).
2 2 .8 .2  I n  s itu  assay of P-galactosidase
During the transfection optimisation procedure, the plasmid pCHllO, encoding for 
the P-galactosidase enzyme, was used, as its presence could be easily detected and 
subsequently used as an assessment of transfection efficiency. The enzyme activity of P- 
galactosidase can be detected in situ, on the plate, using the synthetic substrate 5-Bromo-4- 
chloro-3-indolyl-P-D-galactopyranoside (X-gal). 48 hr following transfection, cells were 
washed twice with PBS and then fixed with 5 ml fix solution (0.2% (v/v) glutaraldehyde; 
0.02M phosphate buffer, pH 7.3; 0.004M EGTA; 0.002 M MgCl2) for 10 min at RT. This step 
was repeated once. The cells were then washed twice for 10 min each with 5 ml rinse solution 
(0.02 M phosphate buffer, pH 7.3; 0.002M MgCl2; O.lmg/ml sodium deoxycholate; 0.2 fil/ml 
NP-40) before 1 ml of stain solution (1 mg/ml X-gal; 1.65 mg/ml potassium ferricyanide (K^Fe 
(CN)6) ; 1.65 mg/ml potassium ferro-cyanide K4 Fe (CN)r, in rinse solution) was added to each 
well and the plates returned to the incubator overnight. The following day, the cells were 
examined under the microscope. Cells that stained blue produced p-galactosidase and were 
therefore successfully transfected. Untransfected cells remained clear.
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2.2.8.3 Cell Lysis
A commercial lysis buffer (Roche-Boehringer-Mannheim) used in P-galactosidase 
and luciferase assays was supplied as a 5x concentrate and prior to use this was prepared by 
diluting 1 part lysis buffer with 4 parts distilled water. Media was aspirated from the cells 
which were then washed once in PBS. Lysis buffer was then added to each well in the plate 
(100 (J.1 for 24 well plate). The plates were then placed on a rocking platform for at least 15 
min to allow for complete lysis of the cells.
2.2.8.4 Luciferase assays
After lysis cellular debris were spun out in a microtitre plate centrifuge and the 
resultant lysate was checked for desired enzymatic activity. The promoter constructs used 
contained a luciferase (Photinus pyralis) reporter gene and the level of luciferase within the 
extracted cell lysate was determined by analysing light emission on the addition of luciferin, 
ATP and 0 2 ( Dual-Luciferase™ Reporter Assay System, Promega). The supplied luciferase 
assay reagent was resuspended in 10 ml of luciferase assay buffer and 50 |j.l was pre-dispensed 
into a luminometer tube or luminometer assay plate. The luminometer (Labsystems 
Luminoskan RS) was programmed to perform a 2 second pre-measurement delay followed by 
a 10 second measurement period for each reporter assay. 20 fj.1 of the cell lysate was 
transferred into the luminometer tube/well containing the luciferase assay reagent. The 
contents were mixed by pipetting prior to the initiation of the measurement period. After the 
measurement period had elapsed the reading on the luminometer was noted. A number of 
methods are available which allow for the normalisation of the transfection efficiency between 
each transfection. One of the simplest means of recording transfection efficiency was through 
the co-transfection of a second plasmid which encodes a different luciferase gene, in the case of 
the Dual-Luciferase™ assay this second plasmid contained the Sea pansy (Renilla) luciferase 
gene. The system works through the quenching of the first reaction using the Stop & Glo™ 
reagent and the initiation of the second reaction with a different substrate, for Renilla this was
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coelenterazine and 0 2. After the initial reading the background reading was measured through 
the addition of the Stop & Glo™ reagent (supplied in Promega Kit as a 5 Ox concentrate which 
was diluted to lx  with luciferase assay buffer lx). 50 pi of the Stop & Glo™ reagent was 
added to the vial and the background measurement was performed. Once the reading was 
noted the next set of reactions were carried out.
2.2.8.5 p-galactosidase assay
Initial experiments did not use the Dual Luciferase assay and therefore in order to 
normalise luciferase values the pCHl 10 plasmid which encodes P-galactosidase was used. For 
each sample to be assayed mix 3 pi of lOOx Mg solution (0.1M MgCl2 and 4.5M p~ 
mercaptoethanol), 6 6  pi of lx  ONPG (o-nitrophenyl-p-D-galctopyranoside) ( 4 mg/ml ONPG 
in 0.1M sodium phosphate, pH 7.5 which is made by mixing 41 ml of 0.2M Na2HP0 4 . 2H20 , 
9 ml of 0.2M NaH2P0 4 .2 H20  and 50 ml H20), 30 pi of cell extract and 201 pi of 0.1M sodium 
phosphate. The reactions were incubated for 30 min at 37°C until a faint yellow colour had 
developed. The reactions were stopped by adding 500 pi of Na2C0 3  to each tube. The optical 
density of each of the samples was then read at 420nm. P-galactosidase enzyme (Boehringer 
Mannheim) was used as a positive control for the reaction and also as a standard in order to 
determine the amount of enzymatic activity.
2.2.9 Cloning of PCR products
This protocol is based on the commercial PCR-Script™ Amp cloning kit which was 
supplied by Stratagene. The pPCR-Script plasmid (see appendix 1) allows the blunt ligation of 
PCR products into its multiple cloning site. In order to identify potential clones the plasmid 
also allows for blue white screening where white colonies indicate clones that are positive for 
insert. This is due to the disruption of the lac Z gene which encodes p-galactosidase.
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2.2.9.1 Purification of PCR products
50 pi PCR reactions were carried out according to conditions described in section
2.2.3.2 with the exception that Pfu, a high fidelity polymerase was used instead of Taq. 50 pi 
of a DNA binding solution supplied by Stratagene was then added to the PCR reaction tube. 
The contents of the PCR tube were then transferred to a purification column. The column was 
spun in a microfuge for 30 s at maximum speed (13,000 rpm). During this stage the DNA is 
bound to the fibre matrix within the column while all other contaminants pass through. The 
DNA was then washed twice with an ethanol containing buffer (Stratagene) by adding 750 pi 
of wash buffer to the fibre matrix and spinning for 30 s at maximum speed. After the second 
wash, 50 pi of elution buffer was added to the column which was then incubated for 5 min at 
RT. Afterwards the column was placed in a microcentrifuge and spun at maximum speed for 
30 s. The eluted DNA was stored at 4°C until required.
2.2.9.2 Ligation of the PCR products into pPCR-Script Amp
The concentration of DNA after PCR can be found by using the method outlined in 
section 2.2.7.6. The PCR cloning procedure requires a high ration of insert to vector for 
ligation. For sample DNA a range of 40: 1 to 100 : 1 is recommended. The following 
equation was used to optimize conditions for the insert.
X ng of PCR product = (number of bp of PCR product) (10 ng of pPCR Script cloning vector)
2961 bp of pPCR Script cloning vector
where X is the quantity of PCR product (in nanograms) required for a 1:1 insert to vector molar 
ratio. The following table provides examples of optimal insert to vector molar ratios calculated 
using the above equation.
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Size of PCR produci (bp) Quantity of PCR product required (ng) 
40x-100x
250 33-85
500 67-169
750 101-253
1000 135-338
1500 202-506
2000 270-675
3000 405-1013
To prepare the ligation reaction the following components were added in order to a 
0.5ml microcentrifuge tube
1 pi of pPCR-Script Amp cloning vector (10 ng/pl)
1 pi ofPCR-Script 1 Ox reaction buffer 
0.5 pi of 10 mM ATP
2-4 pi of the blunt ended PCR product (40x-100x range)
1 pi of Srf I restriction enzyme (5 U/pl)
1 pi of T4 DNA ligase (4 U/pl)
Distilled water to a final volume of 10 pi
The reaction was mixed gently and left for 1 hr at RT. The ligation reaction was then 
heated to 65°C for 10 min. The mixture was kept at 4°C until transformation. The 
transformation procedure is similar to that outlined in section 2 2 .1 2  with the exception that 
the LB Amp plates were spread 100 pi of a 2% X-gal and 100 pi of lOmM LPTG 30 min prior 
to spreading of the bacterial colonies, thus allowing for blue white screening. When the pPCR- 
Script plasmid ligates with an insert it’s ability to process X-gal is disrupted as it no longer can 
encode for a functioning P-galatosidase enzyme. Therefore positive clones can easily be 
distinguished from negative clones which grow as blue colonies as they still retain their ability 
to process X-gal.
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Positive clones (white colonies) were picked and grown over night at 37°C in LB Amp 
broth (50 ng/ml). The following day colonies were mini-prepped according to section 2.2.7.3. 
The plasmid DNA was then assessed for insert content by restriction digest which is outlined in 
section 2.2.7.4. Restriction enzymes used to cut out the insert were Xho I and Sac I. Once 
positive clones were identified they were grown overnight in 500 ml of LB Amp broth (50 
ng/ml) and maxi-prepped according to section 2.2.7.5.
2.2.10 Ligation of matrilysin introns into pGL2-Promoter
pPCR-Script clones, positive for matrilysin intron inserts were identified and maxi- 
prepped. In order to examine the introns for the presence of silencers/enhancers the introns 
were cut from the pPCR-Script plasmid and ligated into pPGL2-Promoter vector (Promega, see 
appendix 1) which contains a luciferase reporter gene controlled by an SV-40 promoter. 
Insertion of the matrilysin introns before the SV-40 promoter will determine if 
silencers/enhancers exist within the intron.
Introns in the pPCR-Script plasmid were cut out using Sac I and Xho I restriction 
enzymes (see section 2.2.7.4 for restriciton digest protocol). The pGL2-Promoter was also 
linearised using Sac I and Xho I which cut the plasmid in its multiple cloning site. Thus 
introns cut with Sac I and Xho I could be cloned directly into the pGL2-Promoter plasmid. 
Once the restriction digests were complete the contents were run out on a low melting agarose 
gel (0.7%) in order to separate the pPCR-Script plasmid from the intron inserts and also to 
isolate linearised pGL2-Promoter plasmid. The fragments of interest were cut from the gel, 
taking care to remove as much of the agarose as possible and inserted in to microcentrifuge 
tubes. The ligation of the DNA fragments was carried out using the following protocol which 
allows for the ligation of DNA fragments in gel slices.
The gel slices were melted in a 70°C water bath for at least 10 mins. This temperature 
was hot enough to melt the agarose without denaturing the DNA. An insert to vector ratio of 
approximately 1 0 : 1  was used for the ligation reaction. Because the concentration of DNA 
within the gel slice was unknown the ratio had to be estimated from the initial amount of DNA
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used in the restriction digest. Both the intron and pGL2-Promoter DNA were added to a single 
micro centrifuge tube with the final volume being 9 jj.1. The combined DNA fragments were 
kept at 37°C in order to keep the agarose from solidifying. To each tube containing the DNA 
mixture 11 pi of an ice cold mixture containing 2x buffer including ATP (final conc. will be 
Ix) and 2 jj.1 of T4 DNA ligase (4 U/pl). The tubes are mixed immediately by flicking and are 
then incubated overnight at 15°C on a shaking platform. Even though the mixture solidifies 
the DNA fragments can still be ligated. After the ligation reaction is complete the mixtures are 
melted for 5 to 10 min using a 73°C waterbath. Competent bacteria were transformed 
according to section 2.2.7.2 with the exception that 5 pi of the ligated products were added to 
200 pi of competent bacteria. Cells were grown on LB Amp (50 ng/ml) plates over night at 
37°C. Individual colonies were picked and mini prepped (see section 2.2.7.3). Restriction 
digests of isolated plasmid DNA was carried out according to section 2.2.7.4. Clones that 
contained the correct inserts were then maxi-prepped. In order to determine if silencers and 
enhancers were present in the introns the plasmids were transiently transfected into various cell 
lines and luciferase activity was subsequently analysed (see section 2.2.8.4).
2.2.11. Electrophoretic mobility shift assay (EMSA)
2.2.11.1 Nuclear Cell Extracts
Buffers used in this protocol were kept at 4°C and prior to use the following was added 
(final concentration of each in brackets): DTT (0.5mM), PMSF (0.2mM), Leupeptin (lpg/pl), 
Aprotinin (lpg/pl), and Pepstatin (0.25 pM). Cells were grown to approximately 70% 
confluency in 100mm cell culture dishes under normal conditions (DMEM S5 at 37°C). Cells 
were then serum starved overnight. The following day the cells were washed with PBS and 
treated with various cytokines (see 2.2.1.5 for dilutions) for 8 hr at 37°C in serum free media. 
After incubation the supernatant was removed and the cells were washed three times in PBS 
solution. 1 ml of PBS was added to each plate and using a cell scraper the cells were collected. 
The cells were spun out (pulse spin in microfuge ~ 13,000 rpm for 30 s), the supernatant was 
removed and the cells were resuspended in hypotonic buffer (lOmM HEPES, pH 7.9 at 4°C
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1,5mM MgCl2, lOmM KC1, 50mM NaF, and ImM NaV0 4 ). The cells were pulsed briefly in a 
microfuge and the resultant pellet was resuspended in two packed cell volumes (approx. 1 0 0 - 
200 pi) of hypotonic buffer. The cells were then incubated on ice for 10 min. In order to 
promote cell lysis 1 pi of 5% NP-40 was added to the cells and the suspension was mixed by 
pipetting 3-4 times with a pasteur pipette. The cells were then analysed for lysis by taking lpl 
of the cell suspension and adding trypan blue exclusion reagent. When approximately 60% of 
the cells were blue in colour, thus indicating that the cell walls had been disrupted, the nuclei 
were immediately pelletted and washed once in hypotonic buffer. The supernatant was 
removed and the cells were gently resuspended in a Vi packed nuclear volume (approx. 50-100 
pi) of low salt buffer (20mM HEPES, pH 7.9 @ 4°C, 1.5mM MgCl2, 0.02M KC1, 0.2mM 
EDTA and 25% glycerol). A Vi packed nuclear volume (approx. 50-100 pi) of high salt buffer 
(20mM HEPES, pH 7.9 at 4°C, 1.5mM MgCl2, 1.2M KC1, 0.2mM EDTA and 25% glycerol) 
was added drop by drop with careful mixing after each drop. The suspensions were then 
placed on a rocker/rotator for 30 min at 4°C. One volume of dialysis buffer (20mM HEPES, 
pH 7.9 at 4°C, lOOmM KC1, 0.2mM EDTA and 20% glycerol) was then added to the 
suspension which was then pulsed in order to remove debris. The supernatant was then placed 
in visking tubing and dialysed overnight at 4°C in dialysis buffer using an agitated vessel. 
Once dialysed the contents of the dialysis tubing were removed into separate tubes, flash frozen 
in liquid nitrogen and stored at -80°C. One tube from each sample was retained and a BCA 
protein assay (See section 2.2.4) was performed in order to determine the concentration of 
protein. Samples were also run on SDS-PAGE gels (see section 2.2.5.1) in order to confirm 
that the isolated nuclear proteins were intact.
2.2.11.2 Preparation of radioactively labelled probes
Oligonucleotide primers for PEA3 (optimal, proximal, upstream and downstream) 
and TCF were generated (MWG Biotech, UK) and N labelled using yP32-ATP (see table2.4). 
Radioactive probes were made of each using the following protocol: 50 ng of the
• . . .  • 32oligonucleotide of interest was aliquoted into sterile 0.5ml tube. To this was added lp l of y-P 
labelled dATP (3000 Ci/mmol, NEN Life science products, Zaventen, Belgium), lpl lOx
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buffer (supplied with enzyme), 1 pi of T4 polynucleotide kinase (NEB, Hitchin, Hertfordshire 
UK) in a final volume of 10 pi. The reaction was then carried out in a 37°C water bath for 1 hr. 
In order to separate unincorporated radioactive dATP from the reaction the contents of the 
tubes were inserted into post reaction purification columns (N’ oligo post reaction purification 
columns, Sephadex G-10 size, Clontech, Basingstoke, Hampshire, UK). Prior to addition of 
the reaction contents the columns were prepared according to manufacturers instructions. 
Briefly this involved inverting the contents of the tube and spinning at 3000 rpm for 2 min. 
The reaction contents were then added to the top of the purification column. The tubes were 
spun at 3000 rpm for 2 min and labelled probes were collected at the bottom of receptacle 
tubes while unincorporated yP32-ATP remained in the column. Scintillation counts were then 
performed on the labelled probes which were subsequently diluted to 50,000 counts per min 
(cpm) per pi. For the gel shift assay the reactions were prepared in the following manner. 10 
pi of 2x dialysis buffer, X pi H20*, 1 pi poly dldC (2 mg/ml stock solution, Amersham Int.), 5 
pg of Nuclear extract protein and 1 pi of yP32 labelled oligo (50,000 cpm/pl). Asterisk denotes 
that water was added to take the final volume to 20 pi. The reaction was incubated in a 37°C 
water bath for at least 30 min.
Probe Oligonucleotide Sequence
-168 PEA3 5 ’-GTGTGCTTCCTGCCA ATAACG ATGT-3 '
-144 PEA3 5’-GTAATACTrCCTCG'mTAGTTAATG-3 ’
-55 PEA3 5 ’-CCTATTTCC ACATTCGAGGC-3 ’
-194 TCF 5 ’-GCAAAATCCTTTGAAAG ACAAATCGCTCrCCTT-3 ’
-109 TCF 5’-CACATACnTCAAAGTrCTGTAGACTCCCTCrCCTT-3’
Table 2.4 Oligonucleotide sequence of matrilysin PEA3 and TCF probes
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2.2.11.3 EMSA gel preparation
Resolving gels used in the assay were 4% acrylamide/bis-acrylamide and made up to 
a final volume of 50 ml.
6.7 ml 30%(w/v) acrylamide/bis-aciylamide (37.5:1 ratio)
1 ml Glycerol
41.75 ml 0.5x TBE Buffer
500 pi 10% APS
50 ]A TEMED
Once the gels had set they were placed in a vertical gel box and pre-warmed by running 
at 200V for 30 min at RT. Once the nuclear extract reactions were complete the samples were 
loaded (no loading buffer was added to the samples with the exception of the free probe sample 
which was added as a guidance aid for loading) and were run at 200V at RT. Once the dye 
front had migrated to approximately % distance the gels were stopped. The gels were placed 
on filter paper, then transferred to a vacuum dryer and dried at a medium heat for 1 hr. The 
gels were then placed in a photo-intensifying cassette, covered with radiosensitive photography 
film (Kodak X-OMAT AR) and then placed at -80°C for up to 2 weeks. Films were developed 
using an Amersham-Pharmacia film developer.
2.2.11.4 ‘Supershift’ Electrophoretic Mobility Shift Assays
In order to identify nuclear proteins binding to sequences of interest, antibodies 
generated against a particular protein were added to the nuclear extracts. The antibody-protein 
complexes were allowed to form by incubating at 4°C for 30 min. The other reactants (see 
section 2.2.11.3) were then added to the tubes and incubated at 37°C for 30 min prior to 
running on the gel. ‘Supershift’ bands migrate more slowly through the gel due to a higher 
molecular weight complex formed by the antibody and protein thus resulting in a higher band 
when compared to the control.
64
Biocoat Matrigel invasion chambers provided a system that allowed assessment of 
cells invasive activity in vitro. The cell culture inserts contained an 8 jj.m pore size membrane 
that was coated with a layer of matrigel basement membrane matrix. The layer of matrigel 
serves as a reconstituted basement membrane in vitro. This layer occludes the pores of the 
membrane blocking non-invasive cells from migrating through the membrane. In contrast, 
invasive cells were able to migrate through the Matrigel coated membrane. The 6 -well plate 
invasion chambers were removed from 4°C storage and allowed to come to room temperature 
and warm (37°C) serum-free culture medium was added to the interior of the inserts and 
allowed to rehydrate for 2 hr at RT. After rehydration the media was removed from the inserts 
and replaced with 2 ml cell suspension in serum-free medium prepared at 3.5xl05 cells/ml. 
Chemoattractant 2.5 ml (media containing 20% FBS) was added to the wells of the plate. The 
plates were then incubated for 48 hr at 37°C in 5% C 0 2 incubator. After incubation, the non­
invading cells are removed from the upper surface of the membrane by scrubbing with a cotton 
tipped swab. The cells on the lower surface of the membrane were then fixed in methanol for 2 
min, stained for 1 min in Mayers Haematoxylin solution and rinsed in tap water several times. 
The membrane was then counterstained for 1 min using Eosin stain. The cells and membrane 
were then dehydrated by incubating for 2 min each in a series of ethanol solutions (30, 50, 70, 
90, 100% ethanol). The membranes were then removed from the insert housing and mounted 
on slides using DPX mounting medium. Invading cells were then viewed under the 
microscope at 40 X magnification and counted. The percentage invasion for each cell line was 
calculated by counting all of the stained cells on the filter underside and dividing by the total 
number of cells plated. For experiments involving the effect of cytokines on invasion, 
cytokines were added to the media used to rehydrate the inserts, the cell suspension, and to the 
media containing the chemoattractant at the concentrations given in section 2 .2 .1 .5.
2.2.12 In  vitro invasion assays
65
2.2.13 Zymography
Zymography was used to localise enzyme activity by molecular weight. The gel was 
prepared by incorporating the protein substate of interest (gelatin) within the polymerized 
acrylamide matrix. 1 0  % or 15% acrylamide gels were used and the amounts for one gel are 
given below, volumes for 15% gels are in brackets.
Resolving gel: 2.5 ml [2.5 ml] Buffer A (1.5 M Tris-HCl, pH 8 .8 ; 0.4% (w/v) SDS)
2.5 ml [2.5 ml] 3 mg/ml gelatin stock
3.3 ml [5 ml] 30% acrylamide stock
1.7 ml [0 ml] distilled water
33 pi [3 3 pi] 10% ammonium persulphate (freshly prepared)
5 pi [5 pi] TEMED
Stacking gel: 0.8 ml Buffer B (0.5 M Tris-HCl, pH 6 .8 ; 0.4% SDS)
0.5 ml 30% acrylamide stock
2  ml distilled water
3 3 pi 10% ammonium persulphate (freshly prepared)
5 pi TEMED
Samples were mixed 3:1 with 4X sample buffer (10% sucrose; 0.25 M Tris-HCl, pH 
6 .8 ; 0.1% (w/v) bromophenol blue) and loaded. The gels were run at 20 mA per gel in running 
buffer (0.025 M Tris; 0.19M glycine; 0.1% SDS) until the dye front reached the bottom of the 
gel. Following electrophoresis the gel was soaked in 2.5% Triton-X-100 with gentle shaking 
for 30 min at RT with one change. The gel was then rinsed in substrate buffer (50 mM Tris- 
HCl, pH 8.0; 5 mM CaCl2) and incubated for 24 hr in substrate buffer at 37°C. The gel was 
then stained with Coomassie blue for 2 hr with shaking and destained in water until clear bands 
were visible.
To confirm bands as metalloproteinases, identical gels were run as described above 
except the substrate buffer contained one of the following protease inhibitors: lOmM EDTA
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(MMP inhibitor), 0.3 mM 1,10-phenanthroline (MMP inhibitor), 1 mM PMSF (serine 
proteinase inhibitor), or 1 mM pepstatin A (aspartic proteinase inhibitor).
2.2.14 Reverse Zymography
Reverse zymography was used to detect the presence of TIMPs, SDS-PAGE gels 
were prepared with the incorporation of matrix metalloproteinases and gelatin into the 
acrylamide matrix o f the gel. 15% gels (10 ml volume) were prepared as in section 2.2.13 
except that the water component of the gel is reduced by 1 ml to allow for the addition of 0.5 
ml of MMP-rich conditioned medium from both the BHK92 cells and the HT-1080 cells. Gels 
were loaded and ran as above, T1MP standard, containing TIMP-1, TIMP-2 and TIMP-3 
(Chemicon Ltd.), was loaded as a positive control. After electrophoresis, gels were incubated 
in a solution of 2.5 % Triton-X-100; 50 mM Tris-HCl, pH 7.5; 5 mM CaCb once for 15 min, 
then again overnight at RT with gentle shaking. Next day gels, were rinsed three times with 
water, then incubated in 50 mM Tris-HCl pH 7.5 and 5 mM CaCl2 for 24 hr at 37°C to allow 
digestion of the gelatin substrate. Gels were then stained in Coomassie blue for 2 hr and 
destained until the desired contrast was achieved. The majority of the gel does not stain as the 
gelatin has been degraded. Dark bands represent inhibition of gelatin degradation by TIMPs 
within the sample.
2.2.15 Densitometry and statistics.
Densitometry of protein and RT-PCR gels was performed using a Pharmacia 
Amersham Densitometer with Imagemaster software. Two tailed T tests were performed using 
Microsoft Excel™.
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Chapter 3
The effect of cytokines on matrilysin mRNA and protein 
expression in human colon cancer cell lines
3. Introduction
Matrilysin is one o f the smallest members of the matrix metalloproteinase family 
and is capable o f degrading many components o f the basement membrane and interstitial 
ECM. Matrilysin has been implicated in many disease processes, such as, cancer invasion 
and metastasis, and rheumatoid arthritis (Adachi et al., 1999 and Cawston, 1998). 
Recently, several reports have shown that matrilysin is involved, not just in ECM 
breakdown but in a wide range of normal biological processes including proliferation, 
wound healing, angiogenesis and the activation of other MMP members involved in the 
proteolytic cascade resulting in total ECM degradation (Sang et al., 2000, Nagashima el 
al., 1997, Lu et al., 1999 and, Barille et al., 1999)
3.1 Structure and function
Matrilysin is similar to the stromelysins in its substrate specificity and to 
interstitial collagenase in the crystal structure o f its catalytic domain but the enzyme is 
unique in that it lacks the carboxyl terminal domains present in other MMPs (Wilson and 
Matrisian, 1996). Matrilysin has three domains consisting of a pre, pro and catalytic 
domain which are essential for cellular processing of the protein and enzymatic activity. 
Matrilysin is secreted as an inactive protein with a molecular weight of 28 kDa which is 
subsequently proteolytically cleaved to produce the active 19 kDa enzyme. The cDNA 
encoding human matrilysin was first isolated by Muller et al. (1988) from a mixed tumour 
library in an effort to clone stromelysin related genes involved in tumour invasion and 
metastasis. The cDNA, at 1078 bp, was shown to be derived from a previously 
undescribed gene by comparison to stromelysin and collagenase sequence to which it was 
49% and 44% homologous, respectively. The gene was initially termed pump-1 to 
indicate that it encoded a putative metalloproteinase, with similarity to other MMPs but 
lacking sequence encoding the caboxyl-terminal hemopexin-like domain. Subsequent 
purification of the matrilysin protein and analysis of the enzymes substrate specificity 
revealed that it was capable of degrading a wide spectrum of high molecular weight 
proteins including fibronectin, gelatins, collagen, laminin, entactin, and elastin (Quantin et 
al., 1989)
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3.2 Matrilysin in disease processes
The MMPs are primarily involved in ECM remodelling and their activity is 
tightly regulated at the transcriptional and protein level. When the regulation of MMPs 
becomes aberrant in diseases such as cancer, then there is excessive ECM destruction 
which may ultimately lead to tumour invasion and metastasis to a secondary site. 
Matrilysin, which plays an important role in ECM degradation, has been reported to be 
overexpressed in a number of tumour types, in particular, breast, colon and prostate 
cancers (Rudolph-Owen et al., 1998a, Wilson et al., 1997 and Udayakumar et al., 2001). 
Moreover, recent studies have shown that matrilysin is also involved in other aspects of 
tumourigenesis including, growth, migration and angiogenesis (Chambers and Matrisian 
1997, Wilson et al., 1997 and Patterson and Sang, 1997).
3.2.1 The genetics of human colon cancer.
Approximately 22,000 new cases of cancer arise in Ireland each year. Non­
melanoma skin cancer is the commonest diagnosis but these are easily detected, treated 
and rarely cause death. O f the more serious cancers, colon cancer, is the most common 
accounting for approximately 9% or just under 2000 of total new cases. Males are at a 
slightly higher risk of developing the disease. The 5 year survival rates for colon cancer 
patients are less that 55% and colon cancer attributes to 13.5% of the total of cancer 
related deaths (National Cancer Registry of Ireland, 1997). Colon cancer can be sporadic 
or inherited. Inherited forms of colon cancer include familial adenomatous polyposis 
(FAP) and hereditary nonpolyposis colon cancer (HNPCC) which account for up to 20% 
of total colon cancer cases. The mean age for patients with sporadic colon cancer tends to 
be over 60 while FAP and HNPCC patients tend to present with colon cancer much earlier 
with the ages being approximately 20-30 and 40 years old respectively. In 1990, Fearon 
and Vogelstein put forward a hypothesis for colon cancer progression whereby a number 
o f genetic mutations or ‘hits’ were required for the progression o f colon cancer (see figure 
3.1), (Fearon and Vogelstein, 1990).
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Figure 3.1 Flow diagram illustrating that colon tumourigenesis is a ‘multi-step process’. One of the most 
common mutations in colon cancer is the APC gene. The mismatch repair system which is disrupted in 
patients suffering from HNPCC contributes to several stages of the tumourigenic process. DNA 
hypomethylation also leads to the ‘switching on’ of potential oncogenes. The accumulation of these genetic 
mutations, however, is more important than the order in which they occur.
3.2.1.1 The APC m utation
The APC (adenomatous polyposis coli) gene mutation is involved in an inherited 
form o f colon cancer referred to as familial adenomatous polyposis (FAP). FAP is highly 
penetrant and patients usually develop hundreds to thousands o f adenomatous polyps 
during their second and third decades o f life. The risk o f  developing subsequent 
carcinomas and invasive carcinomas in these patients is greatly enhanced (Sieber et al.,
2000). Approximately 80% of sporadic colon cancer cases also contain APC mutations
which implies that the APC protein plays an important role in the development o f both 
sporadic and familial colon cancer. A major function o f the APC protein involves 
targetting o f a cytoskeletal protein known as P-catenin for degradation. Mutated APC 
proteins do not have the ability to assist in the degradation o f P-catenin, therefore excess 
P-catenin accumulates within the cytoplasm. The excess p-catenin is efficiently 
translocated to the nucleus where it effects the transcription o f several target genes 
including cyclin D, c-myc (He et ah, 1998) and, as will be discussed later, the MMP 
matrilysin (see figure 3.2). APC also plays an important role in cytoskeletal organization 
as it has been shown to bind to the microtubule cytoskeleton via its basic domain. In 
normal epithelial cells this association occurs at actively migrating regions o f the cell 
membrane. For example if  cell migration is induced by wounding a cell monolayer or 
treating with a human hepatocyte growth/scatter factor APC clusters intensify at the edges 
o f  migrating cell membranes (Smith et ah, 1994 and Nathke et ah, 1996). APC has also 
been shown to indirectly modulate the organisation o f the actin filament network and 
consequently affects cell morphology polarity and migration. This modulation occurs via 
the binding o f Asef to APC which in turn enhances the interaction o f Asef with Rac, a 
molecule which is involved in the regulation o f the actin cytoskeleton ( Kawasaki et ah, 
2000).
Ubiquitination of 
P -catenin in the
0  presence of wild1 type APC
Translocation of 
p -catenin in the 
presence of 
truncated APC
Matrilysin, c-myc and 
cyclin D expression
Lef-1/ p -catenin
Figure 3.2 The role of APC in the regulation of P-catenin
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3.2.1.2 The ras mutation
Another important early somatic alteration identified in colon tumours is the ras 
gene mutation. When transfected into suitable recipient host cells it was found that 
mutated ras genes conferred neoplastic properties. The importance of the ras gene 
mutation in early colorectal tumourigenesis was further bolstered by experiments 
examining a number of patient samples. It was found that 50% of colorectal carcinomas 
and a similar percentage of adenomas greater than 1cm in size had a ras gene mutation. In 
contrast such mutations have been identified in fewer than 1 0 % of adenomas less than 
lcm  in size regardless of whether the tumours arose sporadically or in patients with an 
inherited predisposition for their formation (Bos et ah, 1987 and Vogelstein et al., 1989). 
The ras gene product is a small membrane bound GTPase protein which plays an 
important role in the transduction of cell signals. It is involved in several signalling 
cascades which include the mitogen activated protein kinase (MAPK) pathway and 
phosphoinositol (PI) pathway which will be dealt with in more detail later. In its inactive 
state the Ras protein is GDP bound. Stimulation of receptor tyrosine kinases such as the 
EGF receptor leads to the activation o f Ras, hence the activation of the subsequent 
signalling cascades associated with Ras. This is achieved via the tyrosine kinase activity 
o f the receptor which subsequently activates SOS (son of sevenless, a GTP exchange 
molecule) via an intermediate docking protein known as GRB. SOS facilitates the 
activation o f Ras via the exchange of GDP for GTP. Activated Ras is then involved in the 
activation of various signalling cascades. Once the required effects have been achieved 
by the cell, Ras reverts back to its inactive state via NF1-GTPase activating protein (see 
figure 3.3).
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Fig 3.3 RAS activation. The ras protein is bound to the cytoplasmic cell membrane via a 15 carbon 
isoprenyl (fameysl group). Activation of the inactive GDP bound Ras molecule involves the GTP exchange 
molecule SOS. Ras mediates its effects via several pathways including the mitogen activated protein kinase 
(MAPK) and the phosphoinositol-3 kinase (PI-3-K) pathways. Ras is also an important modulator of the 
cell cytoskeleton. Once Ras has mediated its effects it reverts back to its inactive state via the activity of 
NFl-GTPase activity.
Ras gene mutation is a common event in human colon cancer and mutation 
typically results in the permanent activation o f the Ras protein. Therefore the Ras protein 
constantly stimulates the cells with mitogenic signals which subsequently leads to 
enhanced tumourigenesis.
3.2.1.3 The 18q deletion (DCC/SMAD4/SMAD2)
One of the most common regions o f allelic loss in carcinomas is chromosome 
18q which is absent in more than 70 % of carcinomas and 50% of late adenomas 
(Vogelstein et al., 1989 and Delattre et al., 1989). Initially it was thought that the 18q 
deletion resulted in the loss o f a single gene, DCC (deleted in colon cancer). However 
recent studies have shown that other candidate tumour suppressor genes such as SMAD4 
and SMAD2 are also present in this chromosome region. The function o f the DCC gene
protein product was initially thought to be involved in cell adhesion but it was later 
identified as a receptor (semaphorin) for extracellular chemotactic proteins (netrins) which 
are involved in cell migration. It is now thought, however, that the SMAD deletion is 
more important in colon tumourigenesis as SMAD4 knockout mice were shown to 
develop colon cancers whereas DCC knockout mice remained cancer free. The SMAD 
proteins are involved in TGF-P (transforming growth factor P) signalling. TGF-P is a 
multifunctional cytokine and has a wide variety o f functions including the inhibition of 
cell proliferation and induction o f ECM proteins. TGF-p mediates its effects via a Type I 
and Type II receptor which in turn utilise the SMAD molecules. Loss of the SMAD 
molecules would therefore result in the cell ignoring TGF-P mediated cell proliferation or 
inhibition. SMAD4 and SMAD2 function is commonly lost in colon cancer. The net 
result o f the loss of SMAD4 and SMAD2 is a loss of differentiation, increased 
proliferation and altered cell adhesion (Tafara et al., 2000).
3.2.1.4 The 17p loss (p53)
The loss of a large portion of chromosome 17p through chromosomal loss or
mitotic combination has been detected in 75% of colorectal carcinomas but this loss is not
apparent in early adenomas. Moreover, in several patients this loss was found to correlate
with the progression of adenoma to carcinoma (Fearon et al., 1987). Other cancers such
as lung, breast and bladder have also shown a loss in this chromosomal region (Yokota et
al., 1987, MacKay et al., 1987 and Hartmann et al., 2000). The region lost on
chromosome 17p has been identified and contains the p53 gene, which is essential in
maintaining and regulating normality during the cell cycle. p53 is known as the ‘guardian
o f the genome’ and plays an important role in coordinately blocking cell proliferation,
stimulating DNA repair and promoting apoptosis. p53 can mediate its effects directly by
acting as a transcription factor and binding to specific sites within the promoter of target
genes such as BAX, p21 and insulin like growth factor binding protein 3 (IGFB3). p53
can also indirectly inhibit the expression of proto-oncogenes such as jun and fos through
its interaction with the TATA binding protein (TBP). By inhibiting the interaction of TBP
with the TATA site within the promoter of these genes p53 can prevent gene transcription.
Thus a point mutation and/or loss of the p53 gene is commonly associated with
carcinomas from several tissues including colon tumours. p53 activity can also be
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regulated by MDM2 (murine double minute clone 2) which directly controls the rate of 
p53 degradation.
Studies examining many colon cancer samples have shown that the genetic 
mutations outlined above take place during certain stages of colon tumourigenesis leading 
to the hypothesis that colorectal carcinoma development is a step wise procedure, however 
accumulation of these mutations is more important than the order in which they occur.
3.2.1.5 Hereditary non-polyposis colon cancer (HNPCC)
Other forms of inherited colon cancer include Lynch syndrome or Hereditary
Non Polyposis Colorectal Cancer (HNPCC). HNPCC is a common cancer predisposition
syndrome with a familial component that has been recognised for over a century (Bradley
and Evers, 1997). Historically HNPCC, which is inherited in an autosomal dominant
fashion, has been difficult to define but three minimum criteria, known as the Amsterdam
criteria, must be met for a diagnosis of HNPCC: i) at least three relatives, one of which is
first degree, should have histologically verified colorectal cancer, persons with FAP
should be excluded, ii) at least two successive generations should be affected and iii) one
o f the three relatives must have a cancer that was diagnosed prior to the age of 50 (Vasen
et a l ,  1991). HNPCC is thought to account for approximately l%-5% of all colorectal
carcinomas but estimates of up to 15% have been reported (Cunningham and Dunlop,
1994 and Bellacosa et al., 1997). Strict adherence to the criteria set out above should
rectify these figures. By studying family histories via RFLP (restriction length fragment
polymorphisms), scientists discovered the location o f the genes involved in HNPCC on
chromosome 2pl6-15 and 3p and the role of the genes located at these positions and their
role in the development o f colorectal cancer are now being elucidated. The current theory
for function of the mutated genes in HNPCC implicates a defective DNA mismatch repair
system producing microsatellite instability in HNPCC tumours. The mismatch repair
system is responsible for correcting deletions or expansions that occur as a result of
physical damage to the DNA, misincorporation of nucleotides during DNA replication, or
mismatched nucleotides that occur during genetic recombination (Fishel et al., 1993).
Thus the major function of the mismatch repair system is to correct the errors that escape
proofreading (Fishel et al., 1993 and Branch et al., 1995). Reports have shown that
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HNPCC tumours have at least a 100 fold increase rate in their mutation rate when 
compared to sporadic tumours (Parsons et al., 1993) which may go some way to 
explaining why HNPCC affected individuals are diagnosed with colorectal cancer at such 
an early age (Parsons et al., 1993). The mismatch repair system was first identified in S. 
Cerevisiae and E. Coli and there are a number o f genes involved, /zMSH2 and GTBP 
which are involved in mismatch binding while /zMLHl, /zPMSl and /?PMS2 are involved 
in complex formation. In the majority o f HNPCC patients /zMSH2 and /zMLHl mismatch 
repair enzymes have been found to be defective (Bradley and Evers for review, 1997).
3.2.2 The role of matrilysin in colon cancer
When the proto-oncogenes and tumour suppressor genes involved in hereditary 
and sporadic colorectal cancer development are mutated/deleted the regulation of many 
other genes within the cell are also affected. For example mutations in the ras gene leads 
to a protein product which constantly stimulates the cells to proliferate via signalling 
cascades such as the MAPK pathway. This in turn leads to an increase in transcription 
factors such as jun and fos which bind to the AP-1 sites within the promoters o f target 
genes. MMP promoters contain several transcription factor binding sites such as AP-1 
and therefore mutations in proteins such as ras may directly lead to an increase of MMPs 
including matrilysin. Matrilysin has been shown to be overexpressed in several colon 
tumour studies and the regulation of the matrilysin gene at the transcriptional level by 
oncogenes/tumour suppressor genes will be dealt with in detail later. Matrilysin has also 
been shown to correlate well with colon tumour aggressiveness and its value as a 
prognostic marker has been well documented (Ichikawa et al., 1998 and Adachi et al., 
1999), however, matrilysin has recently been shown to play an important role in early 
colorectal tumouri genesis.
Initial studies focussed on the expression of matrilysin in gastrointestinal cancers 
and using various techniques such as immunohistochemistry and northern blot analysis it 
was established that matrilysin was produced by tumour epithelial cells, unlike most 
MMPs which are secreted by stromal cells surrounding the tumour, and that this 
expression was upregulated in tumour tissue in comparison to that of normal adjacent 
tissue (McDonnell et al., 1991 and Newell et al., 1994). Overall matrilysin mRNA was
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detected in 80% of gastrointestinal tumours via northern blot analysis and in 90% of 
colorectal tumours examined by in situ hybridisation and northern blot analysis. More 
interestingly, studies examining matrilysin levels in a panel of gastrointestinal samples, 
found that matrilysin expression was often upregulated in lesions which were 
histologically classified as pre-invasive, i.e. adenomas and carcinomas in situ, which 
suggested that matrilysin could play a role in gastrointestinal cancer other than that of 
ECM degradation (Newell et al., 1994).
Experimental evidence which supported the role o f matrilysin in intestinal 
tumourigenesis was obtained via the genetically matched human colon adenocarcinoma 
derived cell lines SW480 and SW620 (Witty et al., 1994). The SW620 cell line, derived 
from a lymph node metastasis, expressed matrilysin while the SW480 primary tumour cell 
line, derived from the same patient expressed no matrilysin. Both cell lines were analysed 
for their expression of other MMPs and with the exception of SW480 producing low 
amounts of MMP-9, neither cell line was found to express other MMPs. Transfection of 
the SW480 cell line with either a wild type or an activated form of matrilysin did not 
result in an increase in the in vitro invasive ability using invasion assays. Nor, did it result 
in liver metastasis following orthotopic injection into nude mice, however, an increase in 
tumour load was observed. It was found that when the SW480 parental cell line was 
injected into the cecum of nude mice that no tumours were detected while in the mice 
injected with the matrilysin transfected SW480 cell line, 50 % had detectable tumours. 
The complementary experiment also proved that matrilysin was involved in early 
intestinal tumourigenesis. This involved the transfection of the SW620 cell line with a 
full length anti-sense matrilysin cDNA. Once again no detectable difference between the 
parental and the transfected cell lines was observed with respect to in vitro invasive ability 
however, a significant reduction in tumour incidence was observed when both cell lines 
were injected into nude mice. In this case the incidence o f primary tumours was halved 
from 80% to 40% which suggested that matrilysin, although important in tumour invasion 
and metastasis, plays a significant role in early tumourigenesis (Witty et al., 1994).
Animal models have also been employed to demonstrate the relationship between
matrilysin and early stage intestinal tumourigenesis. Colorectal tumour progression
proceeds in a well defined series of steps from precursor lesions known as aberrant crypt
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foci (ACF) to adenoma, to carcinoma, to invasive carcinoma (Muto and Bussey, 1975 and 
Smith et al., 1994). The genetic lesions associated with this process, as outlined above, 
involve early mutations of the APC tumour suppressor gene and ras oncogene. The 
matrilysin promoter, as will be discussed later in chapter 4, contains an AP-1 transcription 
factor binding site and it has been shown previously that ras induces AP-1 transcription 
factor binding proteins which are essential for the basal transcription of matrilysin. The 
APC gene encodes a 300 kDa protein and as discussed earlier is involved in familial 
adenomatous polyposis (FAP). In FAP and the majority o f sporadic colon cancers the 
APC gene is mutated. The mutation results in a truncated form of the protein which in 
turn is associated with the formation of multiple polyps in the colon, (Powell et al., 1992 
and Miyaki et al., 1994). A mouse model of FAP known as Min (multiple intestinal 
neoplasia) was generated by treating pedigree mice with the mutagen ethylnitrosourea. 
Min mice carry an autosomal dominant germline mutation in the Ape gene which results 
in the development of intestinal polyps (Moser et al., 1990). This and other similar 
models have proved to be invaluable tools in analysing the early development of colon 
tumours and the role that matrilysin plays in their development.
MMP expression was examined in a number of adenomas excised from Min 
mice. The majority of the tumours examined via immunohistochemistry were positive for 
matrilysin expression (22/25 = 88%) and this expression was confined to the tumour 
epithelial cells which was consistent with observations made in human studies (Wilson et 
al., 1997). Similarly, other MMP family members, such as MMP-9 and MMP-3, were 
detected in the stromal cells surrounding the tumour which was again consistent with 
human studies. No matrilysin was detected in normal adjacent tissue which indicated that 
matrilysin was associated with benign tumour formation in the Min mice. In order to 
prove that matrilysin was involved in early tumourigenesis a set o f experiments involving 
the crossing of Min mice with matrilysin null mice (mmp7 -/-) were performed. The 
matrilysin null mice were created by homologous recombination and displayed no overt 
phenotype. The matrilysin null mice were then back crossed into a C57/BL6 background 
and mated with Min mice creating an animal model whereby Min mice in which the gene 
for matrilysin was ablated, could be compared to wild type Min mice. The results showed 
that the average number of tumours in the Min+/+/rnmpT1' decreased by approximately
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58% when compared to the average number identified in the ‘wild type’. A significant 
reduction in tumour size was also observed (Wilson et al., 1997).
To further elucidate matrilysin’s role in early tumourigenesis, the AOM 
(azoxymethane) animal model was employed as it provides a particularly useful system 
that mimics the adenoma-carcinoma sequence observed in humans. AOM treatment 
induces colon cancer that progresses in a step-wise fashion (Vivona et al., 1993). The 
first lesions associated with carcinogen treatment are known as ACF and are regarded as 
pre-neoplastic lesions (McLellan and Bird, 1988 and Vivona et al., 1993). Similar lesions 
are also detected in human colonic mucosa (Pretlow et al., 1991). Both the matrilysin null 
mice (mmp7 -/-) and wild type mice were treated with AOM and after six weeks the 
number of foci per animal were examined. A significant difference was observed 
whereby the number of foci formed in the matrilysin null mice was approximately 50% 
less than those which formed in the wild type mice mice. These results implicated that 
matrilysin expression was important in the initial stages of tumour development 
(Fingleton et al., 1999).
Together these in vitro and in vivo studies demonstrate that matrilysin plays an 
important but as yet undefined role in early colon tumour development.
3.2.3 The role of matrilysin in other cancers
Matrilysin is also involved in the progression of other tumours such as breast, 
prostate, lung, esophageal, myeloma and head and neck squamous carcinomas (Chambers 
and Matrisian, 1996, Barille et al, 1999, Ocharoenrat et al., 1999, Yamashita et al., 2000 
and Udayakumar et al., 2001). Matrilysin is also involved in other diseases such as 
rheumatoid arthritis and osteoarthritis as overexpression of matrilysin leads to excessive 
cartilage destruction (Cawston, 1998).
3.2.3.1 Matrilysin’s role in breast cancer tumourigenesis
After skin cancer, breast cancer is the most common cancer among women with
approximately 1,800 new cases being diagnosed in Ireland each year and is responsible
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for approximately 18% of cancer related deaths (National Cancer Registry Ireland, 1997). 
The 5 year survival rates are less than 55%. Breast cancer is the leading cause of 
mortality due to cancer in non-smoking women in the US (Parker et al., 1997). Lethality 
is usually the result of local invasion and metastasis of neoplastic cells from the primary 
tumour into the underlying stroma, entry into the circulation and growth of the cancer 
cells at distant sites in the body (Liotta, 1986). By the time a patient presents with breast 
cancer, detectable métastasés may be present. Breast cancer can arise sporadically due to 
a series of genetic mutations but approximately 10% of breast cancers occur as a result of 
highly penetrative germline mutations in cancer predisposition genes (Claus et al., 1991). 
These genes include BRCA1, BRCA2 and BRCA3. The BRCA1 and BRCA2 protein 
products have been shown to play an important role in DNA damage repair through their 
interaction with Rad51 (Gowen et al., 1998, Abbott et al., 1999). Rad51 has been shown 
to play a central role in mediating homologous recombination events and can promote 
strand exchange alone in vitro (Bhattacharyya el al., 2000). It has also been suggested 
from studies examining BRCA1 knockout mice that BRCA1 and p53 may operate via a 
common functional pathway (Hakem et al., 1997 and Ludwig et al., 1997).
neu/ErbB-2 is a relative o f the epidermal growth factor receptor and the gene 
protein product (Her2/Neu) is known to mediate cell mitogenesis via signalling pathways 
upon dimérisation. Hence overexpression of this mutated gene leads to increased 
mitogenic signaling in affected cells. Several studies have observed that a high degree of 
neu/ErbB-2 amplification is associated with poor clinical outcome (Slamon et al., 1987 
and Varley et al., 1987). MMPs have been described as being involved in proliferation 
and migration (Sang et al., 2000 and Nagashima et al., 2000) and therefore mutations in 
genes which regulate cell growth such as BRCA1, BRCA2 and neu/ErbB-2 may have a 
direct or indirect effect on MMPs and their deletion or amplification may play a role in the 
regulation o f many MMPs including matrilysin.
The role of MMPs in breast cancer has traditionally focussed on their expression
with respect to invasion and metastasis and several groups have reported that MMP
expression increases with advancing tumour stage (Rudolph-Owen and Matrisian, 1998a).
In particular, MMP-2 and matrilysin mRNA transcripts have been shown to be expressed
at higher levels in malignant than in normal breast tissues (Pacheco et al., 1998). O f all
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the MMPs involved in mammary cancer, matrilysin is important in that it is the only 
MMP almost exclusively expressed in the epithelial component of the tumour, compared 
to the predominantly stromal expression of other MMPs (Rudolph-Owen et al 1998a). 
Matrilysin mRNA has been detected in the neoplastic epithelial tumour cells of 70%-91% 
of breast adenocarcinomas and also in benign breast fibroadenomas which indicates that 
matrilysin by logical inference is involved in not only tumour invasion and metastasis but 
also in early mammary tumourigenesis (W olf et al., 1993 and Rudoph-Owen et al., 
1998b). In a recent report matrilysin has been shown to influence early stage mammary 
tumourigenesis (Rudolph-Owen et al., 1998b). These studies used transgenic mice that 
expressed human matrilysin under control of the mouse mammary tumour virus (MMTV) 
promoter. Overexpression of matrilysin in these animals did not produce any observable 
morphological changes during mammary gland development. However closer inspection 
showed that 50% of the transgenic mice contained abnormal structures in the mammary 
gland in comparison to control mice. These areas of hyperplasia strongly resemble 
structures previously termed HANs (hyperplastic alveolar nodules), which are considered 
to be premalignant precursors that are prone to develop into mammary carcinomas 
(Cardiff, 1984). HANs have been reported as being susceptible to carcinogens and 
exposure to agents such as chemical carcinogens or radiation increases the tumour 
incidence o f the hyperplastic cells and usually decreases the tumour latency period 
(Cardiff, 1984). In order to assess if the HANs type structures observed in mice 
overexpressing matrilysin could be induced to form tumours, the mice were crossed with 
mice which overexpressed Her2/Neu. The result revealed a striking acceleration in the 
onset of mammary tumour formation by 13 weeks. It was suggested that the role of 
matrilysin may be involved in the production of soluble ligands that bind to the Her2/Neu 
receptor hence creating a loop whereby increased matrilysin expression led to increased 
Her2/Neu signalling which in turn leads to cell proliferation and increased matrilysin 
production. Matrilysin has therefore been shown to play an important role in mammary 
tumour formation in conjunction with other mutations.
3.2.3.2 The role of matrilysin in prostate cancer
Matrilysin has also been shown to play an important role in the invasion and
metastasis of prostate cancer (Udayakumar et al., 2001), a disease which afflicts males
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only and the average age of diagnosis is approximately 65 (National cancer registry of 
Ireland, 1997). Recent evidence has shown that factors such as FGF, EGF or their 
receptors are commonly upregulated in prostate cancers and that this upregulation is 
associated with increased matrilysin expression (Udayakumar et al., 2001 and Sundrashen 
et al., 1999). Interestingly, a recent report by Powell et al (1999) has shown that 
matrilysin plays a role in the Fas ligand/Fas receptor (FasL/Fas) mediated apoptotic 
system in the normal involuting rodent prostate. Studies showed that matrilysin can 
process recombinant and cell associated FasL to soluble FasL (sFasL) which was 
subsequently capable of inducing apoptosis in a target epithelial cell population. Mice 
deficient in matrilysin also showed a 67% reduction in apoptotic index in the involuting 
prostate compared with wild type which once again implicates matrilysin in the FasL 
mediated apoptotic process (Powell et al., 1999).
3.2.4 Therapeutic implications
Matrilysin has been shown to play an important role in several tumour types and 
evidence suggests that it is involved in the early tumour development of colon and breast 
tumours besides playing its more traditional role in tumour invasion and metastasis. 
Although we cannot yet define the mechanisms by which matrilysin expression aids 
tumour growth it is clear that its expression confers an important advantage with respect 
to tumour formation. It may therefore be of benefit to treat tumours at early stages using 
MMP inhibitors directed against matrilysin in order to prevent tumour growth, invasion 
and metastasis. As we shall see matrilysin also plays roles in other processes and with 
improvements in drug delivery mechanisms diseases such as breast and colon cancer 
could be treated without deleterious side effects.
3.3 Matrilysin in normal biological processes.
Many studies have investigated the role of matrilysin with respect to cancer 
tumourigenesis and invasion and metastasis but growing evidence suggests that 
matrilysin, has important roles in various normal biological processes which may have 
implications for tumour biology.
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3.3.1 Matrilysin and angiogenesis
Angiogenesis involves the formation of new blood vessels in response to 
angiogenic stimuli secreted by cells (Risau, 1997). The process involves the destruction 
of the ECM by vascular endothelial cells in order to create room for the developing blood 
vessels. MMPs including matrilysin have been shown to play an integral part in the 
regulation of this process. Recent studies have shown that matrilysin is involved in the 
hydrolysis o f plasminogen resulting in the production of angiostatin fragments (Patterson 
and Sang, 1997). Angiostatin is one o f the most potent inhibitors o f angiogenesis, 
however, the physiological relevance of the generation of angiostatin by matrilysin 
remains to be elucidated. This would appear to be contradictory to the role of matrilysin 
in tumour formation and growth as angiogenesis is a key element in tumour growth and 
progression. Models in which matrilysin is not expressed contain angiostatin fragments 
suggesting that other proteases are involved in the process (Patterson and Sang, 1997). 
Matrilysin may have a low catalytic activity for cleavage thus preventing other more 
suitable proteases producing angiostatin fragments thereby allowing the process of 
angiogenesis to proceed at a quicker rate.
3.3.2 Matrilysin and apoptosis
Matrilysin has been shown to be involved in epithelial cell apoptosis via the
generation o f soluble Fas ligand. The Fas ligand/Fas receptor (FasL/Fas) system was first
described as an important mediator of immune cell apoptosis whereby the binding o f FasL
to Fas resulted in the initiation of the apoptotic cascade (Schulze-Osthoff et al., 1998).
Matrilysin has been shown to be involved in the cleavage of many of the high molecular
weight proteins within the ECM and has also been reported to cleave a variety of secreted
and cell surface proteins. These cell surface proteins include the membrane bound
precursor to TNF-a, a member o f the same protein family as FasL. Cleavage of the TNF-
a  precursor by matrilysin and other proteases can result in the release o f active ligand
from the cell surface (Gearing et al., 1994). Further experiments showed that FasL is a
substrate for matrilysin with cleavage resulting in soluble Fas ligand. The soluble Fas
ligand was then shown to induce apoptosis in human epithelial cells (Powell et al., 1999).
This new biological role of matrilysin could be contrary with respect to its role in
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tumourigenesis but it is quite possible that matrilysin may be involved in the generation of 
FasL resistant cells or that the cells may receive other mutations which render them 
resistant to FasL induced apoptosis (Personal communication from Barbara Fingleton).
3.3.3 Matrilysin’s role in innate host defence.
Recently matrilysin has been shown to play an important role in innate host 
defence. A study by Wilson et al. (1999) reported that matrilysin was capable of 
activating molecules known as defensins which are antibiotic peptides secreted by 
epithelial Paneth cells located in the intestinal lumen. The defensins are a family of 
cationic peptides that kill bacteria by membrane disruption. Granulocytes and several 
epithelial tissues, including the Paneth cells of the small intestine of most mammals 
produce a-defensins as prepropeptides. These antibacterial agents are released from 
secretory granules in response to bacteria or cholingeric agents. The pro region of the 
peptides keeps them in an inactive state. Evidence has shown that the expression of 
defensins parallels that of matrilysin in the Paneth cells and that there is an accumulation 
of pro-peptide defensins in matrilysin null mice (Wilson et al., 1999). Further studies 
revealed that matrilysin was capable of directly processing the active form of a-defensin 
(Wilson et al., 1999). The study also showed that in comparison to the wild type mice 
(MAT+/+), the matrilysin null mice (MAT7') died much more quickly upon exposure to a 
virulent strain of Salmonella typhimurium with the LD50 for MAT+/+ being 1.14 x 105 cells 
and MAT’7' being 1.41 x 104 cells. Other MMPs expressed in the mouse small intestine 
(MMP-10 and MMP-13) were also examined but their presence was not detected in the 
Paneth cells which again implicated matrilysin’s involvement in the processing of 
defensins (Wilson et al., 1999). These results clearly show that MMPs such as matrilysin 
may play an important role in the processing of a wide variety of proteins and not just 
those associated with the ECM.
3.3.4 Matrilysin in other biological processes
Matrilysin is also involved in several important normal biological processes
including wound healing, menstruation and herniated disc resorption (Arumugam et al.,
1999, Koks et al., 2000 and Haro et al., 2000). Response to tissue injury begins with the
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deposition of a fibrin rich clot of the provisional matrix. The provisional matrix consists 
o f plasma borne matrix molecules that serve as scaffolding for the ensuing migration of 
cells. During wound repair, multiple cell types must migrate through the clot matrix 
scaffolding, and the migration of these cells through this matrix is dependent on the 
expression o f MMPs such as matrilysin (Arumugam et al., 1999). Matrilysin has been 
shown to be involved in the menstrual cycle and its expression has been found to be at its 
highest during the extensive remodeling o f the endometrium (Koks et al., 2000). In a 
recent report matrilysin has also been implicated in the release o f soluble TNF-a which in 
turn plays an important role in herniated disc resorption (Haro et al., 2000).
3.4 Cytokine function and mode of action
In order for cells to carry out their proper biological functions they need to be 
able to ‘sense’ their external environment and this is typically achieved by the expression 
o f various receptors on the cell surface, for example, cell adhesion molecules (CAMs) and 
hormone and growth factor receptors (Parmiani et al., 2000). When ligands bind to these 
receptors internal signaling pathways are activated which in turn activate the transcription 
of target genes. Cytokines are one of the most common signalling molecules used in 
biology. Cytokines are proteins or glycoproteins that mediate potent biological effects on 
many cell types. Cytokines mediate their effects through various signal cascades and have 
been found to play critical roles in almost all aspects of cellular functions including 
development, migration, haematopoiesis, inflammatory response and the development and 
maintainence of the immune system. Cytokines are also potent mediators of cell growth 
and many of the genes which express either cytokines or the receptors for them are 
considered to be proto-oncogenes and mutations in these genes can have catastrophic 
effects on cellular function including uncontrolled cell proliferation thus increasing the 
affected cells potential to become tumourigenic. Based on their mode o f action cytokines 
can be divided into three groups, i) autocrine, in that they act on the cells which have 
secreted them, ii) paracrine, in that they are secreted by a cell but cause a cellular reaction 
in a neighboring cell, and iii) endocrine, in that they are normally secreted by specialised 
glands, transported in the blood and carry out their effects on distant target cells (see 
figure 3.4).
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Figure 3.4 Mode of action of cytokines on epithelial cells. Cytokines may also act in a juxtacrine manner 
whereby they can signal a neighboring cell by using membrane bound signalling peptides and receptors.
Cells use cytokines and other factors to ‘sense’ their external environment and for 
example when a cell receives a stimulus to proliferate a number of events occur such as 
entry into the cell cycle and D N A  replication. In order for the cell to divide it must loosen 
the bonds of the E C M  which anchor it and this is achieved through the regulation of cell 
adhesion molecules and the expression of proteases such as M M P s  (Beksac el al., 2000 
and Madri and Graesser, 2000). If M M P s  are therefore expressed in response to external 
stimuli from cytokines it is possible that aberrant cytokine expression could result in the 
overexpression of M M P s  resulting both in increased cell proliferation and increased E C M  
degradation.
This chapter focuses on the expression and regulation of matrilysin by several 
cytokines in a panel of colon cell lines. We have chosen the colon system as much work 
to date has shown that matrilysin expression is critical in colon tumour formation, 
proliferation, invasion and metastasis and is unique in that it is the only M M P  expressed 
exclusively by the tumour epithelial cells. W e  have examined a panel of cytokines for 
their effect on matrilysin expression in these cell lines and hope to establish that cytokine 
regulation is an important feature in matrilysin expression during colorectal 
tumourigenesis. The cytokines examined here include IGF-I, IGF-II, EGF, bFGF, IL-6 
and a known upregulator of M M P  expression 12-O-tetradecanoyl-phorbol-l 3-acetate 
(TPA).
3.4.1 EGF and the EGF receptor (EGF-r)
EGF is part of a large family of cytokines which can be characterised by the fact 
that they contain at least one extracellular EGF structural unit (a conserved 6-cysteine
motif that forms three disulphide bonds). Family members include EGF itself, 
transforming growth factor-a (TGF-a), Heparin binding-epidermal growth factor (HB- 
EGF), amphiregulin (AR), betacellulin (BTC), sensory and motor neuron derived factor 
(SMDF) and the heregulins (HRGs). EGF is secreted as a 9 kDa protein which is 
proteolytically cleaved to yield an active 6 kDa form. It is a multifunctional cytokine 
most commonly associated with stimulating the growth of epithelial cells and mediates 
this effect by binding to the EGF-r. The EGF-r is a common receptor for EGF, TGF-a, 
A R  and HB-EGF and the genes encoding for each of these molecules are important in 
growth and development. The EGF-r has tyrosine kinase properties which are used in the 
transduction of external signals and is a member of the src group of oncogenes. Although 
the EGF-r is expressed by a wide variety of adult cell types in vivo and cell lines in 
culture, EGF was so named because of its first recognised activity in an in vivo assay for 
epidermal maturation. Tissues that continue to divide in order to renew themselves 
generally have more EGF-r present or are more responsive to EGF than other tissues. 
These tissues would include the epithelial lining of the gut and epidermal layer of the skin 
(Wilson and Gibson, 2000).
The EGF-r gene encodes a 170 kDa transmembrane receptor with an intracellular 
domain similar to that of the src gene product (see figure 3.5). The EGF-r is characterised 
by its ability to autophosphorylate and upon autophosphorylation dimerisation with 
another nearby EGF-r occurs. The tyrosine kinase receptor can then carry out its function 
via the phosphorylation of signaling molecules docked to its intracellular domain. The 
EGF receptor as has been stated is a trans-membrane receptor with intrinsic tyrosine 
kinase activity and there have been numerous reports on the expression of this receptor 
and its ligands, EGF and TGF-a, in colon tumours. In an immunohistochemical study, 
synchronous expression of EGF and EGF-r in highly invasive colon carcinomas suggested 
that an EGF autocrine loop may play a role in the regulation of these tumours (Karamerias 
et al., 1993). Such autocrine loops have been described in several colon carcinoma cell 
lines where cell growth was inhibited by using antisense TGF-a and blocking antibodies 
to the EGF receptor (Karnes et al., 1992). It has also been reported that the expression of 
EGF-r by colon carcinoma cells directly correlates with their metastatic potential 
(Radinsky et al., 1995). EGF promotes the migration and invasion of a number of cell
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types and has been linked to alterations in cell-ECM interactions. In fibroblasts c-src 
synergistically increases the oncogenic activity of the EGF receptor suggesting that these 
two kinases may be involved in the progression of malignant phenotype. (Brunton et al., 
1997).
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Figure 3.5 The epidermal growth factor receptor. EGF binds to the receptor causing a conformational 
change which allows for receptor dimerisation and autophosphoiylation o f the tyrosine kinase domain
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Figure 3.6 The IGF system. Several proteases including MMPs have been implicated in the production of 
biologically active IGF
3.4.2 IGF-I and IGF-II
Insulin like growth factors (IGF) are so called because of their ability to bind to 
the insulin receptor (also known as the IGF-I receptor). The IGF family is comprised of 
IGF-I and IGF-II, both of which have an active molecular weight of 7.5 kDa. IGFs are 
multifunctional polypeptides that are capable of regulating growth, diiferentiation and 
survival in several cell and tissue types. The tGF system includes ligands (IGF-I and IGF- 
II), receptors (IGF-IR and IGF-IIR), IGF binding proteins (IGFBP-1-7) and IGFBP 
proteases (see figure 3.6).
The IGF system regulates pre- and postnatal growth, the establishment and 
maintenance of differentiated çdl function via paracrine, autocrine and endocrine 
signalling. ÎGFs are jpolent mitogenic and anti-apoptotic molecules involved in the 
regulation of cell proliferation in renewing epithelial cell populations of organs including
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breast, prostate, colon and lung. Unlike many other regulatory peptides, IGFs have 
characteristics of both classic ‘endocrine’ hormones and also characteristics of tissue 
growth factors (Jones and Clemmons, 1995 and Rajaram et al., 1997). Circulating levels 
of IGFs are subject to complex physiological regulation and the vast majority of IGFs are 
bound to high affinity binding proteins which need to be proteolytically cleaved in order 
to produce the active IGF cytokine. It has been shown that >90% of circulating IGF is 
bound to a high molecular weight complex comprised of IGFBP-3 and a separate protein 
known as the acid labile sub-unit. However, IGF bioactivity in tissues is not merely a 
function of circulating levels, as local expression of genes encoding IGFs, IGFBPs, and 
proteases that digest IGFBPs are also important (Ramajaran et al., 1997). The classic 
source of IGF-I is the liver, where the peptide is produced in response to growth hormone. 
It is considered a primary growth regulator in pre and post-natal life. In contrast to IGF-I, 
the physiological function of IGF-II is mainly involved in stimulating undifferentiated 
cells and plays a key role in foetus development (Poliak, 2000). The IGF-I receptor is 
structurally very similar to insulin and is comprised of 2a subunits and 2(3 subunits which 
are linked by disulphide bonds (see figure 3.7). The receptor is comprised of an 
extracellular, transmembrane and intracellular domain. When a ligand binds, the IGF-I 
receptor undergoes rapid auto-phosphorylation and the intracellular domain once 
phosphorylated is a potent tyrosine kinase and mediates its effects through the 
phosphorylation of secondary signaling molecules. The IGF-II receptor is similar to the 
receptor for mannose-6-phosphate, is structurally very different to that of IGF-I, and is 
capable of binding both IGF-I and IGF-II. As IGFs are potent mitogenic agents it is quite 
possible that aberrant gene expression may result in an increased rate of epithelial cell 
division which in conjunction with other oncogene expression may induce malignant 
transformation.
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Figure 3.7 A The IGF-I receptor is comprised of 2a and 2(3 subunits. Once the IGF ligand has bound the 
intracellular tyrosine kinase domain is activated. B The IGF-II receptor which is similar in structure to the 
mannose-6- phosphate receptor
3.4.3 Interleukin-6
Interleukin-6 (IL-6) is a member of the family of cytokines collectively termed 
“the interleukin-6 type cytokines”. IL-6 is variably glycosylated and the 22-27 kDa 
secreted glycoprotein serves as a prototype for a family of molecules that includes 
leukemia inhibitory factor (LIF), oncostatin M  (OSM), ciliary neurotrophic factor 
(CNTF), cardiotrophin-1 (CT-1) and IL-11. Although all these molecules possess a similar 
helical structure, their association is due to their functional redundancy and receptor 
interactions (Hibi et al., 1996). IL-6 achieves its effects through the ligand-specific IL-6 
receptor (IL-6R). Unlike most other cytokine receptors, the IL-6R is active in both 
membrane bound and soluble forms. Among its many functions, IL-6 plays an active role 
in immunology, bone metabolism, reproduction, arthritis, neoplasia, and aging. IL-6 
expression is regulated by a variety of factors, including steroidal hormones, at both the 
transcriptional and post-transcriptional levels (Keller et al., 1996).
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Figure 3.8 The IL-6 receptor is comprised of 2 chains, the a/gp80 chain and the p/gpl30 chain.
The human IL-6 receptor, also known as gp80 and IL-6R, is an 80 kDa protein 
consisting of 467 amino acids (Keller et ah, 1996). The receptor is comprised of an 
extracellular region, a transmembrane region and an intracellular region. The IL-6R is not 
capable of mediating signal transduction directly and must initially bind to gp-80 which 
gives rise to a low affinity receptor complex. Homodimerisation of gp-130 is 
subsequently required for IL-6 signal transduction (Murakami et ah, 1993) (see figure 
3.8). Although it was originally considered that one unit of IL-6 and the IL-6R bound to a 
gp-130 homodimer, the stoichiometry and number of this reaction appears to involve a 
hexameric complex consisting of two molecules each of IL-6, IL-6R gp-80, and gp-130 
(Hammacher et ah, 1994). This complex forms a high affinity binding site for IL-6, as 
opposed to the low affinity binding observed with IL-6 and IL-6R gp-80 in the absence of 
gp-130.
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The IL-6 receptor is expressed in a variety of cells and the number of receptors 
normally range between 100-2000 sites per cell. However, in myeloma cell lines up to 
29,000 sites per cell have been observed (Snyers et al., 1989). The receptor has also been 
shown to be upregulated in several cancers including bladder and prostate cancer (Meyers 
et al., 1991 and Siegsmund et al., 1994). IL-6 is a pleiotropic cytokine and is involved in 
initiating several cellular processes including proliferation and differentiation. IL-6 is also 
involved in the inflammatory response cascade and is often found at high levels in the 
stroma surrounding advancing tumours. Many of the promoters of M M P  genes contain 
transcription factor binding elements to which transcription factors triggered by IL-6 such 
as NF-IL6 (nuclear factor interleukin-6), can bind and these will be discussed later. 
Therefore, a possible link with cancer proliferation and overexpression of MMPs, 
including matrilysin, due to increased expression of IL-6R or IL-6 by the tumour cell may 
exist.
3.4.4 Basic fibroblast growth factor (bFGF)
Fibroblast growth factors are a family of secreted peptide ligands containing at 
least 15 members. Signalling by the FGFs and their receptors, which are a family of 4 
transmembrane protein tyrosine kinases in mammals, is critical for diverse aspects of 
embryonic, foetal and post natal development of a variety of tissues (see figure 3.9) 
(Matsui et al., 1999). Acidic and basic fibroblast growth factors (aFGF and bFGF) were 
among the first members of the FGF family to be isolated. bFGF plays a role in autocrine 
and paracrine regulation of cell proliferation, migration, angiogenesis and vascular 
development (Olson et al., 2000 and Sezer et al., 2001). bFGF is secreted as an 18 kDa 
protein and mediates it’s effects through binding to the FGF receptor-2 (FGFR-2). 
Various forms of bFGF also exist in that the gene which encodes for the bFGF protein has 
several transcription initiation start sites. bFGF has also been shown to be essential in the 
formation of monolayers of cells and has been found to be present as an insoluble 
proteoglycan incorporated into the E C M  which indicates its role as a local regulator of 
cell migration, proliferation and regeneration during wound healing (Aktas and Kayton, 
2001).
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Angiogenesis is an essential requirement for tumour progression and because 
bFGF is involved in the angiogenic process its overexpression by developing tumours 
results in blood capilliary formation which in turn feeds the tumour with oxygen and other 
essential requirements. bFGF has been shown in various studies to play an important role 
in colon cancer invasion whereby the invasion of colon cancer cells using an in vitro 
invasion assay was promoted by the addition of exogenous bFGF (Galzie et al., 1997). 
Reverse experiments which focussed on the inhibition of endogenous expression using an 
antisense strategy resulted in colon cancer invasion inhibition (Netzer et al., 1999). As 
M M P s  are involved in colon cancer invasion and metastasis and angiogenesis it is 
possible that bFGF may have a role in the direct or indirect regulation of M M P s  including 
matrilysin.
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Figure 3.9 A representative diagram of the FGF receptor family. The FGF receptor is a potent tyrosine 
kinase and similar to other receptor tyrosine kinases it is activated after ligand binding.
3.5 Cytokine signalling networks
In order for cytokines to mediate their eifects in a particular cell they must first
bind to their receptor. The receptor mediates its action through the phosphorylation of
molecules which interact with the tyrosine kinase portion of the receptor. These
molecules subsequently phosphorylate other molecules and so on until the required
response is carried out. The main targets of the signalling pathways are transcription
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factors which bind to the promoter region of target genes. There are many important 
pathways involved in cell signalling and many of these ‘cross talk’ in that the pathways 
overlap each other or use the same signalling molecules. Signalling pathways can also 
overlap to enhance or silence a particular signal. The regulation of these pathways is also 
important and aberrant expression of mutated receptors which continually ‘fire’ signals at 
the nucleus wreak havoc on the cell and normally result in excessive proliferation which 
when accompanied by other mutations will result in cancer development.
There are many signalling pathways used to effect cellular processes, for 
example, the mitogen activated protein kinase (MAPK) pathway the phosphotidyl 
inositol-3 pathway (PI-3) and the janus kinase/ signal transducer and activator of 
transcription (JAK/STAT) pathway. Several of the receptors outlined above also engage 
these pathways in order to mediate their desired effect. One of the first molecules 
engaged by many of the receptor tyrosine kinases (RTKs) is the Ras protein.
The M A P K  pathways can effect a wide variety of processes but they are primarily 
involved in stimulating cell proliferation. Common transcription factors stimulated by the 
M A P K  effector molecules include those of the AP-1 and Ets family. As discussed earlier 
many of the M M P  gene promoters including that of matrilysin contain D N A  binding 
regions for these transcription factors and therefore stimulation of the M A P K  pathway 
may lead to increased proliferation as well as increased M M P  gene transcription.
3.5.1 Ras and the M APK pathways
Ras proteins activate multiple signalling pathways (see figure 3.10). Ras binds to 
at least three types of effector protein : i) kinases of the raf family including M A P K  and 
ERK, ii) phosphoinositide-3 kinases (PI-3) and iii) RalGDS (guanine nucleotide 
disassociation stimulator) proteins (McCormick, 1999). The molecular mechanisms that 
lead to the activation of Ras effectors are complicated and unclear and the downstream 
consequences of activation are more complicated still. Both the Raf and PI-3 pathways 
have been shown to be involved in proliferation, migration and angiogenesis via their 
signalling networks and their complex interaction or ‘cross talk’ with other networks. The
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RalGDS is also involved in gene transcription and its mechanisms of signalling are now 
being elucidated.
Several receptor tyrosine kinase (RTKs) including the EGFr and the FGFr use 
Ras in order to signal to the cell nucleus. Tyrosine phosphorylation of specific residues 
on the internal domain or the receptor creates binding sites for several molecules including 
Src- homology 2 (SH2) and phosphotyrosine binding (PTB) domain containing proteins. 
Some of these proteins are enzymes that are tyrosine phosphorylated and thereby 
activated, such as Src, phospholipase Cy (PLCy) and PI-3 kinase, whereas She, Grb2, 
Grb7 and Nek are adaptor molecules that link RTKs to downstream signalling pathways 
(Hackel et al., 1999).
Growth factor receptor bound protein 2 (Grb2) is a small adaptor protein that is 
essential in the Ras signalling pathway (Lowenstein et al., 1992). Il is comprised of one 
SH2 domain of approximately 100 amino acids surrounded by two SH3 domains, each 
containing about 60 amino acids. After receptor dimérisation and tyrosine trans­
phosphorylation Grb2 docks with the internal domain of the receptor and upon 
phosphorylation Grb2 then recruits SOS proteins. SOS accelerates the change of GDP to 
GTP in Ras, which leads to Ras activation. Once loaded with GIT, Ras is then capable of 
interacting with effectors such as Raf which ultimately leads to the activation of the 
mitogen activated protein kinase (MAPK) pathway.
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Figure 3.10 Once activated, membrane bound Ras proteins activate a number of signalling pathways 
including the mitogen activated protein kinase pathway. An increase in Fos and other AP-1 transcription 
factor family members may also lead to an increase in MMP activity.
The chain of events leading to M A P K  activation take place within the cell 
cytoplasm. Having been recruited to the cell membrane and activated by Ras, Raf 
proceeds to phosphorlyate, hence activate, serine residues on the mitogen activated protein 
kinases 1 and 2 (MKK1, MKK2). The discovery of the first mammalian M A P K  pathway 
was based on the identification of p42 and p44 MAPKs (Ray and Sturgill, 1987). p42/p44 
MAPKs, once activated, have been shown to be translocated to the nucleus upon growth 
factor stimulation (Lenormand et al., 1993). This nuclear translocation allows the 
MAPKs to contact and phosphorylate key substrates. In vitro studies show that p42/44 
MAPKs have the ability to phosphorylate a number of substrates including EGF-r,
phospholipase A2, protein kinase p90RSK, Myc and Elkl, however, in vivo the p42/p44 
M A P K s  have been best characterised by their interaction with the nuclear transcription 
factor Elkl. After phosphorylation by MAPK, Elkl is responsible for the induction of c- 
fo s gene expression. The p42/p44 M A P K  pathway can, therefore, integrate the signals 
coming from various growth factor receptors and by translocation to the nucleus and 
activation of transcription factors, relay this information to modulate gene expression 
accordingly.
3.5.2 Ras and the PI-3 kinase pathway
Oncogenic Ras suppresses apoptosis through the PI-3 kinase pathway, partly 
through the activation of protein kinase B (PKB) (see figure 3.11). The precise role of 
PKB in suppressing apoptosis is complex: PKB phosphorlyates BAD, a member of the 
Bcl-2 family that promotes cell death, and caspase 9, a protease that degrades cellular 
substrates during the process of cell death. However, PKB also regulates transcription 
through the phosphorylation of Forkhead proteins, which might themselves regulate other 
effectors of apoptosis, suggesting a much more complex and indirect route to cell survival 
(McCormick, 1997). Ras activated PI-3 kinase also plays a role in promoting cell growth 
through the inhibition of glycogen synthase kinase 3 (GSK3) by PKB. Activated GSK3 is 
capable of degrading, via ubiquitination, the cyclin D1 proteins which drive the cell cycle 
from the G1 to the S phase. Inhibition of GSK3 therefore promotes cell division through 
the accumulation of cyclin D1 (Garbay et al., 2000).
The PI-3 kinase pathway may also stimulate the production of M M P s  indirectly 
via the increase of transcription factors associated with cell proliferation. As discussed 
earlier matrilysin has been shown to cleave FasL into its soluble form and is involved in 
FasL/Fas mediated apoptosis. Since the PI-3 kinase pathway can increase levels of Fas L 
it may also be appropriate that the pathway lead to an increase in molecules which are 
capable of converting FasL to its soluble form such as matrilysin.
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Figure 3.11 Ras is also capable of activating the PI-3 kinase pathway which has numerous effects.
3.5.3 The JAK/STAT pathway
The STATs (signal transducers of and activators of transcription) constitute a 
multiple member family of signal transduction proteins that are activated in the cytoplasm 
by the binding of extracellular polypeptides to the transmembrane receptors which then 
regulate the transcription of immediate response genes (Horvath and Darnell, 1997), (see 
figure 3.12). The Janus kinase-signal transducer and activator of transcription factor 
(JAK-STAT) signalling pathways were originally identified in the study of interferon 
signalling and are now believed to be the important pathways in signal transduction for 
many cytokines including IL-6. These pathways have been implicated in a variety of 
cellular functions in the haematopoietic, immunologic, neuronal and hepatic systems 
(Chen et al., 1999). It is well established that binding of IL-6 to the IL-6 receptor-a chain 
induces homodimerisation of the signal transducing (3 chain, gpl30, which is followed by
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the activation of the receptor associated tyrosine kinases JAK1, JAK2 and Tyk2. A  
process assisted by ROS (reactive oxygen species). This receptor tyrosine kinase complex 
interacts with and activates the Src homology 2 (SH2) containing cytoplasmic STAT3 
transcription factor, which then translocates to the nucleus to activate the transcription of 
many target genes including JunB, C C A A T  enhancer binding protein (C/EBP) and 
p21 WA^ '/C'pi (Chen et al, 1999). Although it is clear that JAKs serve to phosphorylate 
STATs in receptors that lack intrinsic tyrosine kinase domains, it has also been shown that 
RTKs have the ability to activate STATs without recruiting JAKs (Horvath and Darnell, 
1997).
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Figure 3.12 Activation of the JAK/STAT pathway leads to the activation o f several transcription factors and 
the production of various gene products including IL-6 and MMPs
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3.6 Summary
Matrilysin is the smallest M M P  family member, has one of the largest substrate 
specificities and has been shown to play a role in many normal and disease processes. 
Much of the research into matrilysin thus far, has been associated with its role in cancer 
invasion and metastasis, in particular, its involvement in the spread of colon and breast 
tumours. More recently, matrilysin has been shown to play an important role in several 
aspects of colon and breast tumour progression with respect to initial tumour formation, 
growth and angiogenesis. Matrilysin is also unique in that it is the only M M P  member 
expressed exclusively by the epithelial cells of advancing colon tumours. These 
characteristics of matrilysin have combined to make it an exciting therapeutic target. 
While much is known about the matrilysin protein and its substrates, relatively little is 
known about how matrilysin gene expression is regulated. Cells in order to function 
properly need to ‘sense’ their external environment and this is achieved through signalling 
molecules such as cytokines and signalling pathways which carry these signals to the 
nucleus. Overexpression of cytokines or their receptors in combination with other 
mutations leads to the uncontrolled proliferation of cancer cells. As matrilysin is involved 
in the growth and invasion and metastasis of colon cancer it is quite possible that aberrant 
cytokine signalling may subsequently lead to matrilysin overexpression in tumours 
however the mechanisms of this interaction between cytokine stimulation and matrilysin 
expression has yet to be elucidated. In order to determine if a link exists we have taken a 
panel of colon cell lines and investigated whether matrilysin expression at the 
transcriptional level and protein level can be affected by cytokines which employ several 
different signalling pathways in mediating their effects.
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3.7 Results
A  panel of colon cancer cell lines (HCT116, SW480, SW620, LoVo, WiDr and 
HCA7) were investigated with respect to their expression of matrilysin and if this 
expression could be regulated via cytokine treatment using IGF-I, IGF-II, EGF, IL-6 and 
bFGF. Properties of the cell lines used and a summary of the oncogenes expressed in each 
are illustrated in table 2.1 in section 2.2.1. The HCA7, LoVo and SW480 cell lines all 
represent early to late adenocarcinomas while HCT116, SW620 and W i D R  represent 
colon carcinomas at later stages of development. The SW480 and SW620 cell line have 
both been isolated from the same patient and are a genetically matched pair. SW480 was 
established from a primary adenocarcinoma in the colon which was classified as Duke’s B 
while the S W620 cell line was derived from a lymph node metastasis of the same tumour 
from which SW480 was derived. Interestingly, SW480 has been shown not to express 
matrilysin while SW620 has previously been shown to express matrilysin at the basal 
level (Witty et al., 1994).
3.7.1 RNA isolation from colon cancer cell lines
Prior to reverse transcription polymerase chain reaction analysis the total R N A  
isolated from each cell line was examined for degradation by running an aliqout of each 
isolated R N A  sample (see figure 3.13). The presence of 28s, 16s and 6s R N A  ribosomal 
sub-units is typical of undegraded RNA.
28 s 
1 6 s
6 s
Fig 3.13 Total RNA was isolated and examined for the presence of 28s, 16s and 6s ribosomal sub-units. 
The samples shown here were isolated from the LoVo cell line (left to right : Control, IGF-I, IGF-II, EGF, 
IL-6, bFGF, TP A) and similar results were obtained for other cell lines.
Isolated R N A  was quantified by measuring the absorbance of the samples at 
260nm (1 O D  unit equals 40 pg RNA). The quality of R N A  was also determined by 
measuring the absorbance of the samples at 280nm. The absorbance 260/280 ratio is 
typically between 1.6 and 1.8 for total R N A  free of DNA, protein and organic chemical 
contaminants.
3.7.2 RT-PCR/W estern analysis of matrilysin expression in colon cancer cell lines
Once the total R N A  had been isolated and purified, lpg of sample was used in 
the RT-PCR procedure outlined in section 2.2.3. The RT-PCR procedure was semi- 
quantitative and P-actin, a constitutively expressed cytoskeletal structural protein, was 
used as an internal control. Due to the similarity in product size the p-actin PCR reaction 
was performed in a separate tube to that of the matrilysin PCR reaction. The levels of (3- 
actin served to normalise the amount of matrilysin m R N A  expression observed in control 
and cytokine treated cell lines. Figure 3.14 shows P-actin levels for control and treated 
samples for the LoVo cell lines. The figure illustrates that cytokine treatment of the LoVo 
cell line has no effect on P-actin levels. This result was consistent in all cell lines 
investigated and therefore the levels of P-actin in the LoVo cell line are illustrated as an 
example while the p-actin data for other cell lines are not shown.
Cytokines used in the study included IGF-I, IGF-II, EGF, bFGF. TPA was also 
used as a positive control as it has been previously shown to upregulate M M P s  (Mackay et 
al, 1992). Figure 3.15 demonstrates RT-PCR analysis of matrilysin m R N A  in the LoVo 
cell line in normal and cytokine treated samples. The lower panel in the figure shows the 
entire gel and illustrates that non-specific binding of the matrilysin primers did not occur 
and the expected product size of 341 bp was obtained. This was also observed in the other 
cell lines investigated. In order to clearly see increases/decreases in matrilysin m R N A  
levels, the section which contains the matrilysin PCR products has been enlarged. 
Subsequent RT-PCR and western blot analysis have also been presented in this enlarged 
manner.
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Figure 3.14 RT-PCR analysis of P-actin mRNA expression in the LoVo cell line. The expected PCR 
product size for P-actin was 383 bp. MM; molecular marker, IGF-I; Insulin like growth factor I, IGF-II; 
Insulin like growth factor II, EGF; epidermal growth factor, IL-6; interleukin 6, bFGF; basic fibroblast 
growth factor, TP A; tetradecanoyl, phorbol acetate, E+T; cells treated with EGF and TPA, I+T; cells treated 
with IL-6 and TPA, B+T; cells treated with bFGF and TPA, E+B+I; cells treated with EGF, bFGF and IL-6, 
ALL: cells treated with EGF, IL-6, bFGF and TPA.
2 0 0 “
Fig 3.15 RT-PCR analysis of matrilysin expression in the LoVo cell line. Matrilysin PCR product size was 
341 bp. Concentration of all cytokines and TPA were 50ng/ml. MM; molecular marker, IGF-I; Insulin like 
growth factor I, IGF-II; Insulin like growth factor II, EGF; epidermal growth factor, IL-6; interleukin 6, 
bFGF; basic fibroblast growth factor, TPA; tetradecanoyl, phorbol acetate, E+T; cells treated with EGF and 
TPA, I+T; cells treated with IL-6 and TPA, B+T; cells treated with bFGF and TPA, E+B+I; cells treated 
with EGF, bFGF and IL-6, ALL: cells treated with EGF, IL-6, bFGF and TPA, H20: sterile water used as a 
negative control in PCR, +ve; positive PCR control using matrilysin cDNA. Illustrated molecular marker 
units are in base pairs. The lower gel indicates that no non-specific binding occurred, an observation which 
was consistent in all cell lines examined.
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The effects of cytokine treatments on matrilysin m R N A  expression on each of the 
cell lines investigated are displayed in figures 3.17 to 3.21. In order to confirm that the 
cytokine effects on matrilysin expression at the m R N A  level were resulting in higher 
levels of matrilysin protein, western blot analysis was also performed on the normal and 
cytokine treated cell lines (for methodology see section 2.2.6). Supernatants were 
measured for total protein content and equal amounts of total protein were loaded onto 
SDS-PAGE gels, ensuring that the protein levels detected are as a direct result of cytokine 
treatment. These results for each individual cell line are also shown in figure 3.17 to 3.21.
Matrilysin m R N A  and protein was detected in all cell lines with the exception of 
SW480 (see figure 3.16 and data not shown).
SW480
M K +
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Figure 3.16. Matrilysin was not detected at the mRNA level in the SW480 using RT-PCR. Treatment with 
various cytokines and cytokine combinations failed to initiate the transcription of matrilysin. Western blot 
analysis also failed to detect the presence of matrilysin protein in SW480 samples (data not shown).
Experiments on both m R N A  and protein expression were performed in triplicate. 
Densitometry was performed on the gels and blots and the average results with standard 
deviation from the mean (Microsoft Excel™) are detailed in figure 3.17-3.21.
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Figure 3.17 Analysis of matrilysin expression in the HCA7 cell line using A: RT-PCR analysis and B: 
western blot analysis. Figure legends have been previously described in figure 3.14. C Densitometric 
analysis of matrilysin mRNA and protein expression. Experiments were performed in triplicate and error 
bars represent standard deviation from the mean.
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Figure 3.18 Analysis of matrilysin expression in the WiDr cell line using A: RT-PCR analysis and B: 
western blot analysis. Figure legends have been previously described in figure 3.14. C Densitometric 
analysis of matrilysin mRNA and protein expression. Experiments were performed in triplicate and error 
bars represent standard deviation from the mean.
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Figure 3.19 Analysis of matrilysin expression in the LoVo cell line using A: RT-PCR analysis and B: 
western blot analysis. Figure legends have been previously described in figure 3.14. C Densitometric 
analysis o f matrilysin mRNA and protein expression. Experiments were performed in triplicate and error 
bars represent standard deviation from the mean.
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Figure 3.20 Analysis of matrilysin expression in the HCT116 cell line using A: RT-PCR analysis and B: 
western blot analysis. Figure legends have been previously described in figure 3.14. C Densitometric 
analysis of matrilysin mRNA and protein expression. Experiments were performed in triplicate and error 
bars represent standard deviation from the mean.
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Figure 3.21 Analysis of matrilysin expression in the SW620 cell line using A: RT-PCR analysis and B: 
western blot analysis. Figure legends have been previously described in figure 3.14. C Densitometric 
analysis of matrilysin mRNA and protein expression. Experiments were performed in triplicate and error 
bars represent standard error from the mean.
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Time and dosage experiments found that the optimal time point for endogenous 
matrilysin m R N A  expression subsequent to cytokine treatment was 8 hours. Time points 
of 2, 4, 6 12 and 24 were also examined (data not shown). Cytokine concentrations of 10 
ng/ml, 25 ng/ml, 50 ng/ml and 100 ng/ml were examined and 50 ng/ml of each cytokine 
was found to be the maximum concentration for induction (data not shown). For protein 
analysis, cell lines were incubated with 50 ng/ml of the appropriate cytokine for 48-72 
hours.
Expression of matrilysin in the HCA7 cell line was observed at both the m R N A  
and protein levels (see figure 3.17). An increase in matrilysin m R N A  expression was 
generally observed when the cells were treated with EGF, IL-6, bFGF or TPA. This 
increase was also observed at the protein level using western blot analysis. The effect of 
bFGF on matrilysin protein expression in the HCA7 cell line appears to be similar to that 
of the control level but subsequent studies showed that bFGF was capable of stimulating 
matrilysin protein expression in this cell line in a similar manner to that of EGF and IL-6 
as shown by densitometric analysis. Interestingly, IGF-I appears to have little or no effect 
on matrilysin expression and seems to inhibit the production of matrilysin protein. 
However repeat experiments do not consistently show a significant inhibition in matrilysin 
protein expression in the H C A 7  cell line upon treatment with IGF-I suggesting that IGF-I 
has little or no effect on the regulation of matrilysin expression. IGF-II also appears to 
have little or no effect on matrilysin regulation in the HCA7 cell line. In vivo there may 
be many signals from different signalling molecules converging on the matrilysin 
promoter in order to initiate its transcription. Therefore matrilysin expression may not 
necessarily be initiated/enhanced by a single cytokine but in response to a number of 
cytokines working in concert to promote matrilysin gene expression. W e  therefore 
investigated if treatment of the HCA7 cell line and other cell lines with a combination of 
cytokines would further enhance matrilysin gene transcription. Combination of cytokines 
(outlined in figure 3.17) showed an increase in matrilysin expression in the HCA7 cell 
line, in particular at the m R N A  level, but these increases were not much greater than those 
observed when the cells were treated with individual cytokines such as EGF. Cells were 
also treated with IGF-I and IGF-II in combination with TPA but the observed effects were 
similar to individual TPA treatment which again suggested that neither IGF-I or IGF-II 
were involved in the regulation of matrilysin in the HCA7 cell line (data not shown).
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The WiDr cell line was also found to express matrilysin at both the m R N A  and 
protein level. However in contrast to HCA7, cytokine treatment appeared to have little or 
no effect on the expression of matrilysin (see figure 3.18) at either the m R N A  or protein 
level.
The LoVo cell line expressed matrilysin at the m R N A  and protein level and this 
expression could be modulated by a number of cytokines including EGF, IL-6 and bFGF. 
TPA stimulates the expression of matrilysin m R N A  and protein expression to a greater 
extent than EGF, IL-6 and bFGF. Combination of cytokines with TPA or with each other 
do not appear to stimulate matrilysin m R N A  expression any more than individual 
treatments but the effect on matrilysin protein appears to be more pronounced. IGF-I and 
IGF-II do not appear to have any effect on matrilysin m R N A  or protein expression (see 
figure 3.19).
The HCT116 cell line expressed matrilysin at the m R N A  and protein level and 
this expression could be modulated by EGF, IL-6 and bFGF. Treatment of the HCT116 
cell line also increased matrilysin m R N A  and protein. Combination treatments appear to 
have little effect on the level of matrilysin m R N A  expression in comparison to individual 
cytokine treatment but the effect was more pronounced at the protein level in a similar 
manner to that observed in the LoVo cell line. This may suggest that the m R N A  half life 
was increased by combination treatment of the cells with various cytokines (see figure 
3.20).
The SW620 cell line exhibited a similar matrilysin expression pattern in 
comparison to the HCA7, LoVo and HCT116 cell line in that the normal levels of 
matrilysin expression can be enhanced by EGF, IL-6 and bFGF. IL-6 and bFGF in 
particular appeared to strongly enhance matrilysin at the protein level in the SW620 cell 
line. TPA treatment was again found to enhance matrilysin expression. Combination 
treatments slightly enhanced matrilysin m R N A  and protein expression (see figure 3.21).
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3.7.3 Analysis of matrilysin gene expression using a promoter-lueiferase construct
In order to elucidate the mechanisms through which cytokines such as EGF, IL-6 
and bFGF were stimulating matrilysin gene expression, two matrilysin promoter 
constructs were obtained. 2.3 kbp (pHMATPro-2.3-Luc) and 335 bp (pHMATPro-335- 
Luc) of the human matrilysin promoter were inserted into a luciferase reporter gene vector 
(see table 3.1). Thus increases in matrilysin promoter activity, as a response to cytokine 
treatment, could be determined by an increase in luciferase protein product. The regions 
of D N A  within the matrilysin promoter responsible for transcription factor binding will be 
the subject of chapter 4. The promoter-reporter transient transfection technique is 
extremely sensitive and unlike RT-PCR is a quantitative method. The methodology 
involves transfection, cytokine treatment and luciferase detection which are outlined in the 
methods and materials section 2.2.8. On average transfection efficiencies of 10-20% were 
obtained (see figure 3.22)
Name Size Diagnostic Cut 
(Expected fragments)
Description
PH M A T Pro-2 .3-Luc 7.9 kb Eco RI (5.6 kb and 2.3 kb)
A 2.3 kb M fe I fragm ent o f  the hum an m atrilysin 
prom oter was cloned into the E coR l site o f  
pB luescript (Stratagene). The fragm ent was then 
cut using Hind III and BamHI and cloned into 
the Hind III and Bgl II sites in the pG L2-Basic 
vector (Prom ega).
PH M A TPi'o-335-Luc 5.9 kb Eco RI (5.6 kb and 335 bp)
T his plasmid was constructed in a similar 
m anner to that o f  pH M A T Pro-2.3-L uc with the 
exception that only 335 bp o f  the human 
m atrilysin prom oter was inserted into the pG L2- 
B asic vector
PR L-SV 40 3.7 kb Bam H I and Pst I (1.4 kb 
and 2.3 kb)
C ontains the SV40 early enhancer/prom oter 
region which gives strong constitutive 
expression o f  R enilla  luciferase.
PC H 110 7.1 kb Pvu II (3.5 kb, 2.6 kb, 700 
bp and 360 bp)
C ontains a functional Lac Z gene, the product o f 
w hich is P-galactosidase. This plasmid can be 
transfected into cells and transfection efficiency 
can be determ ined by assaying for blue cells 
using an X-gal stain
Table 3.1 Characterisation of plasmids used in transfection studies (see appendix 1 for plasmid maps)
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Figure 3.22 Transfection conditions for each cell line was optimised using (3-galactosidase activity. Cells 
which were transfected attained the ability to process X-gal which results in a blue colour. SW620 
transfected cells can be clearly observed against non-transfected cells.
In order to normalise transfection efficiencies between each experiment an internal 
control plasmid (pRL-SV40 at a concentration o f  10 ng) was also transfected with the 
matrilysin promoter construct. This ensured that increases in matrilysin promoter activity 
observed after cytokine treatment were in fact due to the cytokine and not due to 
variations in transfection efficiencies between each sample. The internal control in these 
experiments was Renilla luciferase and was a supplied component o f  the Promega Dual 
Luciferase™ kit. Stimulation o f  matrilysin promoter activity by several cytokines was 
observed in all cell lines using the promoter-reporter construct (see figure 3.23 to 3.28). 
This increase was even more pronounced when combination treatments were used, e.g. 
EGF with IL-6 and bFGF which may imply that a number o f  elements were required to 
bind to the matrilysin promoter before transcription could occur. Similar results were 
observed in the experiments using the 335 bp matrilysin promoter reporter construct 
which suggested that transcription factor binding sites important in effecting the 
transcription ofmatrilysin were located within the first 335 bp.
HCA7
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Figure 3.23 2.3 kbp and 335 bp promoter-luciferase analysis in theH C A 7 cell line. Treatment with EGF,
IL-6, bFGF and combination treatments upregulate matrilysin expression. Legend definitions outlined in
figure 3.14.
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WiDr
% Increase ova- control
Figure 3.24 2.3 kbp and 335 bp promoter-luciferase analysis in the WiDr cell line. Treatment with EGF,
IL-6, bFGF and combination treatments upregulate matrilysin expression. Legend definitions outlined in
figure 3.14.
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Figure 3.25 2.3 kbp and 335 bp promoter-luciferase analysis in the LoVo cell line. Treatment with EGF,
IL.-6, bFGF and combination treatments upregulate matrilysin expression. Legend definitions outlined in
figure 3.14.
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HCT116
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Figure 3.26 2.3 kbp and 335 bp promoter-luciferase analysis in the HCT116 cell line. Treatment with EGF,
11^6, bFGF and combination treatments upregulate matrilysin expression. Legend definitions outlined in
figure 3.14.
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Figure 3.27 2.3 kbp and 335 bp promoter-luciferase analysis in the SW620 cell line. Treatment with EGF,
IL-6, bFGF and combination treatments upregulate matrilysin expression. Legend definitions outlined in
figure 3.14.
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Figure 3.28 2.3 kbp and 335 bp promoter-luciferase analysis in the SW480 cell line. Treatment with EGF,
IL-6, bFGF and combination treatments upregulate matrilysin expression. Legend definitions outlined in
figure 3.14.
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For matrilysin promoter-reporter studies time points of 2, 4, 6, 8, 12 and 24 hours 
were examined and similarly to RT-PCR, 8 hours was found to be the optimal response 
time. In all the cell lines investigated there was a consistent increase in luciferase activity 
with both the 2.3 kb and 335 bp matrilysin promoter constructs when the cells were 
treated with EGF, IL-6, bFGF and TPA. Figure 3.23 demonstrates the effects of cytokine 
treatment on the 2.3 kb and 335 bp matrilysin promoter in the HCA7 cell line. Cytokines 
such as EGF, IL-6 and bFGF and the phorbol ester TPA all gave small but significant 
increases in promoter reporter activity. In general this was found to be the typical 
response in all the cell lines examined (see figure 3.24 to 28). IGF-I and IGF-II also 
showed stimulation of the matrilysin promoter in several of the cell lines treated, in 
particular for HCA7 and LoVo (see figure 3.23 and 3.25 respectively) while other cell 
lines such as WiDr and SW620 showed decreases or very slight increases in matrilysin 
promoter activity in comparison to control (see figure 3.24 and 3.28 respectively). The 
increases in matrilysin promoter activity that were observed after IGF treatment were low 
in comparison to those observed after treatment of the cells with EGF, IL-6, bFGF and 
TPA. These results confirmed the RT-PCR and western results whereby IGF-I and IGF-II 
treatment appeared to have little or no effect on matrilysin gene activity whereas EGF, 
bFGF and IL-6 gave a small but consistent increase in the majority of cell lines examined.
Perhaps the most interesting observation in these experiments was the fact that 
treatment of the cells with a combination of cytokines resulted in a consistently large 
increase in matrilysin promoter activity in comparison to the control. For example 
treatment of the majority of cell lines with EGF , bFGF and IL-6 resulted in an 
approximately 400-700% increase in matrilysin promoter activity in comparison to control 
levels (see figure 3.23 to 3.28). This suggested that the matrilysin promoter may require 
the effect of a number of signalling cascades before gene transcription can commence. 
Interestingly, similar effects with combination treatments were not observed via RT-PCR 
and western blot analysis. This may be due to the fact that the promoter-luciferase 
reporter assay system was much more sensitive than RT-PCR and western analysis or that 
the endogenous matrilysin gene activity within the cell lines investigated was already 
being stimulated and that combination treatments were only slightly able to augment 
endogenous matrilysin activity.
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Surprisingly the SW480 cell line also showed similar increases in matrilysin 
promoter activity in response to cytokine treatment when compared to the other cell lines 
investigated (see figure 3.28). This result was in complete contrast to those obtained for 
SW480 using RT-PCR and western blot analysis whereby endogenous matrilysin was not 
detected nor could it be stimulated by treatment of individual or combination treatment of 
cytokines. W e  therefore hypothesised that although the SW480 cell line contained the 
signalling cascades and transcription factors required to initiate the transcription of 
matrilysin, the matrilysin gene within the SW480 cell line was unresponsive to the effect 
of these transcription factors, a process which may be explained by promoter 
hypermethylation.
In the cell lines investigated with the matrilysin promoter reporter constructs, 
LoVo (figure 3.25) appeared to be the most responsive while WiDr (figure 3.24) appeared 
to be least responsive to cytokine treatment. Many of these cell lines contain activated 
signalling cascades which may result in the cell nucleus being saturated with various 
transcription factors that can promote matrilysin transcription. It may also be possible that 
cytokine treatment only augments the levels of these transcription factors and therefore 
the initial level of transcription factors within the cell may dictate how responsive that cell 
line may be to cytokine treatment. For example the W i D R  cell line may have reached a 
saturation point of transcription factors that are responsible for the stimulation of the 
matrilysin promoter and would therefore be unresponsive to further cytokine treatment.
In the majority of luciferase assays the 2.3 kb matrilysin promoter reporter 
construct typically gave higher values than those of the 335 construct which may be an 
artifact of R N A  polymerase stabilisation as the 335 matrilysin promoter construct also 
gave significant increases after cytokine treatment in comparison to control. These data 
would suggest that the transcription factors responsible for the transcriptional regulation 
of the matrilysin gene bind to the promoter within the first 335 base pairs. However, the 
effect of enhancers or silencers which can be many thousands of base pairs away cannot 
be ignored.
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3.7.4 Silencers and enhancers within the murine matrilysin gene
Silencers and enhancers are elements which repress or enhance gene transcription. 
These can be located up to several kilobase pairs upstream or downstream of the target 
gene or may also be located in the introns within the gene itself (Kamakaka, 1997). 
Enhancers are cis acting elements and stimulate gene expression by binding to 
transcription factors bound to the promoter of the gene in question and causing a 
conformational change which ‘enhances’ gene transcription. Repressor proteins bind to 
silencer elements and slow or ‘silence’ transcription of a particular gene. Even though 
these elements may be thousands of base pairs away silencers and enhancers can still 
mediate their effects due to the helical looping of D N A  which brings them into contact 
with target genes.
The murine matrilysin gene is 15.5 kbp in size and contains 6 exons and 5 
introns. In order to assess these introns for enhancing/silencing properties, the introns 
within the gene were inserted into a promoter plasmid (pGI,2 Promoter. Promega), 
transfected into cells and analysed for luciierase activity. The promoter plasmid contains 
the SV40 gene upstream of the luciferase gene. D N A  fragments containing putative 
promoter enhancer silencer elements can be inserted upstream/downstream of the 
promoter-luciferase transcriptional unit (see appendix 1 for plasmid map). Initial cloning 
of the whole murine matrilysin gene into the promoter vector was unsuccessful due to the 
size of the insert. Thus a different strategy involving PCR cloning of the introns was 
employed, see section 2.2.9 for details.
PCR primers, forward and reverse, were developed for each of the introns within 
the murine matrilysin gene and the expected basepair sizes were as follows; Intron 1, 3 kb; 
Intron 2, 250 bp; Intron 3; 650bp; Intron 4, 1.6 kbp and Intron 5, 1.7kbp. Following PCR 
and isolation of the products (see figure 3.29 A  and B), the D N A  encoding each intron 
was subsequently ligated into pBlueScript™ (Stratagene, see appendix 1 for plasmid map), 
see materials and methods section 2.2.9. Positive clones were miniprepped and the 
introns then ligated into pGLiPromoter. The resultant plasmids were then transfected into 
several cell lines and examined for their effect on the pGL2Promoter’s luciferase activity 
(figure 3.30).
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Fig 3.29 A PCR products of the five introns within the matrilysin gene. The expected base pair sizes 
were 3, 0.25, 0.65, 1.6 and 1.7 kbp for introns 1-5 respectively. B PCR products illustrated in 3.17 A 
were ligated into pBlueScript™. Restriction of the pBS plasmids With. Xho /  and SacI result in the 
separation of the insert from the pBS vector. The resultant stagger ended cDNA fragments were then 
ligated into pGL2Promoter.
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Figure 3.30 Transfection of the promoter intron constructs into the HCT116 cell line. A number of the 
constructs show a decrease in promoter luciferase activity suggesting the possible location of silencer 
elements within the introns.
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3.8 Discussion
Previous reports have shown that M M P  expression can be modulated by a variety 
of agents including cytokines. Matrilysin expression has been shown to be upregulated by 
EGF in colon, prostate, head and neck and cervical cancer (Gaire et al., 1994, Witty et al., 
1994, Sundareshan et al., 1999, O-Charoenrat et al., 1999 and Ueda et al., 1998) while 
bFGF and IL-6 have been shown to be involved in matrilysin expression in the prostate 
and mononuclear phagocytes (Klein et al., 1999, Udayakumar et al., 2001 and Busiek et 
al., 1995). However, the mechanisms of how these agents mediate their effects, in 
particular with respect to matrilysin expression, are poorly understood. W e  have 
investigated the regulation and expression of matrilysin in colon cancer as several studies 
have implicated matrilysin to be clinically relevant in colon tumour invasion and 
metastasis and more recently in early stages of colon tumour growth and development. 
An understanding of how matrilysin is regulated at a gene level is therefore important in 
determining i) how its expression in early tumours is controlled and ii) the link between 
tumour growth and matrilysin expression. Understanding these questions will play a key 
role in the development of therapies which will be effective in inhibiting matrilysin’s role 
in colon tumourigenesis.
In the panel of colon cell lines investigated in this chapter EGF, IL-6 and bFGF 
were found to upregulate matrilysin expression in HCT116, SW620, HCA7 and LoVo 
while in general WiDr matrilysin levels remained unaffected when treated with cytokines. 
The SW480 cell line did not express matrilysin at a basal level and could not be 
stimulated to do so by cytokine treatment.
Semi-quantitative RT-PCR analysis showed that in the 4 cell lines stimulated by 
EGF, IL-6 and bFGF, matrilysin m R N A  expression increased by up to two fold on 
average. RT-PCR is a semi-quantitative method and gives an approximate indication of 
the levels of matrilysin m R N A  in samples. In order to determine a more accurate portrayal 
of the levels of m R N A  after cytokine treatments an internal positive control that is 
normally constitutively expressed was used. (3-actin is a cytoskeletal protein expressed in 
the majority of cell types and was therefore used as a control in the RT-PCR experiments.
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Fig 3.14 shows an example of P-actin expression in the LoVo cells following 
treatment with the various cytokines. In general levels of P-actin did not fluctuate in 
response to cytokine treatment in any of the cell lines. Slight inaccuracies in the addition 
of m R N A  may result in a higher or lower yield of PCR products but using densitometric 
analysis on P-actin m R N A  levels, these inaccuracies can be rectified and matrilysin levels 
subsequently calculated, thus yielding the accurate level of matrilysin m R N A  expression. 
Although the RT-PCR used in these experiments is semi-quantitative, figures 3.17-3.21 
show consistently that in many cell lines there is a distinct increase in matrilysin m R N A  
levels. RT-PCR can be made quantitative, but a means to negate the tube to tube 
variability which is inherent in the procedure must be found. The use of an internal 
standard is normally used to make RT-PCR more accurate. Data presented in figures
3.17-3.21 do not show the P-actin products as the matrilysin and p-actin reactions were 
performed in separate tubes. However earlier experiments did incorporate P-actin into the 
matrilysin PCR reaction and these results were consistent with those displayed in figures
3.17-3.21 with respect to cytokine stimulation of matrilysin at the m R N A  level. Northern 
blot analysis is traditionally used in analysing m R N A  levels but the procedure involves 
radioactive probes and therefore can be quite hazardous. Competitive RT-PCR and 
Northern blot analysis were not used to analyse matrilysin levels as promoter-reporter 
constructs were used to ensure that the cytokines chosen were having a direct effect on 
matrilysin gene expression and that the increase in m R N A  levels observed via RT-PCR 
were not as a result of secondary signalling or stabilisation of the mRNA.
Although matrilysin m R N A  expression was increased in response to EGF, IL-6 
and bFGF, this may not necessarily result in an increase in protein expression. Therefore 
the effects of the cytokines on matrilysin protein levels was also examined. Figure 3.17-21 
shows the detection of matrilysin protein via western blot analysis. The antibody used 
was a monoclonal antibody which detects the latent and intermediate forms of the 
matrilysin protein (Shattuck-Brandt et ah, 1999). Matrilysin protein was detected in all 
the cell lines with the exception of S W480 which is consistent with the m R N A  analysis in 
that no matrilysin expression was observed via RT-PCR. Levels of matrilysin in the 
remaining cell lines could be increased via treatment with EGF, bFGF and IL-6 in varying 
degrees. WiDr however showed only slight increases which is also consistent with RT-
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PCR analysis in that only small increases were observed. Figure 3.17 (HCA7) and figure 
3.20 (HCT116) show that in general the effects on matrilysin m R N A  expression by EGF, 
IL-6 and bFGF resulted in increased levels of matrilysin protein expression. This suggests 
that EGF, IL-6 and bFGF stimulate matrilysin m R N A  expression which is subsequently 
translated into increases at the protein level and therefore the overexpression of these 
cytokines or their receptors in cancer cells could lead to an increase in matrilysin 
expression which, as we have discussed, may subsequently play a role in colon cancer 
tumourigenesis and colon cancer invasion and metastasis.
The use of matrilysin promoter reporter constructs also verified that the increases 
in matrilysin expression observed via RT-PCR analysis were as a result of direct 
stimulation at a transcriptional level by EGF, IL-6 and bFGF. Figures 3.23 to 28 illustrate 
that transient transfection of both the 2.3 kbp and 335 bp matrilysin promoter constructs 
and treatment with EGF, IL-6 and bFGF resulted in an increase in luciferase levels in all 
cell lines including the SW480 and WiDr cell lines. The increase in luciferase production 
for EGF was up to 50% greater than that of the control cells in many of the cell lines. 
Interestingly, some combination treatments with various cytokines showed an increase of 
700% in the production of luciferase. For example, in Figure 3.23, treatment of the HCA7 
cell line with a combination of EGF, IL-6 and bFGF resulted in a 500% increase in 
luciferase production in comparison to control values. These results indicated that the 
transcription factors stimulated by these cytokines converge on the matrilysin promoter 
and synergistically cooperate to enhance matrilysin transcription as an additive effect 
would have only given an increase of approximately 150%. These increases, observed in 
combination treatments, suggest that a number of transcription factors need to be present 
on the matrilysin promoter in order to enhance transcription of the matrilysin gene. It is 
important when examining the effects of a single signalling agent in vitro to realise that 
these agents do not operate in isolation. Many of the signalling pathways used by 
receptors engage molecules used by other receptors and therefore there is a great deal of 
‘cross talk’ between signalling molecules within the signalling cascades. The ‘cross talk’ 
between receptor signalling pathways can serve to inhibit gene expression or enhance the 
signal and increase the rate of expression of target genes. It is therefore plausible that 
combination treatment with factors involved in proliferation, migration, wound response 
and inflammation will result in the ‘cross talk’ between various receptors and their
signalling molecules. This in turn would result in an increase of transcription factors 
geared towards the expression of matrilysin and other target genes. The transcription 
factors stimulated by these receptors converge on the matrilysin promoter and through 
contact with each other and via conformational change of the matrilysin promoter enhance 
the expression of matrilysin.
TP A, a known regulator of several MMPs, was shown in the majority of the 
experiments illustrated in figures 3.17 to 3.21 to increase matrilysin expression at the 
m R N A  and protein level. TPA has been shown to act as a diacyl glycerol analogue in the 
PKC pathway as its effects can be blocked by the addition of staurosporine (Mackay et al., 
1992). The treatment of cells with TPA also resulted in an increase of the AP-1 binding 
site molecules Jun and Fos. Recent evidence has also shown that TPA is involved in the 
activation of the TNF-a converting enzyme (TACE) which converts TNF-a and TGF-a 
into their biologically active form (Jolly-Tornetta and Wolf, 2000). TNF-a mediates its 
effects through the PKC pathway while TGF-a exerts its effects through the EGF 
receptor. Therefore TPA uses a number of pathways which result in the increase of 
transcription factors such as jun and fos which in turn can bind to the AP-1 site located in 
the promoter of many of the M M P s  including matrilysin (Fukasawa et al., 2000). TPA 
was therefore used in experiments as a positive control. In matrilysin promoter reporter 
experiments illustrated in figures 3.23-3.28, TPA treatment resulted in an increase of 
approximately 40% luciferase production when compared to control in the majority of cell 
lines. Combination of TPA with EGF, IL-6 or bFFG enhanced matrilysin promoter 
activity by up to 500% over control. This suggested that although TPA in isolation can 
increase matrilysin via transcription factors such as jun and fos, the promoter also requires 
the presence of other transcription factors stimulated by EGF, IL-6 and bFGF to enhance 
its activity. The resultant increase in promoter activity when cells are treated with a 
combination of TPA and EGF, TPA and IL-6, TPA and bFGF or a combination of EGF, 
IL-6 and bFGF suggests a number of factors are required to stimulate matrilysin activity 
and that these factors act in a synergistic manner.
The large increases observed in promoter-reporter experiments after combination
treatments were not observed to the same extent at the m R N A  and protein level as
evidenced in figures 3.17 to 3.21. Luciferase reporter experiments are extremely sensitive
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and therefore differences in activity are much more pronounced. This is primarily due to 
the long half life of the luciferase protein and the sensitivity of the assay. It is also 
possible that matrilysin gene transcription is rate limiting as the gene can only be 
translated at a certain rate. The control levels of matrilysin were quite high in many of the 
cell lines investigated with the exception of SW480 and so the differences in matrilysin 
activity at the m R N A  and protein levels were not as apparent. WiDr also showed that 
luciferase levels can be stimulated after cytokine treatment although these increases were 
not observed via RT-PCR and western blot analysis. The luciferase technique is quite 
sensitive and therefore increases in m R N A  and protein level may be more difficult to 
observe via RT-PCR and western blot analysis in the WiDr cell line.
Using RT-PCR and western blot analysis, SW480 was found not to express 
matrilysin and could not be stimulated to do so when treated with cytokines in isolation or 
in combination. However matrilysin promoter reporter studies showed that the 
transcriptional machinery required for matrilysin transcription is present in the cells as the 
control experiments produced high levels of luciferase activity and these levels could be 
enhanced even further when the transiently transfected cells were treated with cytokines in 
isolation and in combination. Witty et al., (1994) have shown that the SW480 cell line 
can be stably transfected with the matrilysin cDNA under control of a SV-40 promoter. 
The transfected SW480 cells as a result become much more invasive as was evidenced 
when the cells were injected into nude mice. It is therefore possible that the matrilysin 
gene may be hypermethylated which would suggest that the gene is ‘silenced’ and 
therefore not expressed in SW480. Increased methylation is associated with cancer with 
the genes being ‘silenced’ normally being tumour suppressor genes. It is therefore 
possible that other genes such as matrilysin may be the target of random hypermethylation 
in a G C  area which results in a restriction of expression in the affected gene (Kamakaka et 
al., 1997).
Cytokine treatments were initially performed on the cell lines transfected with the
2.3kbp human matrilysin promoter reporter construct. However, most of the potential
transcription factor binding sites are located within the first 335 bp. Therefore in order to
determine the sites within the promoter that were responsible for the enhanced activity
after cytokine treatment a 335 bp promoter-reporter plasmid was constructed. The
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plasmid was transfected into the same cell lines and the activity of the promoter was 
analysed after the various cytokine treatments. Although the luciferase levels were lower 
than those observed with the larger 2.3 lcbp matrilysin promoter the percentage increases 
over control were comparatively similar. The lower values may have been due to R N A  
polymerase instability due to the length of the promoter but it is also possible that 
additional transcription factor binding sites or enhancers may exist further upstream. The 
fact that the increases over control were similar to those obtained with the 2.3 kbp 
promoter suggested that the key transcription factor binding D N A  sites required for 
matrilysin gene transcription are present in the first 335 bp.
Interestingly, IGF-I and IGF-II, irrespective of dose, proved not to stimulate 
matrilysin expression at the m R N A  and protein level or to stimulate matrilysin promoter 
activity. Previous studies have shown that certain M M P s  are capable of activating IGF-I 
and IGF-II by cleaving bound inhibiting proteins, the IGFBPs (Lahm et al, 1994, Collett- 
Solberg and Cohen, 1996 and Fowlkes et al., 1995). These studies suggest that a link 
between IGF activation and stimulation of M M P  expression may exist. Although IGFs 
may be involved in the stimulation of other MMPs, experimental evidence in this chapter 
indicates that IGF does not play a direct role in the stimulation of matrilysin and therefore 
no autocrine loop between matrilysin stimulation and IGF activation exists.
Doses of IGF-I and IGF-II of up to 200ng/ml were examined but these failed to
increase matrilysin expression (data not shown). Only slight increases were observed in
matrilysin promoter studies but these increases were inconsistent, unlike other cytokines
examined such as EGF, bFGF and IL-6. Matrilysin promoter experiments in which cells
were treated with a combination of IGF-I and IGF-II failed to increase promoter activity.
Addition of TPA with IGF-I and IGF-II increased expression by approximately 40% in a
number of cell lines but this increase was due to the activity of TPA on the matrilysin
promoter as TPA treatment on its own yielded a 40 %  increase in promoter activity. In
many cancer cell lines the production of cytokines and their receptors is elevated or the
receptor may be continually firing irrespective of whether a cytokine is bound or not.
Many of the cell lines examined in this study have high basal levels of matrilysin and this
is not surprising since the majority of the cell lines studied express activated Ras which
switches on pathways involved in cell proliferation, therefore increasing transcription
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factors associated with cell proliferation, such as the AP-1 binding complex of Jun and 
Fos. This increase in transcription factors such as AP-1 in turn increase the expression of 
many of the M M P s  including matrilysin. Slight increases in promoter activity after 
cytokine treatment may therefore be hard to identify in these colon cancer cell line model 
systems. In addition to Ras activation, the cell lines as stated previously may also have 
upregulated or activated mutated receptors. Our studies therefore suggest that while 
matrilysin may play an extracellular role in the activation of IGFs (either directly or 
through the activation of proteolytic cascades) the active IGFs in turn do not play a direct 
role in upregulating matrilysin gene expression.
The presence of enhancer and silencer elements within the introns of the murine 
matrilysin gene was also investigated. Enhancers and silencers can be many thousands of 
base pairs away from their target gene but the helical and looping nature of D N A  ensures 
that these elements come in contact with the promoter region in the gene of interest. 
Enhancers and silencers can be upstream and downstream of the transcription initiation 
site but can also be located in the intron of the gene of interest. Having cloned the murine 
matrilysin introns into a promoter-luciferase reporter plasmid the effects of the introns on 
the promoter were examined in various cell lines. Figure 3.30 gives a representative 
example of the effects of the introns on the promoter-luciferase construct in the HCT116 
cell line. Introns 1, 2 and 5 gave a significant reduction in promoter activity when 
compared to the control while introns 3 and 4 gave only slight increases. This may suggest 
that ‘silencing’ or repressing elements may be present in introns 1, 2 and 5 of the murine 
matrilysin gene. The presence of enhancer elements outside the gene are also possible and 
this will involve cloning of several kilobases at either side of the gene and their 
subsequent examination.
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3.9 Conclusions
This chapter focussed primarily on the expression and regulation of matrilysin by 
IGF-I, IGF-II, EGF, IL-6 and bFGF in a number of colon cancer cell lines. All cytokines, 
with the exception of the IGF members, were found to increase matrilysin m R N A  and 
protein levels in the cell lines tested with the exception of the SW480 cell line. These 
observations were confirmed via matrilysin promoter-reporter experiments which 
indicated that EGF, IL-6 and bFGF are capable of enhancing matrilysin gene 
transcription. Increased promoter activity was observed in all cell lines including SW480. 
Combination treatments of cytokines with or without TP A  increased both the 335 bp and 
2.3kb promoter activity considerably suggesting that the transcription factors stimulated 
by these agents act in a synergistic manner in the activation of the matrilysin promoter 
although these effects were not observed via RT-PCR and western blot analysis. 
Matrilysin promoter experiments coupled with RT-PCR analysis suggested that EGF, IL-6 
and bFGF have a direct effect on the expression and regulation of matrilysin. The 
increases observed using the 2.3 kb promoter experiments were also observed with the 
335 bp promoter experiments and this suggested that the transcription factor elements 
causing the increases were binding to D N A  sequences within the first 335 base pairs of 
the transcription initiation site of the matrilysin promoter.
IGF-I and IGF-II were shown not to affect matrilysin expression thus indicating 
that although matrilysin may be involved in the processing of IGFs into biologically active 
molecules, IGFs are not involved in the direct stimulation of matrilysin gene expression. 
The presence of silencer and enhancer elements within the murine matrilysin gene was 
also examined. Potential silencer elements may exist within introns 1, 2 and 5. The 
existence of silencer and enhancer elements outside the matrilysin gene may also be 
possible but this will require further studies.
Although previous reports have indicated that EGF, IL-6 and bFGF have a 
stimulatory effect on MMPs, including matrilysin, this is one of the first studies 
examining the effect of these cytokines on a number of colon cell lines. However the 
exact mechanisms by which these cytokines and their receptors mediate their effects are 
poorly understood and will be examined in more detail in chapter 4.
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Chapter 4
The mechanisms controlling matrilysin gene transcription : 
EGF upregulates matrilysin expression through activation of
PEA3 transcription factors
4.1 Analysis of the human matrilysin promoter
Experiments carried out in chapter 3 showed that matrilysin gene transcription 
could be influenced by a number of cytokines including EGF, bFGF and IL-6. EGF 
treatment of colon cell lines, in particular, consistently resulted in an increase in matrilysin 
promoter activity. Other reports have shown that EGF can upregulate matrilysin 
transcription in various cancer cell lines including those of a prostate, colon and head and 
neck squamous carcinoma origin (Sundareshan et al., 1999, Gaire et al., 1994 and O- 
charoenrat, 1999). However, no reports have adequately addressed the mechanisms by 
which EGF, or other cytokines for that matter, can upregulate the transcription of 
matrilysin. As discussed earlier cytokines, such as EGF, mediate their effects by binding 
to their specific receptors. The receptor in turn activates a number of signalling molecules 
which then activates other molecules involved in a signalling cascade. This cascade 
converges on the nucleus resulting in the activation/enhanced expression of transcription 
factors. These transcription factors subsequently bind to the promoter of target genes and, 
in combination with other transcriptional elements, prepare the gene for transcription.
Gene transcription is the fundamental cellular process that regulates growth, 
development, cell maintenance and many responses to external stimuli. The transcription 
machinery is exceptionally complicated, consisting of three multisubunit R N A  
polymerases, complex polymerase associated transcription factors, co-activators and 
hundreds (currently defined) to thousands (the projected number) of upstream 
transcription factors that bind to D N A  and interact with the promoter bound transcription 
complex. The transcription factor proteins bind to sequence specific elements within the 
promoters of target genes. The sequence of the human matrilysin promoter has been 
previously reported (Gaire et al., 1994) and insertion of the matrilysin promoter into a 
transcription factor search engine (http://transfac.gbf.de/TRANSFAC/) reveals a number 
of key potential transcription factor D N A  binding sequences within the first 500 base pairs 
(see figure 4.1). The potential transcription factor binding sites within the matrilysin 
promoter include TATA, AP-1, C/EBP, PEA3, Tcf/LEF and Kaiso binding elements.
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Figure 4.1 The structure of the human matrilysin promoter. The sequence of the human matrilysin promoter 
has been previously reported (GenBank accession number L22525). Indicated are the positions of a number 
of potential transcription factor binding sites within the promoter relative to the transcription start site which 
is located at +1. These sites were determined via the transcription factor search engine (Translac). The Tcf 
site at-194 is inverted. Diagram is not drawn to scale.
4.1.1 The TATA binding protein (TBP)
The matrilysin promoter is similar to other eukaryotic promoters in that it is 
composed o f  a myriad o f  binding sites for gene specific regulatory transcription factors as 
well as a core that is composed o f  a TATA box. The general transcription machinery 
assembles over the core promoter and initiates transcription at the start site. The presence 
o f  the TATA binding protein (TBP) at the TATA box appears to be a pivotal intermediary 
step in transcriptional activation and deactivation. With the aid o f  a functional bound 
transcriptional activator, TBP is recruited to the TATA box along with a number o f  other 
regulatory proteins. This activator/TBP complex subsequently or simultaneously recruits 
the RNA polymerase (pol) II holoenzyme allowing it to effectively compete out the 
binding o f  TBP inhibitors and thus allowing gene transcription to commence (see figure
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4.2). Once the transcription factor activator signal is removed, rendering the activator 
non-functional, TBP inhibitors may be at a competitive advantage over the poi II 
holoenzyme thus inhibiting gene expression (see Pugh, 2000 for review).
TFIIA TBP TFIID
TATA ATG
1
[TATA ATG
------- ►
1
Figure 4.2 Simplified diagram of two of the major steps in transcription complex assembly. Activators 
bound to their cognate sites on promoter DNA recruit TFIIA and TBP/TBP associated factors (TAFs) 
complex TFIID to the core promoter. This complex then enables the pol II holoenzyme to bind and initiate 
transcription.
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4.1.2 AP-1 transcription factor binding proteins.
The AP-1 D N A  binding sequence, also known as the TRE site (TPA response 
element), has been shown to bind a number of AP-1 protein complexes. These are 
primarily Jun, JunB, Fos, FosB, Fral, Fra2 and JunD. Each of these proteins can bind to 
form homo or heterodimers and are structurally grouped in the basic leucine zipper class 
of transcription factors (Borden and Heller, 1997). The resultant AP-1 complexes can 
bind to AP-1 D N A  elements, and the content of the complex, i.e. Jun/Fos or JunB/Fos can 
dictate the speed at which gene transcription can take place. Thus within the cell the 
levels of each of the factors which combine and bind to the AP-1 D N A  sequence are 
important in determining whether gene transcription can commence as some complexes 
are weaker activators than others.
The AP-1 D N A  binding site has been shown to play a pivotal role in the 
regulation of M M P  gene expression by growth factors, cytokines and oncogenes (Lafyatis 
et al., 1990, McDonnell et al., 1990 and Hu et al., 1994). Many of the M M P s  contain an 
AP-1 binding site within the first 100 bp of the transcription start site and this is also true 
for matrilysin (see figure 1.3). The general AP-1 sequence, found in many of the M M P  
and TIMP promoters is TGAGTCA. Human matrilysin has been shown to be induced by 
a number of factors such as EGF and TPA (Gaire et al. 1994). In these experiments 
matrilysin-chloroamphenicol acetyl transferase (CAT) promoter constructs were 
transfected into HeLa cells and treated with EGF which resulted in increased C A T  activity 
over control. Gaire et a l , (1994) developed promoter-reporter constructs of various sizes 
which showed that the PEA3 and AP-1 sites were essential for increased promoter activity 
following EGF treatment. Several reports have shown that AP-1 is important in growth 
factor/TPA induction of many of the M M P  genes but the AP-1 site alone is insufficient for 
full activity (Mattei et al., 1990, Lafyatis et al., 1990 and Matrisian et al., 1991). 
Increases in AP-1 transcription factors in the cell nucleus would therefore contribute to 
increased expression of matrilysin. In normal cells the increase in AP-1 transcription 
factors can be as a result of stimulation by external stimuli such as EGF but in cancer cells 
mutations in oncogenes such as ras can lead to constitutively high levels of AP-1 
transcription factor binding proteins. Various reports have shown that AP-1 activity can 
be induced by neoplastic transformation and expression of transforming oncogenes such
as activated H-ras in the colon and breast (Smith et al., 2000 and Sassone-Corsi et al., 
1989). Yamamoto et al., (1995) have also shown that matrilysin can be induced by 
activated Ki-ras via AP-1 in SW1417 colon cancer cells. This was achieved by the stable 
transfection of Ki-ras into the SW1417 cell line and its subsequent activation which 
resulted in increased levels of AP-1 factors (Yamamoto et al., 1995). Thus, the increase 
in AP-1 levels resulted in increased levels of matrilysin in the SW1417 cell line. As 
previously discussed matrilysin is involved in early colorectal tumourigenesis and a ras 
mutation is one of the early genetic ‘hits’ in Fearon and Vogelstein’s colorectal cancer 
progression model which may therefore suggest that mutations in ras lead to increased 
matrilysin expression which is subsequently involved in tumour growth and progression. 
The members of the AP-1 transcription factor family are also capable of forming dimers 
with ATF (activating transcription factor) family members, comprised of ATF1, ATF2, 
ATF3, ATF4, ATF6, CREB, E4TF3 and E2A.E which are also involved in cell growth 
and differentiation (Vinson et al., 1993).
4.1.3 Potential activation matrilysin via the C/EBP element
As previously discussed in chapter 3, the IL-6 receptor is thought to mediate its 
signal via the JAK-STAT signalling pathways. IL-6 binding to the IL-6 receptor a-chain 
induces homodimerisation with the signal transducing (5-chain, gp-130, which is followed 
by the activation of the receptor tyrosine kinases JAK-1, JAK-2 and Tyk-2. This receptor 
kinase complex then interacts with and activates the SRC homology 2 (SH2)-containing 
cytoplasmic STAT3 transcription factor which then translocates to the nucleus and aids 
the transcription of many target genes including, c-jun, c-myc and C C A A T  enhancer 
binding proteins or C/EBPs. The C/EBPs encompass a family of transcription factors 
with structural as well as functional homologies. Similarities between C/EBP family 
members suggest an evolutionary history of genetic duplications with subsequent pressure 
to diversify. The resulting family of proteins vary in trans-activating ability and tissue 
specificity. Since the cloning of the family’s original member, C/EBPa, five other 
C/EBPs have been identified that interact with each other and with transcription factors in 
other protein families to regulate m R N A  transcription. The other five family members 
have been designated C/EBPp, C/EBPy, C/EBP8 C/EBPs and C/EBP^ (see Lekstrom-
Himes and Xanthopoulos, 1998 for review). C/EBPs in general, like many other 
transcription factors, are modular proteins consisting of an activation domain, a D N A  
binding basic region and a leucine rich dimerisation domain. The dimerisation domain or 
‘leucine zipper’ is a heptad of leucine repeats that intercalate with repeats of the dimer 
partner, forming a coil of a-helices in parallel orientation. Electrostatic interactions 
between amino acids along the dimerisation interface determine the specificity of dimer 
formation among family members as well as with transcription factors of the NF-kB and 
Jun/Fos families (Vinson el al., 1993). The presence of a potential C/EBP element 
(CAATT) adjoining the -55 PEA3 site on the matrilysin promoter may indicate that 
matrilysin can be directly activated by factors such as IL-6 via C/EBP stimulation. 
Previous results in Chapter 3 have shown that matrilysin gene activity was enhanced after 
the addition of IL-6 and therefore it is possible that IL-6 mediates its effects on matrilysin 
gene activity via the upregulation of transcription factors such as C/EBP.
4.1.4 The Ets family of transcription factors
There are three potential PEA3 transcription factor binding elements within the 
matrilysin gene suggesting that members of the ETS family of transcription factors are 
involved in matrilysin gene transcription. The v-ets oncogene, the first member of the ets 
gene family to be described, was discovered in the E26 (‘E-twenty-six’) acutely 
transforming retrovirus of chicken from which it derives it name (LePrince et al., 1983 
and Watson et al., 1990). The main family members include Ets-1, Ets-2, GABP-a, Erg, 
Fli-1, D-Elg, E74A, Elf-1, Sap-1, Elk-1, PU.l and PEA3 which were cloned from a 
variety of tissues (see table 4.1). In most family members, the conserved D N A  binding 
domain, the ETS domain, is located at the carboxyl terminus of the protein with the 
exception of Elk-1, SAP-1, and Elf-1, where it is found at the amino acid terminus (Rao 
and Reddy, 1992 and Thompson et al., 1992). The ETS domain, which is approximately 
85 amino acids, has no structural homology to other D N A  binding motifs such as the zinc 
finger, homeodomain, leucine zipper or helix turn motifs but has limited homology to the 
D N A  binding domain of the c-myb oncogene product.
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Protein Molecular
Weight
Amino Acid 
homology to ETS 
domain of Ets-1
Expression/Features
Ets-1 39-52 100%
Elevated expression in the thymus and 
endothelial cells; phosphorylated; alternatively 
spliced; positively autoregulates transcription
Ets-2 58/62 90%
Expression induced following macrophage 
differentiation and T-cell activation; 
alternatively spliced; phosphorylated
Erg 41/52 70% Alternatively spliced; 98% homologous to Fli-1
Fli-1 51 68% 98% homologous to Erg
Elk-1 60 76%
Ets like factor-1; Ets domain located in amino 
terminus of the protein; forms ternary complex 
with SRF; Shows three regions of homology 
with Sap-1
Sap-1 52/58 75%
SRF accessory protein-1; which like Elk-1 
forms a ternary complex with SRF; contains 
three regions of homology with Elk-1; 
including the Ets domain which is located at 
the amino terminus of the protein; the two 
isoforms, Sap-la and Sap-lb, differ in their 
caboxy-termini
PEA3 68 68%
Expressed in brain, epididymis and in 
fibroblast and epithelial cells, down regulated 
in embryonic cell lines in response to retinoic 
acid induced differentiation; subfamily 
members include ERM and ER-81
TCFl-ot 55 55%
Very limited homology to ETS domain exists 
within the HMG box of this factor; expression 
is generally restricted to the thymus and is 
induced following T-cell activation; regulates 
activity of the TCRa enhancer
Table 4.1 Details of selected members of the ETS family of transcription factors.
The sequence conservation of the proteins and chromosome locations of the 
genes provide clues to gene duplication and divergence events which gave rise to this 
gene family. For example the ets-1 and fli-1 genes both map to the same chromosome 
region, llq23, while ets-2 and erg both map to 21q22. This suggests that duplication of 
an ancestral e/.v-related gene may have occurred, giving rise to two sister genes, which 
subsequently diverged over time.
140
The expression of ets genes is controlled at several levels; the initiation of 
transcription, alternative splicing, post translational modification and protein stability. 
The expression of the ets gene family also varies between tissues. Regulation of 
transcriptional initiation is best understood for the human ets-2 gene. Like all other ets 
promoters described and many other oncogene promoters, the ets-2 promoter lacks the 
classical T A T A  and C C A A T  box sequences found in many R N A  polymerase II 
transcribed genes. A  putative Ets-binding site (EBS) has been identified downstream of 
the promoter which may indicate that the ets-2 gene is negatively autoregulated. Adjacent 
to this EBS there is a putative activator protein 1 site (AP-1) and factors bound at these 
sites may cooperate in trans activation. The promoter of the ets-1 gene contains putative 
AP-1, EBS, AP-2 and Spl binding sites. Expression of exogenous AP-2 and Ets-1 
increases the level of transcription from the ets-1 promoter indicating an activating role 
for AP-2 in ets-1 expression and positive auto regulation for ets-1 transcription. The 
human ets-1 m R N A  can be alternatively spliced and gives rise to two forms of ets-1 
mRNA, p68 c'e,s'1 and p54 c'ets'1. Phosphorylation of Ets-1 and Ets-2 results in the loss of 
non-specific binding activity and phosphorylation by a number of signalling molecules, 
including those of the PKC pathway, are thought to be involved (McLeod et al., 1992).
Ets proteins bind to the polyoma enhancing activator 3 (PEA3) element and this 
D N A  sequence can vary (core consensus sequence is typically G G A A )  and gives rise to 
varying degrees of binding affinity depending on the nucleotide content. The p68 c'els~I 
protein binds to the PEA3 element of the polyoma enhancer virus promoter. The D N A  
sequence A G C A G G A A G T  is specifically recognised by p68 c~ets~I in the polyoma 
enhancer and binds p68 c'ets' 1 with moderate affinity as determined by electrophoretic 
mobility shift assays (EMSAs). Mutational analysis of the PEA3 element has identified 
several higher affinity EBS such as A G C C G G A A G T ,  in which the second A  has been 
replaced by a C.
The identification of PEA3 elements in several genes including M M P s  such as
stromelysin-1 and matrilysin, suggests that these genes are regulated by Ets related
proteins. Ets-1 and Ets-2 have been shown to activate human stromelysin and therefore
may be implicated in the activation of other M M P s  (Jayaraman et al., 1999). Many of the
Ets proteins which bind to PEA3 elements trans-activate gene expression through
141
cooperation with AP-1 bound protein complexes and this cooperation is usually in the 
form of interactions between the proteins bound to the promoter. This general 
combination of nuclear oncoprotein Ets and AP-1 binding sites has been dubbed the 
‘oncogene response unit’ and is found in the promoters and enhancers of many other 
genes (see Gutman and Wasylyk, 1991 for review). These interactions result in 
conformational changes which activate expression of the target gene.
The role of ets gene family members as oncogenes has been tested in classical 
transformation experiments in which overexpression of c-ets-1 and c-ets-2 oncogenes in 
NIH-3T3 experiments mouse fibroblasts generated transformed foci in low serum 
conditions (Seth and Papas, 1990). These transformed cells grew in soft agar and formed 
tumours in nude mice. The transforming capacity of the c-ets-1 proto-oncogene may be 
associated with its ability to auto-regulate its own expression. Evidence has also 
suggested that Raf-1 kinase is directly/indirectly involved in activating Ets driven 
promoters following Ras transformation of fibroblasts (Bruder et al., 1992). Another 
interesting aspect of Ets proteins in growth control has been the observation that Ets-1 
expression correlates with the proliferation of endothelial cells in normal blood vessel 
development during normal processes such as wound healing but also with the 
vascularisation of tumours during malignant progression. This evidence combined with 
the ability of Ets proteins to regulate M M P s  such as matrilysin suggests that these 
transcription factors play an important role in tumourigenesis and in tumour progression 
(Wernert et al., 1992 and Wasylyk et al., 1991).
There are three inverted putative PEA3 elements within the matrilysin promoter
located at, -168 (GCTTCCTG), -144 (ACTTCCTC) and -55 (TTCCACAT).
However, it is not clear which members of the Ets family bind to the promoter and
mediate its activation or what mechanisms promote the increases in Ets transcription
factors which bind to the matrilysin promoter. It is perhaps likely that a number of Ets
proteins are capable of binding to these elements but, in a similar manner to the AP-1
protein complexes, the Ets members which bind to PEA3 sites in the promoter may have
different affinities and therefore may be weak or strong activators of matrilysin gene
expression. However, it is clear that the Ets proteins that bind to M M P  promoters such as
collagenase and stromelysin, act in co-operation with AP-1 proteins which in turn activate
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gene expression (White et al., 1997). By considering only two cis elements which are 
common to most of the M M P  promoters including matrilysin, the AP-1 and PEA3 sites, it 
is possible to speculate upon the conditions for the differential transcription of M M P  
genes. For instance, matrilysin expression may be promoted by the presence of Fos and 
JunD in epithelial cells but repressed by Ets-1 in stromal fibroblasts. Collagenase-3 
expression may be dependent on either Ets-1 or Ets-2 in collaboration with an activating 
AP-1 complex. If we consider only two members of the ets family and assume full 
occupation of all AP-1 and PEA3 sites in the M M P  promoters, there are at least 36 
possible Fos/Jun/Ets combinations, each of which could have a different effect on M M P  
transcription. On the other hand, if we consider all of the Ets family members presently 
known and all possible Fos/Jun combinations acting on the stromelysin-1 promoter and 
that each PEA3 and AP-1 site acts independently, there are over 4,000 possible 
combinations. Despite the potential combinatorial complexity of Ets and AP-1 factors, for 
this complexity to have any meaning there must be mechanisms whereby various 
combinations of factors distinguish one M M P  promoter from another. Differences 
between the number and spacing of the oncogene responsive units have been discussed 
and it is possible that these differences are sufficient for differential regulation of the 
M M P  genes. Flowever, such a mechanism of regulation remains highly idealised 
(Crawford and Matrisian, 1996).
4.1.5 The regulation o f Ets transcription factors by various signalling pathways
In general the ultimate target of activated receptor tyrosine kinases and their 
associated signalling cascades are transcription factors within the cell nucleus. Several 
Ets transcription factors have been shown to be the target of the M A P K  pathway, a 
pathway which is employed by the EGF receptor. Experiments carried out in the previous 
chapter showed that EGF upregulated matrilysin gene expression and so the next logical 
questions would be: Does EGF upregulate matrilysin gene expression through the 
activation of the EGF-r and its associated pathways which results in increased activation 
of Ets factors and, do these Ets factors bind to the PEA3 elements within the matrilysin 
promoter and enable its transcription?
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Several studies have shown the involvement and relevance of PEA3 transcription 
factors in breast cancers and how these transcription factors are effected by Her2tneu. 
Her2/«ew proto-oncogene (also known as c-erbB-2) encodes a 185 kDa class I receptor 
tyrosine kinase that is structurally related to the EGF receptor. The EGF receptor family 
includes EGF-r (c-erbB-1), c-erbB-2, c-erbB-3 and c-erbB A . Overexpression of the 
human Uer2/neu is implicated in the genesis of a number of carcinomas affecting several 
different organs including the breast, ovary, stomach, colon, kidney, bladder and salivary 
gland (Hynes and Stern, 1994). In breast cancer, Her 2/new is associated with poor 
prognosis for the patient (Slamon et a l., 1987). Breast tumours expressing Her2/Neu 
protein have an increased propensity to metastasize and respond poorly to hormonal and 
chemotherapeutic agents. The Her2/Neu protein is synthesized at elevated levels in breast 
tumours as a consequence of both Her2tneu gene amplification and transcriptional 
upregulation of those genes that are amplified; transcriptional activation accounts for a 6-8 
fold increased abundance of Her2/«ew m R N A  molecules per gene copy number (Liu et al., 
1992 and Iglehart et al., 1990). The enhanced rate of transcription of Her2tneu in breast 
tumour cells has been ascribed to the increased activity of transcription activators 
including AP-2 and any one of several Ets proteins that regulate transcription initiation 
from the Her2/new promoter (Hollywood and Hurst, 1993 and Scott et a l , 1994). Under 
normal physiological conditions the Her2/Neu protein is activated by ligand binding 
which effects its homodimerisation or heterodimerisation with other EGF-r family 
members, and subsequent auto-phosphorylation at multiple specific tyrosine residues in 
the intracellular cytoplasmic portion of the protein. Effectors of the Her2/Neu receptor 
include GRB-2, GRB-7, SHC, phospholipase C-y, PI-3-kinase, Ras, Src and protein 
tyrosine phosphatase (Pawson, 1995). One of the pathways used by the Her2/Neu 
receptor is the Ras/ERK pathway which, as discussed earlier involves several docking and 
membrane bound molecules which serve to activate signalling pathways such as E R K  and 
JNK cascades (Hynes and Stern, 1994). These activated M A P  kinases directly 
phosphorylate and elevate the activity of a subset of nuclear transcription factors including 
members of the fos, jun and ets families resulting in changes in gene expression.
Previous murine studies have shown that PEA3 transcription factors are
expressed at a low level in normal mammary epithelium (Xin et al., 1992). However, this
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expression of PEA3 is substantially elevated in mammary tumours and lung metastases 
that develop in transgenic mice genetically modified to express normal HER2/Neu in their 
mammary epithelial cells suggesting a potential role for PEA3 in Her2/Neu induced 
mammary tumourigenesis (Trimble et al., 1993). Her2/Neu receptors are overexpressed 
in 30% of breast cancers and 94% of these cases also show increased levels of PEA3 
which suggests that PEA3 may also play a role in human mammary tumourigenesis (Scott 
et al., 1994). To account for the increased abundance of PEA3 transcripts in Her2Ineu- 
induced mammary tumours, it was suggested by O ’Hagan and Hassell (1999) that the 
Her2/Neu tyrosine kinase enhances transcription of the PEA3 gene by stimulating the 
activity of transcription factors that bind to the PEA3 promoter. Recent data also suggests 
that the PEA3 protein itself can regulate the expression of the PEA3 gene by binding to 
sites in the PEA3 promoter. These findings have suggested the possibility that elevated 
levels of PEA3 protein may upregulate transcription of the PEA3 gene thereby leading to 
increased amounts of its transcript and protein product (O’Hagan and Hassell, 1999).
As we have discussed, PEA3/Ets transcription factors can be stimulated by EGF 
and EGF like receptors such as Her2/Neu. The PE A3 group of transcription factors 
belongs to the ETS family and is comprised of PEA3, E R M  and ER-81 which are more 
than 95% identical within their respective DNA-binding domains, the ETS domain, and 
which demonstrate 50% amino acid similarity overall (Brown and McKnight, 1992 and 
Monte et a l., 1994) (see table 4.1). This group of transcription factors possess functional 
domains responsible for DNA-binding, DNA-binding inhibition and transactivation. New 
data suggests that the Ets transcription factors are also targets for signalling cascades such 
as the Ras dependent ones, and thus may contribute first to the nuclear response to 
stimulation and second, to Ras-induced cell transformation (O’Hagan and Hassell, 1999). 
The expression of PEA3 group members in numerous developing murine organs, and 
especially, in epithelial-mesenchymal interaction events, suggests that the PEA3 
transcription factors play an important role in murine organogenesis. Moreover, the 
expression of PEA3 transcription factors in certain breast cancer cells suggests that the 
factors themselves or the proto-oncogenes encoding them are involved in the appearance, 
progression and invasion of malignant cells (de Launoit et al., 1997).
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Various reports have shown that Ets transcription factor activity can be 
modulated by the EGF-r and the MAPK pathway. Recently, Ets-1 and Ets-2 have been 
shown to activate the promoters of MMP-9 and urokinase genes in response to EGF 
(Watabe et al., 1998). In these experiments, the Her2/Neu overexpressing cell line SK- 
BR-3 was stimulated with EGF which resulted in increased levels of Ets-1 and Ets-2 
protein and in a more invasive phenotype. This increase in Ets transcription factors 
correlated with the induction of MMP-9 and uPA. Ets have also been shown to be 
involved in the regulation of EGF molecules such as heparin bound EGF (HB-EGF) 
(McCarthy et al., 1997). HB-EGF gene transcription is rapidly activated in NIH-3T3 cells 
transformed by oncogenic Ras and Raf. Co-transfection o f a 1.7 kbp HB-EGF promoter 
reporter construct with activated Raf was found to enhance HB-EGF promoter activity. 
This activity was dependent on a PEA3/AP-1 element located -974 and -988 bp upstream 
of the transcription initiation site. Co-transfection of Ets-2 and p44 MAPK enhanced this 
stimulation even further which suggested that increased levels of Ets-2, activated by p44 
MAPK resulted in increased levels of HB-EGF.
A large proportion of the MMP family members have been designated as Ets 
target genes and this is mainly due to the fact that many of the MMP promoters contain 
PEA3 binding elements which suggests that increased levels o f PEA3 may play a role in 
the upregulation of MMPs. In agreement with this, overexpression of PEA3 in the non­
metastatic MCF-7 breast cancer cell line leads to an increase in its invasive and metastatic 
properties in cell culture which implies that there is an increase in MMP activity. These 
findings raise the prospect that elevated levels of PEA3 in Her2/Neu positive breast 
tumours may account for their increased metastatic potential (Kaya et al., 1996).
4.1.6 Recent advances in our understanding of matrilysin gene expression
As discussed in the previous chapter the expression of matrilysin has been shown 
to play an important role in early colon cancer development. The mechanisms of how 
matrilysin is ‘switched on’ still remain unclear but several advancements have been made 
in the past 5 years which clarify to some extent the reasons why matrilysin plays an active 
role in cancer progression.
As mentioned earlier, matrilysin gene expression is dependent on the binding of 
the AP-1 transcription factor complex to the promoter, a state which can be induced by 
Ras signalling. Studies with colon cell lines have shown however that AP-1 binding is not 
sufficient for matrilysin expression. For example, the SW480 cell line carries a Ki-ras 
mutation which results in activated ras gene expression but nevertheless the cell line has 
been shown not to secrete matrilysin (see Fingleton et al. 1999 for review). The 
observation that a high proportion of Min tumours (mouse model of FAP), in which both 
of the alleles of the tumour suppressor gene APC  are known to be lost or mutated, 
expressed matrilysin led to the speculation that the APC protein may be involved in 
matrilysin gene expression (Fingleton et al., 1999). The 300 kDa APC protein has been 
shown to regulate cellular levels of the p-catenin protein (Rubinfeld et al., 1997 and 
Polakis, 1997). p-catenin is a component of the cadherin complex at celkcell junctions, 
however, it has also been found to interact with the family of T-cell factor (Tcf) DNA 
binding proteins and therefore can act as a transcriptional regulator.
The regulation of P-catenin is complex and poorly understood. A number of 
mechanisms are involved in controlling the levels of the cytoplasmic pool of P-catenin. In 
epithelial cells, p-catenin is normally found associated with the cytoplasmic tail domain of 
the homotypic cell adhesion molecule E-cadherin (see figure 4.3). E-cadherin is crucial to 
the intercellular adherens junctions which are involved in the organisation and structure of 
epithelial cells and the supression of tumour invasion (Kemler, 1993). Loss of E-cadherin 
expression by tumour cells has been shown to be associated with increased invasiveness 
(Flao et al., 1997). E-cadherin is associated with the actin cytoskeleton via cytoplasmic 
proteins including a-catenin, p-catenin and y-catenin, also known as plakoglobin, which 
together form the cadherin/catenin complex, a-catenin, has sequence similarities to 
vinculin and is responsible for linking E-cadherin to the actin filament network 
(Nagafuchi and Takeichi, 1988). Cellular levels of p-catenin are regulated by APC which 
binds excess P-catenin and directs phosphorylation by the serine/threonine kinase GSK- 
3p. The levels of active GSK-3p in the cytoplasm are determined by the Wnt signalling
4.1.6.1 Matrilysin is a target of [3-catenin/Tcf transcription factors
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pathway (see figure 4.3). Wnt binds to its receptor, frizzled which in turn activates 
dishevelled (Dvl). Activated Dvl prevents GSK-3P phosphorylation of p-catenin which 
inhibits p-catenin being ‘tagged’ for degradation by ubiquitin. It was poorly understood 
how Dvl, GSK-3P and APC combine to phosphorylate P-catenin directly but recently it 
has been shown that axin plays an important role in the preparation of P-catenin for 
ubiquitination (Kikuchi, 1999). Axin contains binding sites for APC, P-catenin, GSK-3P, 
PP2A and Dvl. In this complex, GSK-3P efficiently phosphorylates P-catenin, APC, and 
axin itself. The resultant serine phosphorylated P-catenin can then be degraded by the 
ubiquitin proteasome system. However in the presence of Dvl, the phosphorylation of p- 
catenin does not occur as GSK-3P is inactive and therefore p-catenin translocates to the 
nucleus and carries out its various functions including the activation of matrilysin gene 
transcription. Therefore truncating mutations in APC which prevent it binding to P- 
catenin, or mutations in P-catenin which prevent its phosphorylation by GSK-3P, result in 
an accumulation of p-catenin in the cytoplasm. This excess P-catenin can then translocate 
to the nucleus where it interacts with Tcf transcription factors and activates the 
transcription of specific genes containing Tcf sites such as c-myc and cyclin D and 
matrilysin (He et al., 1998, Brabletz et al., 1999 and Crawford et al., 1999).
Analysis of both familial and sporadic colon cancers has revealed that in most 
tumours either the Ape (FAP and sporadic) or the (3-catenin (sporadic) gene itself are 
mutated, resulting, in either case in an accumulation of stabilised p-catenin protein in the 
cell. This is then free to interact with members of the Tcf transcription factor family 
which could in turn activate genes involved in the tumour process. A correlation between 
P-catenin accumulation, which can be detected via immunohistochemistry, and matrilysin 
expression was observed in Min tumours. In cells with obvious matrilysin expression, P- 
catenin was always clearly detectable. This observation coupled with an examination of 
the matrilysin promoter which revealed the existence of Tcf binding sites in both the 
human and murine matrilysin promoters allowed Crawford et al. to show that matrilysin 
was a target of the APC/p-catenin/Tcf pathway (Crawford et al., 1999).
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Figure 4.3 Recent developments in die regulation of matrilysin transcription. When P-catenin is released 
from the cadherin/catenin complex it is degraded via APC, axin and GSK-3(3. If undegraded then p-catenin 
translocates to the nucleus and interacts with Tcf bound Lef-1 which results in derepression of the matrilysin 
promoter. In early colorectal tumourigenesis, the APC  gene is often mutated and therefore the accumulation 
of p-catenin may lead to increased matrilysin gene expression.
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Using matrilysin promoter lueiferase constructs it has been shown that matrilysin 
can be upregulated up to 7-16 fold in response to P-catenin co-transfection (Crawford et 
al., 1999). The human matrilysin promoter contains two putative Tcf sites at -194 
(CTTTGAA in the reverse orientation) and at -109 (TTCAAAG). The upregulation 
observed in the matrilysin promoter after P-catenin transfection is dependent on the Tcf 
binding site located at -109 as mutation of this site partially abrogates the induction by (3- 
catenin. Additionally, in cell lines in which a high level of P-catenin/Tcf complex exists 
(as determined by EMSA analysis), cotransfection of the matrilysin promoter with the 
cytoplasmic E-cadherin domain which binds P-catenin thus preventing the interaction of 
P-catenin with Tcf, significantly downregulated matrilysin promoter activity. Again this 
effect was demonstrated to be Tcf site dependent as the promoter with a mutated Tcf site 
did not show the same response. Crawford et al. (1999) also found that basal activity 
from the promoter construct containing the mutated Tcf binding site was higher than the 
wild type promoter construct in those cell lines with low amounts of P-catenin/Tcf 
complexes. This suggested that binding o f the Tcf factor alone to the matrilysin promoter 
represses transcription from the promoter. This was confirmed by co-transfection of the 
promoter with the Tcf family member LEF-1 which resulted in a down regulation of 
matrilysin promoter activity. Tcf factors are known to induce DNA bending and this may 
be the mechanism of repression (Love et al., 1995, Giese et al., 1992). Binding of P- 
catenin to Tcf relieves its repressing bending activity, essentially freeing the DNA to be 
transcribed (Behrens et al., 1996). This would therefore suggest that p-catenin is 
permissive for matrilysin gene transcription. Crawford et al. (1999) have also found areas 
in AOM tumours where P-catenin was present but not accompanied by matrilysin. This 
indicates that although P-catenin is essential for matrilysin transcription in a similar 
manner to AP-1 it is not sufficient on its own to stimulate matrilysin transcription. 
Matrilysin therefore appears to be a target for the APC/p-catenin pathway which is so 
often activated in colon tumours. As APC  mutations are associated with the earliest stages 
of tumourigenesis, being a target of this regulatory pathway may help explain the early 
appearance of matrilysin as well as its strong association with intestinal adenomas in 
particular.
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4.1.6.2 Potential role for pl20ctn/Kaiso in matrilysin gene activation
p l 2 0 ctn is an armadillo repeat protein which is related to p-catenin and y-catenin. 
All members of this family interact with the cytoplasmic tail of E-cadherin which is a 
principal component of the adherens junctions. P-catenin and y-catenin bind to the COOH 
domain of E-cadherin in a mutually exclusive manner (Daniel and Reynolds, 1995). 
p l2 0 ctn binds to the proximal membrane region of E-cadherin (see figure 4.3) (Thoreson et 
al., 2000). Unlike P-catenin, p l2 0 ctn does not interact with a-catenin, APC or Lef-1, 
suggesting that it has unique binding partners and plays a distinct role in the 
cadherin/catenin complex (Lampugnani et al., 1997). Using p l2 0 ctn as bait a yeast two 
hybrid system recognised a novel transcription factor named Kaiso (Daniel and Reynolds, 
1999). Kaiso’s deduced amino acid sequence revealed an amino terminal BTB/POZ-ZF 
(Broad complex Tramtrack Bric-a-brac, Pox virus and zinc finger) protein/protein 
interaction domain and three carboxy-terminal zinc fingers of the C2H2 DNA binding type 
(Albagli et al., 1995). Monoclonal antibodies specific for Kaiso, co-precipitated with a 
variety of p i 20 antibodies but not with antibodies to a-catenin, P-catenin, E-cadherin or 
APC suggesting that Kaiso interacts with different and as yet undefined binding partners 
(Daniel and Reynolds, 1999). Like other POZ-ZF proteins, Kaiso was found to localise to 
the nucleus and was associated with specific nuclear dots. Kaiso homodimerises via its 
POZ domain and translocates to the nucleus. Other proteins grouped in the same family, 
for example, PLZF (promyelocytic leukaemia zinc finger), form macromolecular 
complexes with nuclear transcriptional machinery which aid the transcription process 
(Chang et al., 1996). It is therefore possible that Kaiso may be involved in mediating 
p l2 0 c<" signalling. The presence of a putative Kaiso site overlapping a PEA3 site in the 
matrilysin promoter suggests that Kaiso, once released from the E-cadherin/p 120ctn 
complex may translocate to the nucleus and effect the transcription of several genes 
including matrilysin in a similar manner to that of p-catenin. It is also possible that Kaiso 
may be involved in matrilysin regulation at the various stages of colorectal tumour 
progression and excess Kaiso in the free cytoplasmic pool of proteins may translocate to 
the nucleus and facilitate the transcription of matrilysin.
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Several studies have examined the levels of E-cadherin and the cadherin/catenin 
complex in human colorectal tumours (Van Acken el ah, 1993 and Dorudi el ah , 1993). It 
has been shown that decreased expression of E-cadherin and its associated cytoplasmic 
proteins results in increased dysplasia. Therefore low levels of expression of the 
cadherin/catenin complex in cancer cells would result in decreased cell-cell interaction 
and allow the cells to invade more readily. Previous reports have shown that matrilysin 
activity can be modulated by E-cadherin. In squamous cell carcinomas of the head and 
neck the expression o f matrilysin was found to directly correlate to the level of cell-cell 
interaction and E-cadherin played an important role in this observation. Therefore 
increased E-cadherin levels in the cell resulted in decreased matrilysin gene expression 
which makes sense in that, the levels of ‘free pool’ p-catenin are reduced due to increased 
interaction with the cytoplasmic tail of E-cadherin (Borchers et ah, 1997). In a normal 
cell, with wild type APC and P-catenin, the levels of cytoplasmic ‘free pool’ p-catenin can 
be controlled by the release of p-catenin from the E-cadherin/catenin complex and the 
activity of GSK-3P which is controlled through Wnt signalling. Therefore, if  the Wnt 
pathway is activated and there is a release of P-catenin from the adherens junctions, there 
is an increase of free pool P-catenin in the cell cytoplasm which translocates to the 
nucleus and effects the transcription of several genes including matrilysin. The question 
that remains, however, with respect to the E-cadherin release of P-catenin is, under what 
circumstances in the normal cell does this process occur and what ‘triggers’ the release of 
P-catenin from the cadherin/catenin complex? Is it possible that the release of p-catenin 
by E-cadherin could be mediated by receptor tyrosine kinases such as the EGF-r? 
Previous studies have shown that overexpression of E-cadherin in human colon cell lines 
results in a decrease in proliferation as a result of an increase in the level of cyclin 
dependent kinase inhibitor p27/£,/j/, a molecule whose levels are decreased during EGF-r 
stimulated proliferation (St. Croix et ah, 1998). Subsequent experiments showed that 
inhibition of E-cadherin via antibody addition, and the addition of TGF-a to the media 
resulted in a 14-fold increase in growth rate. The mechanism of interaction between the 
EGF-r and E-cadherin was proposed to be via the increase in endogenous phosphatase 
activity by E-cadherin (through the addition of sodium vanadate which prevents
4.1.6.3 Potential role for EGF-r in the release of P-catenin from E-cadherin
phosphatase activity). It has also been shown that several receptor protein tyrosine 
phosphatases (RPTPs) are activated across the cell membrane and have been shown to 
colocalise with the cadherin/catenin complex. Tight adhesion mediated by E-cadherin, 
may therefore serve to strengthen interactions with adjacent RPTPs, ensuring high 
continuous phosphatase activity which could result in the dephosphorylation of the EGF-r 
(St. Croix et al., 1998). Interestingly, it has been shown via immunoprécipitation studies 
that P-catenin is linked to several receptor tyrosine kinase receptors including EGF-r and 
Her2/Neu (St. Croix et al., 1998). It has also been shown in some studies that the EGF-r 
can interact with P-catenin through phosphorylation which in turn leads to the 
destabilisation of the cadherin/catenin complex and results in the release of p-catenin as 
phosphorylated P-catenin is not found at the cadherin/catenin complex. Earlier studies 
conflicted with these observations and have shown that p-catenin phosphorylation is not 
required for complex destabilisation (St Croix et al. 1998). However, other more recent 
reports have confirmed that phosphorylation of P-catenin does indeed cause 
cadherin/catenin complex destabilisation. In vitro experiments showed that tyrosine 
phosphorylation of p-catenin by pp60c'i,c resulted in decreased binding to the E-cadherin 
cytoplasmic domain (Roura et al., 1999). Other studies have also shown that in src and 
ras transformed cells, tyrosine phosphorylation of adherens junction components is related 
to the impairment of cell-cell adhesion, indicating that increases in phosphorylation result 
in destabilisation of the cadherin/catenin complex (Lampugnani et al., 1997).
These studies suggest that the phosphorylation of the cadherin/catenin complex 
leads to its destabilisation and subsequent detachment from the cadherin/complexes of 
other cells, hence, the ‘rounding up’ of the cell. This detachment is necessary in normal 
cell processes for migration and proliferation. It may be possible, therefore, that when a 
cell receives a mitogenic signal from its external environment, for example EGF/EGF-r 
interaction, the cadherin/catenin junctions destabilise through either direct or indirect 
action of the tyrosine kinase activity of the EGF-r cytoplasmic domain. A number of in 
vitro studies have demonstrated that EGF is a potent morphogen affecting cell shape and 
motility. Indeed, a link between the EGF-r and the cytoskeleton has been recognised for 
several years: activation of the EGF-r by EGF initiates a number of cellular changes 
including cell rounding, membrane ruffling, cytoskeletal reorganisation and redistribution
of the EGF-r (Kadowaki et al., 1986). Furthermore, EGF-r has been demonstrated to bind 
to the actin cytoskeleton (den Hartigh et al., 1992) and has been shown to co-localise with 
the cadherin/catenin complex at the lateral membrane of epithelial cells (Kirkpatrick et al., 
1995). Another report has shown that the EGF-r interacts with (3-catenin and y-catenin 
and catalyses their phosphorylation which, as mentioned earlier, leads to the 
destabilisation of the cadherin/catenin complex (Solic and Davies, 1997). Overall EGF 
has been shown to decrease cell-cell contact by affecting components o f the adherens and 
desmosomal junctions and to increase cell-substratum interactions by enhancing integrin 
expression. As EGF and the EGF-r have been shown to play a role in the destabilisation 
of the E-cadherin/catenin complex it is plausible that EGF can regulate matrilysin through 
the release of [3-catenin which translocates to the nucleus and interacts with the LEF 
bound Tcf site within the matrilysin gene promoter.
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4.1.7 Summary
Analysis o f the matrilysin promoter reveals a number o f potential transcription 
factor binding sites. Previous experiments have shown that binding of AP-1 protein 
complexes to the AP-1 site within the matrilysin promoter were essential for gene 
transcription. Recently it has been demonstrated that P-catenin is involved in matrilysin 
gene transcription via its interaction with the LEF bound Tcf sites within the matrilysin 
promoter. In chapter 3, we observed a consistent increase in matrilysin gene activity 
following treatment with EGF. EGF and the EGF related receptor Her2/Neu have been 
shown to be involved in the upregulation of PEA3 transcription factors in breast cancer. 
In addition the EGF receptor has also been shown to be involved in modulating the 
cadherin/catenin complex in various colon cancer cell lines. In chapter 4 the mechanisms 
by which EGF regulates matrilysin gene transcription in number o f colon cell lines 
(SW480, HCA7 and HCT116) were investigated.
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4.2 Results
The experiments detailed in chapter 4 used three cell lines; SW480 cells which did 
not express matrilysin at the mRNA or protein level, HCT116 cells which expressed 
intermediate levels of matrilysin at both the mRNA and protein level and HCA7 cells 
which expressed high levels of matrilysin at the mRNA and protein level.
Artificial promoters containing multiple sequence motifs for AP-1, ETS and PEA3 
(see table 4.2) were constructed and transfected into the SW480, HCT116 and HCA7 cell 
lines. For example, the transcription factor binding site for PEA3 contains an 
AGCAGGAAGT core DNA consensus sequence which PEA3 transcription factors 
recognise via their ETS domain. In an artificial promoter this sequence is repeated a 
number of times and is attached to a luciferase reporter-gene. Therefore increases in 
PEA3 protein activity within the nucleus would result in increased expression of a PEA3 
artificial promoter. As EGF has been shown to mediate its effect through the MAPK 
pathway we also analysed an AP-1 and ETS artificial promoters as AP-1 and Ets 
transcription factors can also be stimulated via the MAPK pathway. The results show that 
following the addition of EGF, the activity of the PEA3 promoter increased by up to 70% 
indicating that EGF may indeed be stimulating an increase in PEA3 transcription factors 
(see figure 4.4). Increases in AP-1 promoter activity were also observed but this activity 
was lower in comparison to that of the PEA3 promoter. The ETS artificial promoter 
showed only a slight increase in activity after EGF treatment. These data suggested that 
PEA3 activity was being stimulated in the colon cancer cell lines via EGF treatment. 
After transfection with the PEA3 artificial promoter the SW480 and HCT116 cell lines 
were found to be most responsive to EGF treatment. The increase in PEA3 artificial 
promoter activity observed in the HCA7 cell line was much lower in comparison to the 
SW480 and HCT116 cell lines which may indicate that PEA3 levels are already quite high 
in the HCA7 cell line (see figure 4.6).
4.2.1 EGF increases PE A3 artificial promoter activity
i
Artificial promoter plasmid Sequence No. of repeats
PEA3 AGCAGGAAGT 3
ETS GCCGGAAGT 5
AP-1 TGAGTCA 5
Table 4.2 Details of the PEA3, ETS and AP-1 artificial promoters
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Figure 4.4 PEA3, AP-1 and ETS artificial promoters were transfected individually into various cell lines 
which were subsequently treated with EGF (50 ng/ml) for 6 hours. In many of the cell lines increases of up 
to 80% were observed in PEA3 activity.
4.2.2 EGF increases PEA3 protein and PEA3 activity
Having shown that PEA3 transcription factors were being stimulated by EGF 
using artificial promoter reporter experiments, we investigated whether nuclear levels of 
PEA3 protein were upregulated in order to determine if EGF was stimulating PEA3 
protein expression. Nuclear extracts from cells were prepared in order to examine the 
levels o f PEA3 protein within the nucleus after EGF treatment (see methods and materials 
section 2.2.11.1). The phosphorylated species o f the PEA3 transcription factors were also 
examined and this was achieved through the addition of sodium vanadate which prevents 
phosphatase action and protects against the dephosphorylation o f substrates. Once the 
nuclear protein was extracted it was quickly aliquoted into small volumes, flash frozen 
and maintained at -80°C. The concentration of protein in the samples was subsequently
assayed (see section 2.2.4) and prior to experimentation was analysed for signs of 
degradation by running the samples on an SDS-PAGE gel (see section 2.2.5.1). In figure
4.5 equal volumes of protein were loaded for the control and EGF samples of each cell 
line.
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Figure 4.5 N u c le a r  e x tr a c t  s a m p le s  (a fte r  6  h o u rs o f  E G F  (5 0  n g /m l)  tr e a tm e n t)  from  e a c h  c e ll  l in e  w ere  
a n a ly s e d  fo r  p r o te in  d e g r a d a tio n . E q u a l a m o u n ts  o f  p r o te in  fo r  e a c h  c e l l  l in e  w e r e  run o n  S D S -P A G E  g e ls .  
T h e  g e ls  w e r e  sta in e d  w ith  C o o m a s s ie  b r illia n t  b lu e  and  th e n  d e sta in e d .
Results, via western blotting, show that in the cell lines examined the level of 
PEA3 protein was increased after treatment with EGF, suggesting that EGF enhanced the 
expression of the PEA3 transcription factor (see figure 4.6). The phosphorylated species 
of the PEA3 protein migrates to a position slightly higher than that of the 
unphosphorylated PEA3 protein. Western blot analysis with a PEA3 antibody which 
recognises both species showed that EGF treatment also increased the amount of 
phosphorylated PEA3 within the nucleus.
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Figure 4.6 Western blot analysis of PEA3 protein levels in a variety of colon cell lines following EGF 
treatment (50 ng/ml) for 6 hours. The antibody used also recognises the phosphorylated form of PEA3. 50 
jag of total protein was loaded for each sample.
4.2.3 Increased levels of PEA3 via EGF treatment result in increased binding to 
optimal PEA3 probes
Initial experiments showed that EGF treatment resulted in an increase in PEA3 
protein expression and in the PEA3 phosphorylated form. However, this may not 
necessarily mean increased binding to the PEA3 sites within the matrilysin promoter. In 
order to ascertain first of all if  the increase in PEA3 protein would result in increased 
binding to PEA3 DNA binding sites we used an optimal PEA3 probe. PEA3 DNA 
binding sites differ slightly in terms of nucleotide content but primarily are comprised of a 
GCAGGAAGTG core. The PEA3 probe used in these experiments was designed for 
optimal binding o f PEA3. The effect o f EGF on the binding o f PEA3 protein to the 
optimal probes was analysed via electrophoretic mobility shift assay (see section 2 .2 .1 1 ). 
Briefly the technique involved mixing nuclear protein extract samples with radioactively 
labelled oligonucleotide probes and retard their migration through the gel. If PE A3 
transcription factors were present then they would bind to the probes. The samples were 
run on an acrylamide gel which separates the transcription factor bound probe from the 
free probe. Results showed clearly that in all the cell lines assayed using this technique 
EGF stimulated PEA3 transcription factors which in turn led to increased binding to the 
optimal PEA3 oligonucleotide probe (see figure 4.7 and 4.8).
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Figure 4.7 EMSA analysis of PE A3 optimal probe. EGF 
treatment resulted in increased PEA3 protein activity which in 
turn led to increased binding to the optimal PEA3 probe. 
(EGF conccentration = 50 ng/ml, samples collected after 6 
hours).
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Figure 4.8 EMSA analysis of PEA3 optimal oligonucleotide probe. Graphical anaylsis shows 
that treatment of various cell lines results in a significant two fold increase in PEA3 
transcription factor binding to the optimal PEA3 oligonucleotide probe.
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4.2.4 EGF stimulated PEA3 protein binds to matrilysin promoter PEA3 sites
We examined if the PEA3 transcription factors would bind to the potential PEA3 
oligonucleotide sites within the first 335 bp of the matrilysin promoter. Oligonucleotides 
for each of these PEA3 sites, located at -55, -144 and -168 bp down stream from the 
initiation site were radioactively labelled (see section 2.2.11 for probe sequence). The 
PEA3 sites contain a core GGAA sequence which is recognised by the ETS family of 
transcription factors. The flanking DNA however differs slightly at each of these sites and 
can dictate how well different transcription factors can bind. Results showed that in 
HCT116 nuclear extracts, PEA3 transcription factors bound to all of the PEA3 sites within 
the matrilysin promoter and that stimulation of PEA3 transcription factors via EGF 
treatment resulted in increased binding to these sites (see figures 4.9 and 4.10). Similar 
results were also found for other cell lines (SW480 and HCA7, data not shown). It was 
noted that PEA3 transcription factors bound with similar intensities to each of the sites 
suggesting that all three are important in the activation of matrilysin gene expression. 
Interestingly, the PEA3 sites at -168 and -55 overlap with potential Kaiso and C/EBP 
sites respectively and it is possible that these transcription factors may co-operate or 
compete with PEA3 transcription factors in binding to the matrilysin promoter and 
therefore offer an alternative means of regulating matrilysin gene transcription.
4.2.5 ‘Supershift’ EM SA confirmation o f PEA3 transcription factors
In order to confirm that PEA3 transcription factors were binding to the PEA3 
oligonucleotide probes, the samples were mixed with a PEA3 antibody (see section 
2.2.11). The PEA3 antibody complexes with the PEA3 transcription factor and the 
radiolabelled oligonucleotide probe which results in a ‘supershift’ as the complex has a 
much higher molecular weight than the probe and transcription factor combined (see 
figure 4.11). Results, using the optimal PEA3 probe show that the bands only partially 
‘supershift’ which suggests that other factors belonging to the PEA3 subfamily such as 
ERM and ER-81 may also be involved in the activation of matrilysin gene expression. 
Previous reports have shown that other ETS family members such as Ets-1 and Ets-2 bind 
to the matrilysin promoter but are very weak activators even in the presence of c-jun 
(Crawford et al., 2001).
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Figure 4.9 EMSA analysis of the PEA3 sites within the 
m airily sin promoter. EGF treatment (50 ngrnl) of the 
HCT116 cells results in increased PEA3 protein activity 
which in turn leads to increased binding to each of the PEA3 
sites within the promoter. This may suggest that all three 
elements are important in the activation of matrilysin gene 
expression.
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Figure 4.10 EMSA analysis of PEA3 binding sites within the matrilysin promoter. Graphical 
analysis shows that treatment of the HCT116 cell line with EGF (50 ngfail) resulted in 
significant increases in the binding of PEA3 transcription factors to each of the PEA3 sites 
within the matrilysin promoter. Cant; Control samples, Con+Ah; Control sample plusPEA3 
antibody, EGF; Epidermal growth factor, EGF+Ab; Epidermal growth factor plus PE A3 
antibody
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Figure 4.11 ‘Supershift’ EMSA analysis o f PEA3 optimal oligonucleotide probe shows partial 
‘supershifting’ of the PEA3-probe complex on addition of the oc-PEA3 antibody. This suggested that other 
members of the PEA3 subfamily, ERM and ER-81 may also be involved in the regulation of matrilysin gene 
expression. Con+Ab; Control sample plus PEA3 antibody, EGF; Epidermal growth factor, EGF+Ab; 
Epidermal growth factor plus PEA3 antibody.
4.2.6 Analysis of mutations in the PEA3 sites of the 335 bp matrilysin promoter- 
reporter construct.
The matrilysin promoter contains three PEA3 sites and in order to determine how 
essential each o f these sites were for matrilysin gene expression, matrilysin promoter 
reporter constructs with a mutation in either the -168, -144 or the -55 sites, achieved by 
the PCR-splicing by overlap extension method (Horton et ah, 1989), were analysed (see 
table 4.3). Results showed that mutations in each of the sites resulted in a decrease in 
matrilysin gene expression in comparison to the wild type control (see figure 4.12). 
Treatment with EGF increased this activity but not to the level observed in wild type 
experiments. Each o f the mutations resulted in a similar decrease in promoter activity 
which suggested that all three elements were equally important for matrilysin gene 
activity.
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PEA3 Site Wild Type Mutations
-168 PEA3 5’-GTGTGCTTCCTGCC AATAACGATGT -3 ' 5 ’ -GTGTGCTTCTTGCC AATAACGATGT-3 ’
-144 PEA3 5’ -GT AATACTTCCTCGTTTT AGTTAAT G-3 ’ 5 ’-GT AAT ACTTCTTCGTTTT AGTTAATG-3 ’
-55 PEA3 5 ’ -CCTATTTC C AC ATTCGAGGC-3 ’ 5 ’ -CCTATTTCIAC ATTCGAGGC-3 ’
Table 4.3 Mutated PEA3 positions within the matrilysin promoter (Crawford et at., 2001). The mutated 
positions are underlined.
MAT M55PEA3
MAT M144PEA3
MAT M168PEA3
WT MAT
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Figure 4.12 Matrilysin promoter constructs with mutations in each of the PEA3 sites were transfected into 
the HCT116 cell line. Cells were treated with EGF and analysed after 8 hours. MAT M168PEA3 indicates 
that the 335 matrilysin promoter construct has a mutation in the -168 PEA3 site. MAT Ml 44PEA3 indicates 
that the 335 matrilysin promoter has a mutation in the -144 PEA3 site while MAT M55PEA3 indicates that 
the 335 matrilysin promoter has a mutation in the -55 PEA3 site. WT MAT indicates the wild type 335 
promoter. EGF concentration = 50 ng/ml
4.2.7 Does the EGF-r activity have a direct effect on the cadherin/catenin complex at 
the adherens junction?
Several reports have indicated that the EGF-r once activated plays an important
role in the destabilisation o f the cadherin/catenin complex (Lampugnani et al., 1997,
Roura et al., 1999 and Solic and Davies, 1997). Other studies have also shown that the
interaction between (3-catenin and Tcf site bound Lef-1 is essential for matrilysin gene
activation however it must cooperate with AP-1 and PE A3 for gene transcription to
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commence (Crawford et al., 1999). It has already been observed that only the ETS sub 
family members o f PE A3 bind to the three PEA3 sites within the matrilysin promoter 
(Crawford et al., 2001). Other studies have shown that PEA3 transcription factors can be 
directly stimulated by EGF, most likely via the MAPK pathway (O’Hagan and Hassell. 
1999), but there is also another possibility which is that EGF may be able to stimulate 
matrilysin expression through its interaction with the cadherin/catenin complex. We have 
therefore investigated if the interaction between the EGF-r and the catenin/cadherin 
complex could promote the expression of PEA3 transcription factors by using the PEA3 
artificial promoter construct.
These experiments involved the transient transfection of the PEA3 artificial 
promoter reporter with a number of plasmids that encoded for full length E-cadherin (E- 
cad), E-cadherin with a deletion in the region where P-catenin binds (E-cadcytoA) and a 
truncated stable form of P-catenin which does not interact with APC and therefore avoids 
ubiquitination (b-cat). The artificial PEA3 promoter was used as no PEA3 promoter- 
reporter plasmid was available. Results, illustrated in figure 4.13, showed that, EGF 
increased PEA3 artificial promoter activity (PEA3 vs. PEA3+EGF). This mechanism 
most likely involved stimulation of PEA3 transcription factors through the MAPK 
pathway (O’Hagan and Hassell, 1999). However, following co-transfection of the PEA3 
artificial promoter with the full E-cadherin plasmid construct we observed a reduction in 
normal PEA3 promoter activity. We also observed that E-cadherin can inhibit the 
stimulation of the PE A3 promoter by EGF. Perhaps increases in E-cadherin levels within 
the cell also increased the receptor protein tyrosine phosphatases (RPTPs) associated with 
E-cadherin which in turn reduce the activity of phosphorylation cascades within the cell. 
Treatment with EGF appears to stimulate PEA3 promoter activity in the presence of E- 
cadherin which suggests that EGF can reverse the effects of E-cadherin through 
stimulation of the phosphorylation cascades. Co-transfection of the PEA3 promoter with 
E-cadcytoA, which has a deletion in the region that binds p-catenin, showed a decrease in 
PEA3 promoter activity but this decrease is less than that observed with experiments using 
the full length E-cadherin. Treatment with EGF again results in an increase in PEA3 
promoter activity in the presence of E-cadcytoA. These effects may indicate that p- 
catenin plays a role in the regulation/activation of PEA3 transcription factors. We
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therefore performed experiments whereby a stable p-catenin protein (b-cat) with a 
deletion which prevented interaction with the APC protein, hence degradation, was 
cotransfected with the PEA3 promoter and E-cadherin or E-cad cytoA. If P-catenin was 
playing a role in the regulation/activation o f PEA3 transcription factors we would have 
expected a large increase in PEA3 promoter activity in the E-cad cytoA/p-catenin 
experiments as P-catenin, would translocate to the nucleus and effect the transcription o f 
PEA3. No increase in PEA3 artificial promoter activity was observed after co­
transfection with the E-cadherin and P-catenin constructs which suggested that EGF 
mediated release o f P-catenin does not result in an increase ofPEA3 transcription factors.
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Figure 4.13 HCT116 cells transfected with PEA3 artificial promoter. A number of co-transfections were 
also performed and the effects on PEA3 promoter activity were observed. E-cad refers to the full length E- 
cadherin protein construct while E-cadcyto refers to the E-cadherin protein with a deletion in the region 
which binds P-eatenin. b-cat refers to the P-catenin construct which encoded for a truncated P-catenin 
protein which could not interact with the APC protein. EGF concentration = 50 ng/ml
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4.2.8 EMSA analysis of P catenin/Tcf interaction after EGF treatment.
Having shown that EGF-r interaction with the cadherin/catenin complex did not 
lead to increased stimulation of the PEA3 artificial promoter we analysed via EMSA the 
effect o f EGF treatment on the interaction between p-catenin and the Tcf sites within the 
matrilysin promoter. Within the matrilysin promoter there are two potential Tcf sites in 
the region proximal to the transcription initiation start site and also further down stream 
(proximal cis Tcf site at -109  TTCAAAGT while inverted downstream Tcf site at -194 
CTTTGAA) (Crawford et al., 2001). As discussed earlier p-catenin mediates its effect 
through its interaction with Lef-1 which is bound to the Tcf site and causes derepression 
o f the matrilysin promoter thus allowing gene transcription to commence. Previous 
studies have shown that the proximal Tcf site within the promoter is essential for the 
activation of matrilysin gene expression. Results show that in the SW480 and HCT116 
cell line, in particular, that the level of interaction between p-catenin increases after 
treatment with EGF (see figure 4.14). Both of these cell lines have low levels of 
cytoplasmic pool p-catenin and therefore we suggest that EGF treatment activates the 
EGF receptor which in turn has been shown to destabilise the cadherin/catenin complex 
through its interaction with P-catenin (Crawford et al., 2001). The resultant increase in 
free pool P-catenin subsequently leads to increased interaction with the Tcf site. The 
results also show that this effect was most obvious with the proximal Tcf site and not with 
the Tcf site located downstream of the transcription initiation start site.
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Figure 4.14 EMSA analysis of p-catenin interaction with the proximal (Prox) and downstream (down) Tcf 
sites located within the matnlysin promoter. The lower band indicates LEF-1 bound to the Tcf probe while 
the higher band represents the (J-catenin/LEF-l/Tcf probe complex. Results indicate that the proximal Tcf 
element is important in matnlysin gene transcription activation (Howard C. Crawford, personal 
communication).
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4.3 Discussion
Although matrilysin has been studied for many years and has been implicated in 
both normal and disease processes the regulation of this enzyme and what factors combine 
to switch on its expression still remain somewhat of a mystery. Recently, however, some 
exciting findings have brought us closer to understanding the conditions which trigger the 
expression of this important MMP family member. Initial studies showed that the 
matrilysin gene contained a TRE (TPA response element, now known as an AP-1 site) and 
several ETS sites within the promoter region. These studies also showed that removal of 
these sites reduced the promoter activity and suggested that the transcription factors bound 
to the ETS and AP-1 elements acted synergistically in the activation of the matrilysin 
promoter (Gaire et al., 1994).
In the past two years a key finding by Crawford et al. (1999) has been the 
identification of the role which p-catenin plays in the activation of matrilysin gene 
expression through its interaction with the proximal Tcf site in the matrilysin promoter. 
APC is responsible for the ‘tagging’ of P-catenin for degradation by ubiquitin but when 
APC is mutated the degradation of P-catenin in the cytoplasmic pool does not take place. 
The P-catenin protein subsequently translocates to the nucleus and is involved in the 
transcription of several target genes including matrilysin. The fact that APC is mutated in 
many cases of early human colorectal cancer may also explain why matrilysin is 
associated with the early stages of colon tumourigenesis. This would indicate that 
matrilysin expression, although initiated as a result of the expression of mutated APC 
protein, may not be directly involved in early tumour growth. However, experiments by 
Wilson et al. (1997) have shown that elimination o f the matrilysin gene results in 
decreased number and tumour size when matrilysin null mice are crossed with APC Min 
mice. Therefore, it is obvious that matrilysin expression, although switched on perhaps 
after cells receive an APC mutation, is subsequently involved in the tumour growth. 
Studies have also shown that while P-catenin derepression of the matrilysin gene is an 
essential requirement for transcription to take place the presence of p-catenin alone does 
not promote expression of the gene indicating that other factors are also required 
(Crawford et al., 1999).
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We have shown earlier in chapter 3 that EGF stimulated matrilysin gene 
expression via RT-PCR, western blot and promoter-reporter analysis in a variety of cell 
lines. Other factors such as IL- 6  and bFGF were also shown to stimulate matrilysin gene 
activity, even more so when the cells were treated with combination ‘cocktails’ of these 
cytokines. Flowever, in chapter 4 we were primarily interested in the mechanisms of how 
EGF was increasing matrilysin gene transcription and in determining the identity of the 
transcription factors which caused this increase.
EGF has been shown to stimulate a number of pathways which ultimately lead to 
the activation of several transcription factors including AP-1 and ETS family members 
(Lenormand et al., 1993). We therefore initially tested a number of artificial promoters 
that contained either AP-1, ETS or PEA3 repeat sequence motifs to which AP-1, ETS or 
PEA3 transcription factors could bind. Treatment with EGF showed that the PEA3 
artificial promoter gave up to a 1 0 0 % increase over control in the cell lines examined 
(SW480, F1CT116 and HCA7) suggesting that PEA3 transcription factors were being 
stimulated by EGF treatment. AP-1 and ETS artificial promoter responses were also 
increased but not to the same extent as the PEA3 promoter. This increase was expected 
since EGF can stimulate both AP-1 and ETS transcription factors via the MAPK pathway. 
From this data it was possible that PEA3 or any of the ETS family members could be 
responsible for the activation of the matrilysin promoter. As mentioned earlier, interesting 
work by O ’Ftagan and Hassell showed that in breast cancer, increases in the EGF receptor 
related Her2Ineu gene product were associated with an increase in PEA3 transcription 
factors (O’Hagan and Hassell, 1999). PEA3 is a member of the ETS family of 
transcription factors and analysis of the matrilysin promoter reveals three potential PEA3 
binding sites within the promoter. We therefore hypothesized that a possible method of 
stimulating matrilysin gene activity by EGF may be via an increase in ETS transcription 
factors such as PEA3. We subsequently analysed if EGF was capable of stimulating 
PEA3 transcription factors and if this increase was associated with increased binding to 
the PEA3 sites within the matrilysin promoter.
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Analysis via western blotting showed that EGF increased PEA3 transcription 
factor levels after 6  hours and that the level of the phosphorylated species of PEA3 also 
increased. The increase in the level of phosphorylated species by EGF can be accounted 
for through EGF’s activation of the MAPK and associated phosphorylation pathways. 
EGF has been shown to mediate its signalling cascade via Ras which in turn has been 
shown to upregulate a number of cascades including MAPK (O ’Hackel et al., 1999). The 
terminal signalling molecules in this pathway may therefore be responsible for the 
phosphorylation, hence activation, of the nuclear PEA3 transcription factors. The increase 
in levels o f PEA3 protein may also be due to the fact that the PEA3 gene, in a similar 
fashion to other Ets family members is capable of (Chen et al., 1995 and Seth and Papas,
1990). Therefore increases in phosphorylation of the PEA3 protein may result in the 
increased expression of the PEA3 gene which in turn could lead to increased nuclear 
levels of active PE A3 protein. To examine if the increase in PEA3 activity resulted in 
increased binding to the PEA3 sites within the matrilysin promoter we initially used an 
optimal PEA3 probe which showed that in all the cell lines tested, EGF treatment resulted 
in increased binding to the matrilysin promoter. The same was also found when the 
individual PEA3 sites within the matrilysin promoter were examined. It should be noted 
that there is some non-specific binding to the PEA3 probes. In order to clearly confirm 
that PEA3 was binding to the probes, various controls should be employed such as the use 
o f recombinant PEA3 as a positive control and the use of mutated PEA3 probes as a 
negative control. Interestingly, PEA3 binding activity in the control samples was quite 
high and this may be due to the fact that several of the cell lines examined have activated 
Ras or other oncogenic mutations, such as p53, leading to an overall increase in growth 
promoting transcription factors, hence gene transcription. This may also explain why 
matrilysin levels in all the cell lines tested, with the exception of SW480, were so high.
Confirmation that PEA3 transcription factors were responsible for the increased 
binding to the PEA3 sites within the matrilysin promoter was achieved by ‘supershift’ 
EMSA. However only partial shifting of the band was observed indicating that subfamily 
members of the PEA3 family, ER-81 and ERM may also be involved. ER-81 and ERM 
have also been shown to be upregulated in breast cancers where Her2/Neu is activated 
(O’Hagan and Hassell, 1999).
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Our findings suggest that PEA3 transcription factors play an important role in 
effecting the transcription of matrilysin and that the levels within the cell can be 
augmented by EGF. A recent report by Crawford et al (2001) is also in agreement with 
our studies in respect to the importance of the PEA3 family of transcription factors and 
their essential role in the regulation o f matrilysin gene transcription. Crawford et al. 
(1999) had previously shown that the matrilysin gene was a target of the p-catenin/Tcf 
transcription factor complex and although this interaction was necessary for matrilysin 
gene activation, it was not enough on its own to activate matrilysin transcription 
(Crawford et al., 2001). This inferred that co-activation of matrilysin gene transcription 
with other transcription factor proteins bound to the matrilysin promoter was necessary. 
Crawford et al. (2001) used a human embryonic kidney 293 (HEK293) cell line and co­
transfected the HEK293 cells with the matrilysin promoter and a number of Ets family 
members including, Ets-1, Ets-2, PU .l, Fli-1, ER-81, ERM, PEA3 and the AP-1 binding 
protein Jun. Analysis of the results showed that all the Ets family members or Jun when 
transfected in isolation with the matrilysin promoter showed only minimal increases in 
promoter activity. However when the cells were transfected with Jun/PEA3 or Jun/ER-81 
or Jun/ERM an induction in matrilysin promoter activity of over 50 fold was observed 
thus suggesting that the matrilysin promoter preferentially binds members of the PE A3 
subfamily of transcription factors (Crawford et al., 2001). These data suggested that a 
number of elements are required for activation of the matrilysin gene. This is in 
agreement with earlier studies in chapter 3 which showed that treatment of cells with EGF 
and TPA resulted in a significant increase in matrilysin promoter-reporter activity over 
control. From our findings it is therefore possible that all three members of the PEA3 
family, which can be stimulated by EGF, interact with the PEA3 probes and this is why a 
full supershift with the a-PEA3 antibody was not observed. Reports have also shown that 
the majority of colon cell lines used in this study ( HCT116, SW480, HCA7 and SW620) 
express large amounts o f PEA3, ER-81 and ERM (Crawford et al., 2001).
Further studies by Crawford et al. (2001) have shown that all matrilysin 
expressing tumours of the Min mouse (APC -/-) expressed all members of the PEA3 sub­
family as well as all colon cell lines examined. This was also the first report of PEA3
subfamily members in intestinal tumours. Their frequent expression in Min mouse
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tumour cells and human colon tumour cell lines suggests that members of the PEA3 
subfamily are targets of a common early alteration in a tumour associated signalling 
pathway. Ets factors have been described as targets of Ras signalling (Wasylyk et al., 
1998). However, Min mouse adenomas do not have activated Ras (Shoemaker et al., 
1997). Thus if Ras signalling is involved in PEA3 regulation in intestinal tumours it is 
just as likely to be as a result of extracellular signals mediated by Ras such as EGF-r 
signalling. EGF-r signalling as discussed earlier has been shown to be of relevance in 
human colon tumour progression and has very recently been implicated in Min mice 
tumour formation (Coffey et al., 1992 and Torrance et al., 2000). This therefore is in 
agreement with our data which shows that EGF upregulates matrilysin gene expression 
through the activation of PEA3 transcription factors.
From gel shift assays examining the binding of PEA3 transcription factors it was 
observed that each of the PEA3 sites within the matrilysin promoter was capable of 
binding PEA3 and that each site did so with more or less the same affinity. Experiments 
where each of the PEA3 sites within the matrilysin promoter were mutated also showed 
that ‘knocking out’ one site led to only partial reduction in promoter activity in 
comparison to the wild type promoter. Treatment of the mutated promoters with EGF also 
increased their activity. These experiments suggest that all of the PE A3 sites within the 
matrilysin promoter play an important part in the regulation of matrilysin. Interestingly 
the PEA3 site at -144 overlaps with a potential Kaiso site, while the PEA3 site located at 
-55 bp downstream of the transcription initiation site overlaps with a potential C/EBP site. 
It may be possible that the interactions between PEA3 and Kaiso or C/EBP or their 
competition with each other may provide another means of matrilysin regulation.
Having determined that EGF has a direct effect on matrilysin expression through
the activation of the PEA3 family of transcription factors we subsequently analysed if
EGF could modulate the expression/activity of PEA3 transcription factors via its
interaction with the E-cadherin/catenin complex. We also investigated if EGF mediated
the release of |3-catenin which would result in increased interaction with the Tcf sites
within the matrilysin promoter. Results with the PEA3 artificial promoter show that
cotransfection with the full length E-cadherin protein resulted in a decrease in PEA3
activity. The presence of excess E-cadherin in the cells may have resulted in an increase
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of phosphatase activity as E-cadherin associates with a number o f protein tyrosine 
phosphatases in order to form tight adherens junctions (St. Croix et al., 1998). Thus an 
increase in the level of cellular E-cadherin may lead to a suppression of the 
phosphorylation cascades by these phosphatases which results in a decrease in the activity 
of the PEA3 promoter. Treatment of the cells with EGF showed only a slight increase in 
PEA3 promoter activity in the presence of E-cadherin. If EGF was involved in effecting 
PEA3 promoter activity via the destabilisation o f the cadherin/catenin complex and the 
release of p catenin then a significant increase in PE A3 promoter activity would have 
been expected as the ‘free pool’ P-catenin ‘mopped up’ by the excess E-cadherin would 
have been released due to phosphorylation via EGF treatment. However, this was found 
not to be the case. In order to confirm that EGF did not affect PEA3 promoter activity via 
cadherin/catenin destabilisation we transfected an E-cadherin construct which had a 
deletion in the region where p-catenin binds into the cells. Once again if p-catenin was 
involved in the activity of PEA3 transcription factors then it would be expected that no 
decrease in PEA3 activity should have been observed as the mutated E-cadherin protein 
would be unable to ‘mop up’ p-catenin located in the cytoplasmic pool and this was found 
to be the case. In both the wild type and mutated E-cadherin transfections, treatment with 
EGF resulted in slight increases in PEA3 artificial promoter activity which may have been 
due to the increase in phosphorylation activity mediated by the activated EGF-r. 
Transfection of cells with the PEA3 artificial promoter, E-cadherin or mutated E-cadherin 
and p-catenin again showed no increase in the activity of PE A3 suggesting that EGF 
interaction with the E-cadherin catenin complex does not lead to an increase in PEA3 
promoter activity.
Several studies have documented the effects o f P-catenin on matrilysin gene 
expression and many have shown that mutations in APC lead to an increase in P-catenin 
levels which in turn aids in the transcription of matrilysin (Brabletz et al., 1999 and 
Crawford et al., 1999). In normal cells p-catenin is sequestered by E-cadherin in the 
formation of the adherens junctions which serves to form tight monolayers of cells. 
However, in order for matrilysin to be expressed by a normal cell line this would involve 
the release o f P-catenin from the E-cadherin/catenin complex. Several earlier reports have 
also shown that increases or decreases in E-cadherin activity lead to repression or
expression respectively of several MMPs and proteases (Frixen et al., 1993, Llorens et al., 
1998 and Miyaki et al., 1995). As mentioned earlier EGF is thought to be involved in the 
destabilisation of the cadherin/catenin complex through its interaction with (3-catenin 
(Kinch et al., 1997, Lampugnani et al., 1997, Roura et al., 1999, Solic and Davies, 1997). 
The matrilysin promoter contains two potential Tcf sites with which (3-catenin can 
interact.
EMSA analysis in chapter 4 examining the relationship between EGF and the E- 
cadherin/catenin complex showed that the proximal Tcf site located -109 bp downstream 
from the transcription initiation start site had increased binding of p-catenin protein. The 
Tcf site further downstream at -194, which is inverted, showed little or no binding o f P- 
catenin. These data suggested that another possible mechanism of EGF upregulation of 
matrilysin gene expression was via its interaction with the E-cadherin/catenin complex 
and the subsequent release o f P-catenin which in turn leads to enhanced matrilysin 
expression in the absence or mutation of the APC protein.
EGF has been shown for several years to be involved in many aspects of cell 
morphology. EGF is a potent mitogen and in order for the cell to replicate it must 
‘loosen’ its bonds to other cells and this is most likely achieved via the destabilisation of 
the cadherin complex. One of the effects of this would be the upregulation of MMPs such 
as matrilysin which would subsequently be involved in the degradation of the ECM, thus 
aiding the ‘rounding up process’ o f the cell. EGF has been shown to involved in the 
progression of many cancers including colon cancers (De Luca et al., 1997 and 
Maleckapanas et al., 1997). It may therefore be plausible that overexpression of EGF or 
EGF-r by the tumour cell could be involved in the increased proliferation and the 
upregulated expression of matrilysin which is also involved in increased tumour 
proliferation and increased invasiveness. Evidence also exists which links matrilysin 
directly to E-cadherin. Recently it has been shown that matrilysin is capable of cleaving 
the ectodomain of E-cadherin from the surface of MCF-7 breast cells. This soluble E- 
cadherin ectodomain can promote tumour invasion through its interaction with uncleaved 
E-cadherin thus preventing the cells forming tight junctions. The cells as a result are 
loosely bound to each other and subsequently can invade more readily (Noe et al., 2000).
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Overexpression of EGF or the EGF-r would therefore lead to the destabilisation of the 
cadherin/catenin complex. This destabilisation results in the increase of cytoplasmic (3- 
catenin which translocates to the nucleus and effects the expression of matrilysin which in 
turn, once secreted, can prevent the formation of tight adherens junctions due to its 
‘sheddase’ effect on E-cadherin. The inability of E-cadherin to form a stable cadherin 
catenin complex may subsequently lead to a reduction in receptor tyrosine phosphatase 
activity and stop the inhibition of the phosphorylation cascades and promote cell growth 
and tumourigenicity.
Thus far we have observed that EGF stimulated matrilysin gene transcription via 
the PEA3 family of transcription factors and also through the destabilisation of the 
cadherin/catenin complex. If EGF is capable of stimulating PEA3, [3-catenin and as other 
studies have shown AP-1 transcription factors then one would expect to see a higher 
increase over control levels when cells were treated with EGF. Studies have shown that 
the interaction between each o f these elements is essential for matrilysin gene 
transcription and that each of these factors when present act in a synergistic manner 
whereby high increases in matrilysin promoter activity are observed (Crawford et al., 
2001). Cell lines used in this study were colon cancer cell lines with various oncogene 
mutations including Ras and p53. EGF mediates its effects via several pathways and in 
many of these pathways, Ras is the effector molecule. Therefore one would expect to see 
a high level of activated transcription factors including those of the ETS and AP-1 family. 
This may partially explain why such high levels of endogenous matrilysin were observed 
in the cell lines used with the exception of the SW480 cell line. Some of the cell lines 
investigated also contain (3-catenin mutations such as HCT116 which again would 
increase matrilysin as excess levels of (3-catenin are not processed for degradation due to 
poor interaction with APC. Treatment of these cell lines with EGF may therefore only 
augment the level o f matrilysin transcription which would explain why only slight 
increases in matrilysin gene expression were observed in the colon cancer cell lines.
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4.3.1 Hypothesis of EGF regulation of matrilysin gene expression
Recent evidence has shown that in order for the matrilysin gene to be transcribed 
a number of factors/complexes such as PEA3, AP-1 and (3-catenin/Tcf must be bound. 
We have shown here that EGF may regulate the transcription of matrilysin by stimulating 
the activity of PEA3 and also through its interaction with (3-catenin via the destabilisation 
o f the E-cadherin/catenin complex at the adherens junctions. As discussed earlier PEA3 is 
upregulated in breast cancer patients due to the overexpression of the EGF-r related 
receptor Her2/Neu and Crawford et al. (2001) have also shown that PEA3/ERM/ER-81, 
and not other Ets family members are required for matrilysin gene transcription. We 
therefore hypothesise that the increases observed in matrilysin gene activity in chapter 3 
may be as a result of EGF stimulating the activity of the PEA3 gene and the activity of the 
PEA3 transcription factor through phosphorylation pathways associated with EGF-r 
signalling including MAPK. EGF may also cause increases in other transcription factors 
in the cell nucleus through its interaction with E-cadherin bound (3-catenin (see figure 
4.15).
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Figure 4.15 Hypothesis for the mechanism o f EGF induction of matrilysin gene transcription. EGF may 
upregulate matrilysin gene transcription via increasing levels of PEA3 transcription factors which in turn 
bind to the PEA3 sites within the matrilysin promoter. The activated EGF receptor may also play a role in 
the destabilisation of the cadherin/catenin complex which results in the release of P-catenin into the 
cytoplasm, p-catenin which is not targetted for degradation translocates to the nucleus where it interacts 
with several target genes including matrilysin.
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4.4 Conclusions
Matrilysin has been shown to be expressed in many cancers and is involved in 
several aspects o f tumour biology including tumour growth, progression and angiogenesis. 
Combining these characteristics of matrilysin with the fact that it is unique amongst other 
MMPs whereby it is expressed only by the tumour epithelial cells makes matrilysin an 
interesting therapeutic target. In order to develop drugs which specifically inhibit 
matrilysin expression it is important to understand how it is ‘switched’ on during the 
tumourigenic process.
We have shown that matrilysin gene expression can be upregulated by EGF 
through its activation of the PEA3 transcription factor family. This conclusion is in 
agreement with other studies which have shown that PEA3 transcription factor family 
members preferentially bind to the matrilysin promoter and effect its transcription 
(Crawford et al., 2001). We have also shown that each of the PEA3 sites within the 
matrilysin promoter are essential for activation of matrilysin gene transcription. Recent 
studies have shown that APC  mutations, common in many colon cancer patients, lead to 
an increase in cytoplasmic p-catenin which tranlocates to the nucleus and effects the 
transcription of several target genes including matrilysin. We have shown that EGF 
interaction with the cadherin/catenin complex results in the release of P-catenin which 
does not affect the activity of the PEA3 transcription factors but does bind and interact 
with the proximal Tcf site located in the matrilysin promoter. This therefore represents 
another mechanism via which EGF can mediate its effect on the matrilysin gene.
Our data suggests that EGF plays an important role in the regulation of matrilysin 
gene expression via a number of different mechanisms. Aberrant expression of EGF or 
the EGF-r by tumour cells may therefore result in enhanced matrilysin expression which 
has been shown to be involved in early stages of colon/breast tumourigenesis and in the 
invasion and metastasis of several cancers.
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Chapter 5
The expression and regulation of matrilysin in leukaemia cell 
lines and its involvement in leukaemia invasion and metastasis.
5.1 The haematopoietic process
The process o f haematopoiesis can be described as the proliferation and 
differentiation o f progenitor stem cells into mature blood cells and these events are 
orchestrated by the complex interactions between the haematopoietic stem cells and the 
surrounding bone marrow microenvironment (Sawyers et al., 1991). The different types 
of blood cells and their immediate precursors can be recognised in the bone marrow by 
their distinctive appearances. In the marrow, the blood cells are intermingled with each 
other as well as with fat cells and stromal cells that produce a delicate supporting 
meshwork of collagen fibres and other extracellular matrix components. In addition, the 
whole tissue is richly supplied with thin walled blood vessels (also known as blood 
sinuses) into which the new blood cells are discharged. Within the bone marrow exist 
stem cells which are the precursors to all blood cells. These cells give rise to colony 
forming units (CFU) daughter cells of either the myeloid or lymphoid variety which in 
turn give rise to highly specialised sets of sub cells. Therefore the stem cell within the 
bone marrow matrix is known as a ‘pluripotent’ stem cell, in that it gives rise to all blood 
cell types. Pluripotent stem cells are found in low numbers in bone marrow and not many 
o f them are actively cycling. The normal behaviour of stem cells has been inferred by 
transplantation experiments that use retroviral vector to create specific integration events 
and clonal markers. The independent viral integration sites are used to define clonal 
progeny o f specific stem cells. The overall impression from such studies is that the 
growth pattern o f the stem cells can best be described by the sequential entry of limited 
numbers of stem cells into cycle and these then dominate multiple lineages in the 
peripheral blood and lymphoid organs. Presumably, if  the progeny of a limited number of 
stem cells can dominate the peripheral blood for extended periods o f time there must be an 
appreciable expansion of that stem cell clone, as well as expansion of the committed 
progenitors for multiple lineages.
Once a cell has differentiated into an erythrocyte or granulocyte or some other 
type of blood cell there is no turning back, i.e. the state of differentiation is not reversible. 
Therefore at some stage in their development, some of the progeny of the pluripotent stem
182
cells must become irreversibly committed to a particular line of differentiation. It is clear 
from microscopic analysis that this commitment occurs long before the final division in 
which the mature differentiated cell is formed. One can also recognise specialised 
precursor cells that are still proliferating but already show signs of having begun 
differentiation. It thus appears that commitment to a particular line of differentiation is 
followed by a series o f cell divisions that amplify the cells of a given specialised type.
The haematopoietic system can, therefore, be viewed as a hierarchy of cells. 
Pluripotent stem cells give rise to committed progenitor stem cells which are irreversibly 
determined as ancestors of only one or a few blood cell types. The committed progenitors 
divide rapidly but only a limited number o f times. At the end o f this series of 
amplification divisions, they develop into terminally differentiated cells, which usually 
divide no further and die after several days or weeks (see figure 5.1).
Although the proliferation rate of developing bone marrow cells is impressive 
there are a number o f checks and balances which limit the overall cellularity of and 
response to stresses such as irradiation or bleeding. There are many examples in the 
literature on specific negative regulators of stem cell and other lineage committed cell 
types. Some of these effects are mediated by soluble factors such as transforming growth 
factor-P (TGF-P). Several reports have described the inhibition of stem cells by large 
granular lymphocytes that require cell-cell contact for function (Barlozzari et al., 1987). 
In all these cases it is worthwhile considering how the normal stem cell and various 
leukaemias escape this down-regulation. An understanding of these controls could 
directly relate to the excessive-growth phenotype of leukaemias and lymphomas. Our 
understanding of the molecular mechanisms regulating the formation, growth and 
differentiation of haematopoietic stem cells is also important in identifying why blood 
cells become leukaemic and considerable advances in this respect have been made 
recently. Particular progress has been made in defining the cytokines, chemokines and 
extracellular matrix components which retain and maintain primitive haematopoietic cell 
populations in bone marrow. Furthermore signal transduction pathways that are critical in 
haematopoiesis and are activated by cytokines have also been identified and further 
characterised.
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Figure 5.1 The haematopoietic process. The pluripotent stem cell normally divides infrequently to give rise 
to more pluripotent stem cells or committed progenitor cells, labelled CFC for colony forming cells. The 
progenitors are stimulated to proliferate by specific growth factors but progressively lose their ability to 
divide and develop into terminally differentiated blood cells which live for only a few days or weeks. In 
mammals all of the blood cells are made in the bone marrow with the exception of the T-cells which mature 
in the thymus (outlined in red).
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5.2 Leukaemia
As discussed earlier, during the haematopoietic process, developing blood cells 
undergo rapid division and differentiation. Mutations in the machinery controlling these 
processes often leads to serious haematological disorders such as leukaemia. Leukaemic 
cells have escaped the constraints governing the growth of normal myeloid cells in that 
they do not require growth factors to survive and proliferate.
5.2.1 C hronic myeloid leukaemia
There are several types of leukaemia of which chronic myeloid leukaemia (CML) 
is perhaps the most extensively studied. CML cells have characteristic cytogenetic 
(Philadelphia chromosome) and molecular (the bcr-abl fusion gene) markers. The 
chromosomal abnormality involves the translocation of the c-abl tyrosine kinase proto­
oncogene to a 6  kb breakpoint cluster region (bcr) composed o f four small introns and 
exons, which are part of the larger gene called bcr. This translocation results in the 
transcription of a fused protein product, p i 20. Experimental analysis and patient studies 
have shown that the bcr sequence activates the tyrosine kinase activity of c-Abl and 
converts Abl to a transforming protein for haematopoietic cells (Sawyers et al., 1991).
CML is a stem cell disease as the Philadelphia chromosome is found in all 
haematopoietic lineages in patients with this malignancy, but not in skin fibroblasts or 
bone marrow stromal cells. The clinical phenotype of the disease is expansion of the 
myeloid compartment during the initial phase but with retention of full differentiation. 
This initial phase termed chronic is followed by eventual progression to acute leukaemia 
which is characterised by circulating undifferentiated lymphoid or myeloid blast cells (see 
figure 5.2). Nearly all patients with chronic phase CML express a 210 kDa BCR-ABL 
protein whereas patients with Ph-positive acute lymphoblastic leukaemia express either a 
210 kDa or a 190 kDa BCR-ABL protein (Sawyers, 1999). Recently, a larger 230 kDa 
BCR-ABL fusion protein was found in a sub group of patients with CML who presented 
with a lower white blood cell count than is usual for the disease and in whom progression
to blast crisis was slow (Pane et al., 1996). The fact that fusion proteins o f different sizes 
can be correlated with different outcomes has led to laboratoiy studies o f the biologic 
activity o f the proteins. The results indicate that the 190 kDa BCR-ABL protein has 
greater activity as a tyrosine kinase and is a more potent oncogene than the 210 kDa 
protein, suggesting that the magnitude o f the tyrosine kinase activity affects the expression 
o f the disease (Voncken et al., 1995).
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Figure 5.2 The progression of chronic myelogenous and acute myelogenous leukaemia. Mature blood cells 
develop from pluripotent stem cells though progenitor cells. In CML the bcr-abl fusion occurs in the stem 
cell and is present in all haematopoietic lineages. In the chronic phase of CML the number of myeloid 
progenitors and mature myeloid cells is increased, but differentiation occurs normally. During blast crisis 
CML, differentiation is arrested at the progenitor stage and the phenotype resembles that of acute leukaemia 
diseases such as APL (acute premyelocytic leukemia).
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Studies of the bcr-abl gene fusion have established that it is a potent oncogene 
which induces leukaemias in animals. Transgenic expression of the 190 kDa BCR-ABL 
protein in mice causes acute leukaemia at birth suggesting that it confers a potent 
oncogenic signal in haematopoietic cells (Heisterkamp et al., 1990). Another animal 
model examining the effects of the expression of the bcr-abl genes involved the infection 
of the gene into the haematopoietic stem cells of normal mice using a retro virus carrier. 
In these animals a range o f acute leukaemias develops that varies in strains with different 
genetic backgrounds (Kelliher et al., 1990). These findings suggest that the pathogenesis 
o f CML is a multistep process. Studies into the function of the BCR-ABL proteins have 
revealed that the protein can transform haematopoietic cells so that they can grow 
independent of cytokines (Gishizky and Witte, 1992). It has also been shown to protect 
the cells from programmed cell death in response to cytokine withdrawal or radiation 
(Nishii et al., 1996). However, in primary CML cells the effects of the tyrosine kinase 
appear to be less dramatic, in particular with respect to apoptosis. BCR-ABL has also 
been shown to increase adhesion of the haematopoietic cells to the ECM by increasing 
integrin activity (Bazzoni et al., 1996). One mechanism of this effect may involve the 
BCR-ABL substrate CRKL, which induces adhesion when it is phosphorylated, by 
allowing the assembly of focal adhesion complexes (Senechal et al., 1998). Curiously, 
primary CML cells adhere poorly to the bone marrow stroma in vitro. These data appear 
to be in contrast with the data presented by cells engineered to express the BCR-ABL 
protein and will require further studies. Nevertheless, the adhesion defect offers another 
mechanism for leukaemogenesis, since CML cells may escape negative regulatory 
influences that stromal cells normally exert on haematopoietic cells through contact 
between stromal and stem cells.
Biochemical studies show that the BCR-ABL protein is a constitutively active 
tyrosine kinase confined to the cytoplasm whereas wild type ABL shuttles between the 
nucleus and the cytoplasm (Lewis et al., 1996). As a consequence of increased tyrosine 
kinase activity, the BCR-ABL protein can phosphorylate several substrates thereby 
activating various signal cascades affecting the growth and differentiation of the cells. 
Substrates of the BCR-ABL protein include CRKL, p62Dok, paxillin, CBL and Rin which
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subsequently utilise pathways such as RAS, JNK PI-3K and STAT (see figure 5.3). It is 
not clear how BCR-ABL protein activates these pathways but an emerging theme is that it 
operates via the same mechanisms as cytokine receptors that control the growth and 
proliferation o f  haematopoietic cells. Since the BCR-ABL gene is constitutively 
expressed, these cells escape constraints on normal growth and become leukaemic.
BCR/ABL
STAT RAS PI-3-K
RAF JNK MYC
Figure 5 3  Signal transduction by  the BC R /A BL protein. Constitutive activation o f  its tyrosine kinase 
domain causes the BC R /A BL protein to activate a number o f  cytoplasmic and nuclear signal transduction 
pathways that affect the growth and survival o f  haematopoietic cells.
5.2.2 Acute promyelocytic leukaemia
Other common forms o f leukaemia include the acute myeloblastic leukaemias 
(AML). Of these, acute promyelocytic leukaemia (APL) accounts for approximately 10% 
o f cases (Warrell et al., 1993). APL was first recognised as a distinctive clinical entity in 
the 1950s and the disease typically presents with bleeding diathesis leading to a relatively 
high rate o f early mortality, primarily from intracranial hemorrhage. The mechanisms 
underlying the haematorrhagic diathesis have been comprehensively studied and it has 
been shown that several processes are involved, including accelerated intravascular 
coagulation, hyperfibrinolysis, and thrombocytopenia (Tallman and Kwaan, 1992).
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Individual differences in the severity o f these processes may explain divergent findings 
among clinical studies. Malignant promyelocytes release pro-coagulant substances that 
activate the coagulation cascade, generate thrombin and deplete fibrinogen.
Early studies showed that APL was consistently associated with a non-random 
chromosomal abnormality characterised by balanced and reciprocal translocations 
between the long arms of chromosomes 15 and 17. In 1987, the gene encoding retinoic 
acid receptor alpha (RAR-oc) was mapped to chromosome 17q21 (Mattei et al., 1988). 
The location of the chromosomal breakpoint in APL and the observation that all-trans- 
retinoic acid was clinically effective, prompted studies on the potential role of the RAR-a 
gene in this translocation. Subsequently several groups cloned the breakpoint and showed 
that the RAR-a gene was rearranged in all the patients tested. Moreover, the breakpoints 
on chromosome 15 were found to cluster tightly in a region containing a previously 
unknown gene, named PML. The 15:17 translocation results in the fusion of genes for 
PML and RAR-a which results in the synthesis of two reciprocal fusion transcripts, 
PML/RAR-a or RAR-a/PML (Alcalay et al., 1992). Thus in acute promyelocytic 
leukaemia (along with other certain acute myelocytic leukaemias and chronic myelocytic 
leukaemia) a translocation generates a disease specific fusion protein that is involved in 
carcinogenesis.
The PML/RAR-a fusion protein contains the amino section of PML (with its 
putative dimérisation and DNA binding domains) and the hormone binding domains of 
RAR-a (Goddard et al., 1991). Although the RAR-a breakpoints on chromosome 17 
always occur in intron 2 the breakpoints on chromosome 15 are clustered in two different 
introns and one exon of PML leading to various fusion proteins. In leukaemic 
promyelocytes PML/RAR-a seems to be considerably more abundant than the wild type 
retinoic acid receptor encoded by the intact chromosome 17 (Pandolfi et al., 1992). These 
observations have suggested that the aberrant PML/RAR-a may exert a dominant effect 
over the normal RAR-a gene product. The HL-60 cell line, derived from a patient with 
acute myeloblastic leukaemia differentiates into granulocytes when treated with retinoic 
acid, an effect which is mediated in part by the retinoic acid receptor. If retinoic acid 
induces maturation in promyelocytes, the hybrid receptor may contribute to
leukaemogenesis by dominantly antagonising differentiation induced by retinoic acid. At 
the molecular level, several mechanisms could explain the dominant effect of the 
PML/RAR-a fusion protein over the wild type retinoic acid receptor and PML proteins. 
Unlike RAR-a, which requires retinoid X receptors (RXRs) for dimérisation and function, 
PML/RAR-a can form a homodimer and thereby effect efficient binding to retinoic acid 
response elements in DNA (see figure 5.4). PML/RAR-a also appears to dimerize with 
normal RXR and PML gene products, potentially leading to the sequestration o f RXR. 
Finally PML/RAR-a can act dominantly to délocalisé PML from its normal nuclear 
position, a process which can be reversed by all-inmv-retinoic acid (Warrell el ah, 1993).
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Figure 5.4 All-fra«s-retinoic acid enters the cell by simple diffusion or by conversion from retinol that has 
been absorbed from the gastro-intestinal tract. All-iraws-RA (retinoic acid) can be metabolised immediately 
and located to the surface of the smooth endoplasmic reticulum (not shown). Alternatively, all-iram-RA or 
its isomers enter the cell nucleus and bind to RA receptors (RAR) or to retinoid X receptors (RXR). After 
dimérisation these RA activated receptors bind to specific DNA segments within the promoter region of 
target genes and facilitate their transcription. CRBP refers to cytochromic retinol binding protein.
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5.3 MMPs and TIMPs in haematopoiesis
As previously discussed, the bone marrow microenvironment contains a 
heterogenous population of stromal cells which express a variety of ECM macromolecules 
and cytokines that serve to support developing blood cells and aid in their differentiation. 
The ECM macromolecules expressed by the stromal cells are mainly comprised of 
collagen types I-IV, fibronectin, vitronectin and laminin and are important not only in 
providing structural support but also in binding adhesion molecules and growth factors. 
Extensive studies have investigated the role of adhesion molecules and growth factors 
during haematopoietic cell development and in leukaemogenesis, however, the role of 
ECM degrading enzymes which are most probably produced by the haematopoietic and 
stromal cells has only recently begun to be explored.
The ECM of the haematopoietic microenvironment plays a pivotal role in the 
promotion of proliferation and differentiation of haematopoietic stem cells. The ECM 
within the bone marrow microenvironment is secreted by the stromal cells. In addition to 
providing a structural support for the cells the ECM provides discrete compartments in 
which different growth factors and cytokines are specifically localised and presented to 
the haematopoietic stem cells (Bussolino et ah, 1994). Specific domains in the ECM 
proteins have been identified as receptors for some growth factors and cytokines 
(Grimaud and Lortat-Jacob, 1994). Several studies have shown that the main mechanism 
of mature blood cell egress involves the down regulation of integrin receptors (Kerst et 
ah, 1993 and Levesque et ah, 1996). New evidence suggest that MMPs through their 
proteolytic action also aid in this process by virtue o f their ECM degrading capacities. 
Several blood cell types have been found to secrete metalloproteinases, in particular 
MMP-2 and MMP-9. In cells of a lymphoid origin the expression of MMP-9 is uniform 
in comparison to MMP-2. MMP-9 expression is observed in reactive and malignant B- 
cells as well as unstimulated resting and activated T lymphocytes (Stetler-Stevenson et ah, 
1997). Large granular lymphocytes isolated from human endometrium also expressed 
high levels of MMP-9 (Shi et ah, 1995). Activation of T-cells also resulted in the 
expression of active and latent MMP-9 as well as MMP-3 (Stetler-Stevenson et ah, 1997).
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The activity of MMPs is effectively controlled by the tissue inhibitors of 
metalloproteinases whose characteristics have been outlined in chapter 1. TIMP-1 and 
TIMP-2 have been shown to be expressed in a variety of leukaemia cell lines including 
those o f a CML and AML origin. TIMPs are multi-functional molecules and exert 
pleiotropic effects in that they not only regulate MMP protein activity but have also been 
shown to be involved in cell proliferation which suggests that they may exert some 
influence on cell growth modulation and cell signalling. Alternatively, this may be 
accomplished in a direct manner whereby TIMPs may positively or negatively regulate 
the actions of growth factors such as bFGF and TGF-p. The direct effects of TIMPs on 
cell growth modulation originated with the observation that TIMP-1 has erythroid 
potentiating activity (EPA). TIMP-1 is capable of stimulating the growth and 
differentiation of erythroid precursors, erythroleukaemic cell lines in vitro such as K562 
as well as stimulating murine erythropoiesis in vivo (Hayakawa et al., 1992 and Niskanen 
et al., 1988). TIMP-2 has also been shown to promote the growth of erythroid precursors 
as well as acting as an autocrine growth factor for SV-40 transformed fibroblasts. A 
broad spectrum of mitogenic activity has been demonstrated for TIMP-2 in a number of 
cell lines including Raji and Burkitt’s Lymphoma and HL-60 cells and the mitogenic 
activity o f TIMP-2 was maintained when its inhibitory functions were destroyed through 
reductive alkylation (Edwards et al., 1996)
5.3.1 Leucocyte associated metalloproteinases
A group of membrane associated enzymes that have been characterised as 
haematopoietic differentiation antigens have also been classified as zinc dependent 
endopeptidases. This group of enzymes which includes CD 10/neutral endopeptidase 
24.11 (CD10/NEP), CD 13/amino peptidase N (CD13/APN) and BP-
l/6C3/aminopeptidase A (BP-1/6C3/APA) have been well characterised and have been 
used as diagnostic markers for haematological malignancies (Shipp and Look, 1993). 
CD 10 has been shown to be highly expressed in acute lymphoblastic lymphomas (ALL) 
and Burkitt’s lymphomas, but is negative in more mature lymphocytes (Ritz et al., 1981). 
CD 13 is highly expressed by leukaemic blasts in acute myeloid leukaemias (Sobol et al.,
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1987). Although little is known about their function in haematological cells these 
enzymes have been well characterised in non-haematological cells. All three enzymes 
have been found to be expressed in the epithelial brush border cells of the renal proximal 
tubules, small intestine and lung (Semenza, 1986). Various studies suggest that these 
enzymes are involved in the regulation of peptides which regulate cell proliferation. 
Bombesin like peptides are not only are potent mitogens, but also act in autocrine loops of 
small cell carcinomas of the lung. Hydrolysis of bombesin by CD 10 inhibits cell growth, 
whereas inhibition of CD 10 has been associated with tumour cell growth (Shipp et al.,
1991). Haematopoietic cells studies using mice suggest that CD10 regulates B-cell 
development by inactivating peptides that stimulate cell growth and differentiation. CD 13 
expression is restricted to cells committed to the granulocyte/monocyte lineage. Its 
enzymatic activity has been associated with the hydrolysis of chemotactic peptides which 
occurs in neutrophil mediated responses (Sakai et al., 1987). The function of BP- 
1/6C3/APA has been studied in murine models and is believed to regulate the growth of 
early B cells activated by IL-7 induced proliferation.
5.3.2 MMPs/TIMPs and the inflammatory response
Metalloproteinases and their inhibitors are thought to play an important role in 
the ECM degradation that occurs as a consequence of the inflammatory response. 
Interactions between monocytes and T-cells induce the secretion of metalloproteinases at 
the site of inflammation (Goetzl et al., 1996). Because of their potentially hazardous 
effects the MMPs are regulated at different steps during the inflammatory reaction. 
Although this control is mainly regulated by cytokines other factors such as 
prostaglandins can also induce metalloproteinases. For example, prostaglandin E 2 
(PGE2) can induce MMP expression through a c-AMP dependent mechanism in 
monocytes and natural killer cells (Zeng et al., 1996). Migration o f monocytes and 
lymphocytes into extra lymphoid tissues requires penetration of the sub-endothelial basal 
lamina. After contact with the matrix proteins T-cells and monocytes are induced to 
produce MMPs. T-cells predominantly secrete MMP-2 and MMP-9 after stimulation with 
(31 integrin, vascular cell adhesion molecule (VCAM) and by inflammatory mediators 
(Nikkari et al., 1996). Expression of MMPs in T-cells is differentially regulated as studies
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have shown that T-eells constitutively expressed MMP-9 whereas MMP-2 required 
induction (Leppert et al., 1995). Macrophages have been shown to produce several types 
of MMPs depending on the antigens displayed on the T-cell surface. Cytokines from both 
Thl and Th2 can either repress or stimulate the production of MMPs by macrophages 
(Campbell et al., 1991). IL -ip and TNF-a are major pro-inflammatory cytokines 
produced by activated monocytes and they control interstitial collagenase, stromelysin-1 
and MMP-9 in a post transcriptional maimer. Furthermore these cytokines increase the 
expression of MMPs without affecting the levels of TIMP (Mauviel et al., 1993 and Saren 
et al., 1996). Unlike IL -lp  or TNF-a, cytokines such as IL-4 and IFN-y possess the 
capacity to inhibit MMP production and this also does not affect the expression of TIMPs. 
IL-10 is secreted by Th2 lymphocytes and is inhibitory to several macrophage functions. 
IL-10 and IL-6 have both been found to increase the expression of TIMP-1. IL-10 has 
also been shown to decrease the expression of MMP-9 (Lacraz et al., 1995 and Roeb et 
al., 1993). The ratio of MMPs.'TIMPs changes throughout the inflammatory process in 
response to changes in the levels of cytokines. Therefore during the first hours of 
inflammation, pro-inflammatory cytokines are produced which enhance the basal levels of 
MMPs but not TIMPs. In the second phase of the response IL-6 is produced which 
enhances TIMP-1 expression. Following secretion of IFN-y and IL-4, MMP expression is 
decreased without changing TIMP-1 levels. In the last phase the anti-inflammatory 
cytokine IL-10 is produced and maximum expression of TIMP-1 is reached whereas 
MMP expression returns to normal basal levels.
5.4 M M Ps and TIM Ps in leukaemia
The balance between MMPs and TIMPs in the bone marrow microenvironment 
during haematopoietic differentiation as well as leukaemic proliferation and 
dissemination/invasion has not been fully investigated. AML and CML in blast crisis are 
characterised by an excessive egress of leukaemic cells from bone marrow into peripheral 
blood followed by infiltration of organs, skin or mucous membranes. These movements 
which are normally restricted to functional mature leukocytes, include the necessity for 
the cells to cross matrix barriers and penetrate blood vessel walls, which is dependent on 
the catalytic modification of the ECM and basement membranes. As discussed in chapter
1 the expression of MMPs is an essential requirement for ECM and basement membrane 
degradation (Ries et al., 1999).
Several reports have examined the expression of MMPs and TIMPs in various 
leukaemia patient samples and cell lines and have found in many cases that the expression 
of MMP-2 and MMP-9 often correlated with poor prognosis for the patient. Ries et al. 
(1999) studied the expression of MMP-2, MMP-9, MT1-MMP, TIMP-1 and TIMP-2 in 
the bone marrow mononuclear cells (BM-MNCs) of patients with AML, CML, 
myelodysplastic syndromes (MDS) and healthy donors. Analysis of the samples found 
that all patients and donors expressed MMP-9 in the BM-MNC conditioned media. 
Interestingly MMP-2 was found to be expressed at high levels in patients suffering from 
primary (73%) and secondary (88%) AML while only 20% of the cases that were 
classified as AML in remission expressed MMP-2. In contrast MMP-2 expression was 
not detected in CML patients with the exception of those who had entered blast crisis. 
TIMP-1 expression was relatively low in all samples and interestingly, MMP-9 mRNA 
transcripts were found to be at a higher level in CML patients and healthy donors. TIMP-
2 expression was also found in samples which expressed MMP-2 and the majority of 
MT1-MMP expression was found in primary AML samples. These data suggested that 
MMP-2 was a potential prognostic marker for the invasion of leukaemia cells. These 
observations for AML samples were in agreement with studies performed by Janowska- 
Wieczorek et al. (1999) who investigated AML patient samples and a number of 
leukaemic cell lines with respect to MMP-2, MMP-9, TIMP-1 and TIMP-2 expression. 
All were found to secrete MMP-9 and the majority of AML samples were found to secrete 
MMP-2. The AML patient samples were found to express TIMP-1 and TIMP-2 mRNA 
and protein. Normal steady state bone marrow immature progenitor cells were also 
examined and it was observed that neither MMP-2 or MMP-9 were expressed but more 
mature mononuclear cells from normal bone marrow expressed and secreted MMP-9. The 
upregulated expression of MMPs and TIMPs again links MMPs to the invasive phenotype 
o f AML.
Although many studies have examined the expression of MMP-2 and MMP-9 in 
various leukaemias there are relatively few reports on how the MMPs are regulated in
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leukaemias. However, one such study has investigated the relationship between IL-6 and 
the expression of MMP-2, MMP-9 and TIMP-1 in malignant Non-Hodgkin’s Lymphomas 
(Kossakowska et al., 1999). Non Hodgkin’s lymphoma (NHL) represents a heterogenous 
group o f tumours which vary in their biological aggressiveness and clinical course. High 
grade NHL have been shown to degrade ECM components in vitro and that MMPs, in 
particular MMP-2 and MMP-9, play an important role in this phenomenon. Elevated 
levels of MMP-2 and MMP-9 in high grade NHL correlate with a poor clinical outcome. 
Subsequent studies looked at the expression of cytokines and growth factors such as IL- 
ip , IL-10, IL-6, TNF-a, TGF-P and bFGF and determined whether these would affect the 
levels of MMP-2, MMP-9 and TIMP-1. Results showed that IL-6 correlated significantly 
with elevated mRNA expression of MMP-2, MMP-9 and TIMP-1. Use of in vitro 
invasion assays also showed that treatment of cells with IL-6 upregulated the invasive 
ability of a number of leukaemic cell lines which could be inhibited by recombinant 
TIMP-1 and a-MMP-9 and a-MMP-2 antibodies suggesting that the increase in in vitro 
invasive ability after IL-6 treatment was due to increased MMP-activity.
Reports have also shown that IL-6 is an important agent during the differentiation 
of various leukaemias. Various studies have shown that retinoic acid treatment of the 
acute premyelocytic cell line HL-60 induces differentiation of the cells towards the 
granulocytic lineage and has also been shown to induce the mRNA and protein expression 
of IL-6 and the IL-6 receptor subunit gpl30. Subsequent analysis in a HL-60 cell line 
which was sensitive to RA differentiation showed that activation of the gpl30 receptor by 
exogenous treatment with IL-6 potentiated the differentiating effects of retinoic acid (Xie 
et al., 2000). The effect of IL-6 on the differentiation of CML cell lines such as K562 has 
also been observed. It has been extensively demonstrated that K562 cells can be induced 
to differentiate towards erythroid and megakaryocyte lineages by various differentiation 
inducers (Xie et al., 1999). Treatment with phorbol myristate acetate induces the K562 
cells to differentiate towards the megakaryocytic lineage and also induces the expression 
of IL-6 and the IL-6 receptor sub unit gpl30. In a similar fashion to that observed in HL- 
60 cells, increased expression of IL-6 promoted the differentiation of K562 cells when 
treated with TPA.
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5.5 Summary
All blood cells are derived from stem cells within the bone marrow. The bone 
marrow also provides ‘scaffolding’ for the developing blood cells in the form of 
extracellular matrix which is secreted by stromal cells. The ECM is important as it also 
docks various cytokines and presents them to the blood cells which in turn aids the 
differentiation process. Therefore remodelling of the ECM during haematopoiesis is an 
essential process which involves the expression of MMPs. Egress of mature blood cells 
from the bone marrow into the peripheral blood vessels also involves the expression of 
MMPs. However, leukaemia cells have also developed the ability to overexpress MMPs 
which aid in their invasion into the blood vessels. Studies thus far have focussed mainly 
on the expression of MMP-2 and MMP-9 and the MMP inhibitors TIMP-1 and TIMP-2 
and many have determined that the expression of MMPs can be used as a diagnostic 
marker. Thus far no studies have examined the regulation or role of matrilysin in 
leukaemia invasion and metastasis. In chapter 5 we have examined the expression of 
matrilysin in two cell lines K562 and HL-60 and have also investigated whether matrilysin 
can be regulated by IL-6 or the phorbol ester, TPA.
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5.6 Results
The K562 cell line is defined as a chronic myeloid leukaemia which was taken 
from a patient in blast crisis while the HL-60 cell line is an acute premyelocytic 
leukaemia. As discussed earlier the chronic myeloid leukaemias progress to blast crisis 
which phenotypically is similar to the acute form of leukaemia. The characteristics of 
both these cell lines are outlined in table 2.2.
5.6.1 In vitro invasive activity of leukaemic cell lines
Degradation of the ECM by leukaemia cells is an important event in the 
dissemination of cells and spread of disease (Kossakowska et al., 1999 and Tapiovaara et 
al., 1996). In this study we decided to examine the invasive activity of two leukaemia cell 
lines, K562 and HL-60 using an in vitro invasion assay. Briefly this assay involved 
plating the cells onto matrigel-coated filters and assaying the numbers of cells that 
invaded to the underside o f the membrane. Our results showed that the K562 cell line was 
up to four times more invasive than the HL-60 cell line (2.33% +/- 0.21% for K562 vs 
0.7% +/- 0.16% for HL-60) (Figure 5.5). Two tailed T-tests showed that the results 
obtained were significant (P value < 0.005).
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Figure 5.5 In vitro invasion analysis of the K562 and HL-60 cell lines using Biocoat™ raatrigel invasion 
chambers demonstrated that K562 were up to 4 times more invasive than HL-60. Experiments were done in 
triplicate and repeated 3 times. The asterisk denotes that P<0.005.
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5.6.2 Expression of matrilysin, MMP-2 and MMP-9 by the K562 and HL-60 ceil lines.
Since the major enzymes implicated in ECM breakdown are the MMPs 
(McDonnell et al., 1999) we examined the MMP expression profile of the K562 and HL- 
60 cell lines using RT-PCR, zymography and western blot analysis. Using RT-PCR the 
mRNA for MMP-2 and MMP-9 was detected in both cell lines while only the K562 cell 
line expressed matrilysin mRNA (Figure 5.6A). The mRNA from both cell lines was also 
amplified for the constitutively expressed gene P-actin (Figure 5.6A). We then looked at 
the MMP protein using zymography and western blot analysis of the conditioned media. 
Figure 5.6B shows that both K562 and HL-60 cell lines secreted MMP-2 and MMP-9 
protein. The identity o f these bands as MMP-2 and MMP-9 was confirmed by western 
blotting (data not shown). The levels o f MMP-9 protein appeared similar in both cell 
lines while the K562 cells appeared to produce more latent MMP-2 than the HL-60 cells. 
However, the HL-60 cell line expressed low levels of active MMP-2 as seen by the 
presence of a faint lower molecular weight band. Expression of matrilysin protein was 
detected using western blotting as the primary antibody had a high affinity/specificity for 
matrilysin and was considered more sensitive than gelatin/casein zymography. Western 
blot analysis (Figure 5.6B) showed that only the K562 cell line produced matrilysin thus 
confirming the results obtained at the mRNA level.
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Figure 5.6 Analysis of MMP expression in the K562 and HL-60 cell lines at the mRNA (A) and protein 
level (B) suggested that matrilysin may be of importance in leukaemia cell invasion. Samples were 
normalised using p-actin which is a constitutively expressed gene.
5.6.3 Expression of TIMP-1, TIMP-2 and TIMP-3 by the HL-60 and K562 cell lines.
Although expression o f MMPs has been shown to be critical for invasion of cells, 
the levels of their inhibitors, the TIMPs also play an important role. The K562 cell line 
constitutively expressed TIMP-1 mRNA while none was detected in the HL-60 cell line 
(Figure 5.7A). TIMP-2 mRNA was expressed in both cell lines with the HL-60 cells 
expressed approximately 2 fold (+/- 0.43) more than the K562 cells (Figure 5.7A). 
Reverse zymography showed that the K562 cells secreted large amounts of TIMP-1 
protein while its presence in the HL-60 conditioned media was not detected (Figure 5.7B). 
In agreement with the RT-PCR analysis, TIMP-2 protein was observed in both cell lines, 
with approximately 2-fold higher levels in the HL-60 cells (Figure 5.7B). TIMP-3 was 
not detected at the mRNA or protein level in either cell line (data not shown).
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Figure 5.7 Analysis of TIMP expression in the K562 and HL-60 cell lines at the mRNA via RT-PCR (A) 
and protein level via reverse zymography (B). Samples were normalised using (3-actin which is a 
constitutively expressed gene.
5.6.4 Effect of matrilysin blocking antibody on the in vitro invasiveness of the K562 cell line.
Following our initial observation that the K562 cell line was more invasive than 
the HL-60 cell line and subsequent MMP and TIMP analysis, the most striking difference 
observed between the two cell lines was in matrilysin expression. These results suggested 
that matrilysin expression in the K562 cell line may play a role in the increased 
invasiveness of this cell line. In order to address this question we used a matrilysin 
blocking antibody to investigate the invasive ability o f the K562 cell line. Following the 
addition o f 50pg/ml of matrilysin antibody we saw a significant 40% reduction in the 
invasiveness of the K562 cells (Figure 5.8). Cells treated with 50p.g/ml anti-rat IgG 
showed no decrease in invasion in comparison to K562 control cells. Two tailed T-tests 
again showed that the results obtained were significant (P value < 0.005).
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Figure 5.8 The effect of a matrilysin blocking antibody on the in vitro invasion activity of the K562 cell line 
shows that matrilysin is a relevant factor in the invasion process. Experiments were carried out in triplicate 
and repeated three times. The asterisk denotes that P<0.005.
5.6.5 Regulation of MMPs in the K562 and HL-60 cell lines
Earlier work carried out in chapter 3 involving the analysis of matrilysin 
promoter/reporter constructs in colon cell lines showed that matrilysin levels could be 
modulated by a range of cytokines and phorbol esters including IL-6 and TPA. 
Interestingly IL-6 has also been shown to have differentiating effects on the K562 and 
HL-60 cell lines. Previous studies have shown that upregulation of IL-6 in patient 
samples was indicative of poor prognosis for the patient and was nearly always 
accompanied by an increase in the expression of MMPs. We therefore examined if there 
was a relationship between IL-6 and matrilysin regulation in the K562 and HL-60 
leukaemia cell lines. RT-PCR analysis of IL-6 and TPA treated RNA extracts showed an 
increase in matrilysin mRNA transcript production after cytokine treatment (Figure 5.9). 
However, cytokine treatment did not appear to induce matrilysin gene transcription in the 
HL-60 cells.
Similar observations were also noted at the protein level whereby production of 
MMP-9 in the K562 cell line can be upregulated through IL-6 and TPA expression 
(Figure 5.10 and 5.11) while HL-60 gives only a slight increase in MMP-9 protein
production following IL-6 and TPA treatment. For the K562 cell line, MMP-2 protein did 
not appear to be upregulated following IL-6 and TPA treatment while both active and 
latent forms of MMP-2 showed moderate upregulation. Western blot analysis (Figure 
5.10) shows that matrilysin is expressed by the K562 cell line only and that it can be 
upregulated by IL-6 and TPA.
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Figure 5.9 Regulation of matrilysin, MMP-2, and MMP-9 at the mRNA level following treatment with 
lOOng/ml IL-6 and/or lOOng/ml TPA. RT-PCR analysis negative control was H20  and positive control was 
plasmid DNA containing the cDNA for the required gene.
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Figure 5.10 Regulation of matrilysin, MMP-2, and MMP-9 protein following treatment with 100ng/ml IL-6 
and/or 100ng/ml TP A. Matrilysin protein was detected using western blot analysis while MMP-2 and 
MMP-9 protein were analysed using zymography.
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Figure 5. JI Graphical analysis of the expression of A; MMP-9 protein expression, B; matrilysin protein 
expression and C; MMP-2 expression.
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5.6.6 Regulation of the TIMPs in the K562 and HL-60 cell lines
RT-PCR analysis on HL-60 and K562 RNA extracts demonstrated that only the 
K562 cell line expressed TIMP-1 while levels in the HL-60 cell line remained 
undetectable even upon treatment with IL-6 and TPA (figure 5.12). K562 cells expressed 
large constitutive amounts of TIMP-1 RNA which was only slightly increased through IL- 
6 and TPA treatment. RT-PCR analysis also revealed TIMP-2 expression in both cell lines 
with untreated HL-60 expressing approximately 3 fold (+/- 0.43) more than the K562 cell 
line (figure 5.12). IL-6 and TPA treatment also upregulated TIMP-2 expression in both 
cell lines. Reverse zymograms showed that K562 secreted large amounts of TIMP-1 
protein while its presence in the HL-60 conditioned media was not detected. The effects 
o f IL-6 and TPA treatment did not appear to have a great effect on TIMP-1 secretion in 
either cell line. TIMP-2 protein was observed in both cell lines and notably the 
differences in expression demonstrated at the mRNA level were not observed at the 
protein level (figure 5.13 and 5.14). This may indicate that TIMP-2 mRNA transcripts in 
the HL-60 cell line may have a longer half life which does not necessarily lead to an 
increase in protein levels. The presence of TIMP-1 and TIMP-2 protein in the conditioned 
media was also analysed via western blot and confirmed the findings of the reverse 
zymography experiments. TIMP-3 was not detected at the message or protein level in 
either cell line (data not shown).
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Figure 5.12 R e g u la t io n  o f  T IM P -1  an d  T I M P -2  at th e  m R N A  le v e l  f o l lo w in g  tr e a tm e n t w ith  1 0 0 n g /m l IL -6  
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Figure 5.13 R e g u la t io n  o f  T IM P -1  a n d  T I M P -2  p r o te in  f o l lo w in g  tr e a tm e n t w ith  1 0 0 n g /m l IL -6  a n d /o r  
lO O n g/m l T P A . T IM P -1  an d  T I M P -2  p ro te in  w a s  d e te c te d  v ia  r e v e r se  z y m o g r a p h y .
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Figure 5.14 Graphical analysis of TIMP-land TIMP-2 protein expression in the K562 and HL-60 cell lines
5.6.7 The effects of IL-6 on K562 and HL-60 in  v it r o  invasion assays.
Having shown that IL-6 and TPA treatment were capable of upregulating 
matrilysin expression we analysed if this increase in matrilysin expression would result in 
the increased in vitro invasiveness of the K562 cell line. Results suggest that there is an 
increase in the invasion of K562 cells but this may be due to increased matrilysin or 
MMP-9 activity (see figure 5.15). Analysis also shows that the observed increases were 
not statistically significant therefore blocking experiments with matrilysin or MMP-9 
antibodies would be unable to determine which MMP was responsible for the increase in 
invasion observed after IL-6 and TPA treatment.
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Figure 5.15 K562 and HL-60 cells were treated with IL-6 and/or TPA (each at 50 ng/ml) in order to 
determine if the subsequent increase in matrilysin and MMP activity would result in increased in vitro 
invasion activity.
5.7 Discussion
Previous studies investigating the role o f  MMPs in leukaemia analysed the 
expression o f MMP-2, MMP-9 and their natural inhibitors TIMP-1 and TIMP-2 
(Janowska-Wieczorek et al., 1999, Ries et al., 1999, Devy et al., 1997, Stetler-Stevenson 
et al., 1997 and Tapiovaara et al., 1996). These studies suggested that leukaemias which 
have acquired the ability to express MMPs have more invasive phenotypes. In this 
chapter we examined two human leukaemia cell lines, K562 and HL-60 and found using 
an in vitro invasion assay that the K562 cells were four times more invasive than the HL- 
60 cells. In order to ascertain why the K562 cells were more invasive than the HL-60 cell 
line we analysed the expression o f various MMPs and TIMPs in these cell lines.
Analysis o f MMP-9 expression showed that both cell lines expressed similar 
levels o f  MMP-9 at both the mRNA and protein level. RT-PCR results were similar to 
those observed in other studies however some reports have shown that the HL-60 cell line 
expressed more MMP-9 than the K562 cell line (Janowska-Wieczorek et al., 1999). RT- 
PCR analysis o f the HL-60 and K562 cell line in other reports show similar levels of 
MMP-9 expression in these cell lines but examination o f MMP-9 at the protein level
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reveals that MMP-9 expression is much higher in the HL-60 samples suggesting post 
translational regulation (Janowska-Wieczorek et al., 1999). Differences between the 
MMP-9 levels observed in our studies and in others may be due to differences in 
incubation times or different cell culture techniques. Only the latent form of the MMP-9 
protein was observed in both the K562 and HL-60 cell lines. A band with a slightly 
higher molecular weight does appear in the HL-60 samples at approximately 96 kDa and 
this may either be a glycosylated form of MMP-9 or MMP-9 bound to another protein 
(Moses et al., 1998). The band at 92 kDa matches the band observed in the BHK 92 
positive control which secretes only the latent form of MMP-9. Previous reports have not 
identified active MMP-9 in either of these cell lines (Janowska-Wieczorek et al., 1999 and 
Kossakowska et al., 1999).
Similar results were observed for MMP-2 at both the mRNA and protein level 
with the exception that active MMP-2 was observed in the HL-60 samples. This suggests 
that there maybe an up-regulation of MMP-2 activators such as MT1-MMP in the HL-60 
samples. The K562 cells were also found to express slightly more latent MMP-2.
Analysis of MMP-2 and MMP-9 expression alone would suggest that both of 
these cell lines should have similar invasion levels, however, the in vitro invasion assays 
showed this was not the case. Several investigators have shown that matrilysin expression 
correlates with the metastasis of colon and breast carcinomas and that over-expression of 
matrilysin in colon cells leads to increased invasion and tumourigenicity (Rudolph-Owen 
et al., 1998b and Witty et al., 1994). We analysed the expression and activity of 
matrilysin in both cell lines which hitherto had not been investigated in a leukaemia cell 
background. Matrilysin mRNA transcripts and protein were observed only in the K562 
cell line, These data suggested that matrilysin expression may play a role in the increased 
invasiveness o f the K562 cell line.
TIMPs are the natural inhibitors of MMPs and have been shown to inhibit 
invasion of metastatic cells (Alvarez et al., 1990). TIMP-1 has been shown to bind 
preferentially to proMMP-9 while TIMP-2 binds to proMMP-2 but this is not a mutually 
exclusive situation as they have been shown to interact with other MMPs (Kahari et al.,
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1999 and Gomez et al., 1997). Recent studies have also shown that TIMPs are 
multifunctional molecules capable of not only preventing ECM degradation through MMP 
inhibition but also of stimulating growth proliferation through erythroid potentiating 
activator (EPA) receptors (Murate et al., 1993). A recent report has shown that in MCF-7 
breast cells, TIMP-1 binds and translocates to the nucleus although the exact function of 
this nuclear form of TIMP-1 remains unknown (Ritter et al., 1999). In order to rule out 
the possibility that K562 increased invasiveness was due to little or no expression of 
TIMPs or that the reduced HL-60 cells invasion was due to high levels of TIMPs we 
investigated the expression of TIMP-1, TIMP-2 and TIMP-3.
Analysis of TIMP-1 showed that the K562 cell line expressed large quantities of 
this inhibitor at both the mRNA and protein level whereas TIMP-1 could not be detected 
in the HL-60 cell line. This would suggest that the K562 invasion should be retarded 
through TIMP-1 mediated MMP inhibition but, as has been shown by Von Bredow et al., 
(1998) this inhibition may be circumvented by matrilysin’s ability to activate TIMP-1.
Analysis of TIMP-2 showed that at the mRNA level the HL-60 cells produced 
approximately 2 fold more TIMP-2 mRNA than the K562 cells. This increase in TIMP-2 
mRNA was also translated into a 2 fold increase in protein when samples were analysed 
via reverse zymography.
Analysis of the MMP profile of the K562 and HL-60 cell lines revealed that both 
cell lines expressed similar levels of MMP-2 and MMP-9 protein. However, only the 
K562 cell line was found to secrete matrilysin. This suggested that there may be a link 
between matrilysin expression by the K562 cell line and its increased invasiveness in 
comparison to the HL-60 cell line. In order to show that matrilysin plays a direct role in 
the invasion of the K562 cells we carried out in vitro invasion assays in the presence of a 
matrilysin blocking antibody. Results of these experiments showed that in the presence of 
the matrilysin blocking antibody there was a significant reduction in the invasion of the 
K562 cells. However, these experiments did not reduce the levels of K562 cell invasion 
to those observed with the HL-60 cell line i.e. 2.3% to 0.7% which suggested that 
additional factors may also be involved. Serine proteinases, cell adhesion molecules
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(Murphy and Gavrilovic, 1999) and MMPs have all been implicated in the complex 
integrated events underlying cell migration and invasion.
Several reports have shown that a number of MMPs, in particular MMP-2 and 
MMP-9 localise to the cell surface of breast epithelial cells. MMP-2 has been shown to 
co-localise with avp3 integrins (Brooks et a l 1996) at the cell surface and MMP-9 has 
also been found to associate with the CD44 antigen on the cell surface (Yu and 
Stamenkovic, 1999). CD44 is the receptor for hyaluran which is incorporated into the 
ECM by the stromal cells and binds to a location on CD44 distinct to that of MMP-9. 
This interaction between CD44 and MMP-9 has been implicated in increased tumour 
invasion. Expression of dominant negative soluble CD44 receptor disrupts this effect 
resulting in decreased invasiveness and in decreased vascularisation. Subsequent studies 
found that the increase in tumour vascularisation was due to MMP-9 activation of TGF-P 
and it was also shown that MMP-9 produces different TGF-p cleavage products (Yu and 
Stamenkovic, 2000). CD44 is present on a wide variety of blood cells including 
progenitor cells and therefore the interaction between CD44 and MMP-9 may represent a 
new and novel mechanism for blood cell/leukaemia egress/invasion. A recent study has 
also shown that a-MMP-9 antibodies significantly reduced the invasion of leukaemia cells 
(Kossakowska el al., 1999). Studies have also shown that the invasive effect of the cells 
was dependent on the interaction of MMP-9 with CD44 as when the cells were transfected 
with MMP-9 secretion vector, tumour invasion was enhanced (Yu and Stamenkovic,
2000). We have observed that the expression of matrilysin by the K562 leukaemia cell 
line is directly involved with its increased invasion. The majority of the matrilysin 
produced by the K562 cell line was secreted into the culture medium but lysis of the cells 
also showed matrilysin was located inside the cells (data not shown). This may suggest 
that matrilysin also localises to the leukaemia cell surface by an as yet undetermined 
mechanism and could aid in the invasion/dissemination process. However, this will 
require further studies as the results suggest that the matrilysin detected in the cell lysates 
is protein which is waiting to be processed for secretion. Yu and Stamenkovic have also 
reported that matrilysin co-localises with CD44 on the surface of breast cancer cells 
(MMP GRC 2001, poster presentation). Matrilysin has also been well documented as a 
sheddase and is capable of processing many of the cell surface molecules including E-
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cadherin and other integrin molecules (Noe et al., 2000). To clarify the mechanism of 
how matrilysin enhances leukaemia invasion, either through secretion or localisation to 
the cell surface, will require more in depth studies.
In order to identify some of the regulatory mechanisms controlling matrilysin 
gene transcription we treated the cell lines with IL-6 and TPA. IL-6 is a multifunctional 
cytokine known to have a growth promoting/differentiating effect on heamatopoietic cells 
(Gao et al, 2000, Xie et al., 2000, Xie et al., 1999). A recent study has shown that IL-6 
expression was generally associated with a poor prognosis in Non Hodgkin’s Lymphoma 
patients (Kossakowska et al, 1999). This was not only as a result of IL-6 growth 
promoting activities but also due to its association with increased MMPs expression, 
suggesting the involvement of IL-6 in MMP regulation. However, the molecular 
mechanism whereby IL-6 up-regulates MMP expression remains unclear. Interestingly, 
the presence of a potential C/EBP (CCAAT/ Enhancer Binding Protein) element within 
the matrilysin promoter may indicate a possible mechanism (Wilson and Matrisian, 1996). 
Reports have shown that when IL-6 binds to its receptor it activates the JAK/STAT 
pathway and subsequently STAT3 has been shown to regulate levels of C/EBP 
transcription factor binding proteins (Chen et al, 1999). We feel that a possible 
mechanism may be the increased binding of the C/EBP transcription factor to the 
matrilysin promoter which in turn leads to increased matrilysin expression. We also 
examined the effects of IL-6 on MMP-2 and MMP-9 expression. TPA has been shown in 
several studies to modulate MMP expression and also to function as a potent 
differentiating agent (Mackay et al, 1992; IJchimaru et al, 1998). Combination treatments 
with IL-6 and TPA were also performed.
Treatment of the K562 cells with IL-6 and TPA treatment showed only slight 
increases in matrilysin expression at the mRNA level but the effect at the protein level 
was more pronounced (almost 2.5-fold over control for TPA/IL-6). Interestingly, we also 
observed an intermediary processed form of matrilysin (antibody does not recognise 
active form) in the IL-6 treated samples. This suggests that IL-6 may also regulate 
transcription of other proteases known to activate MMPs. Matrilysin was not detected at
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either the RNA level or the protein level in the HL-60 cells and its transcription could not 
be induced through IL-6 and TPA treatment.
IL-6 and TPA increased MMP-9 mRNA and protein expression in the K562 cell 
line and when these factors were added in combination a marked increase in MMP-9 
protein was observed by gelatin zymography. The HL-60 cells also responded to IL-6 and 
TPA treatment but not to the same extent as that observed in the K562 samples, which 
perhaps may be as a result of differences in IL-6 receptor expression.
The level of MMP-2 protein did not appear to increase in either cell line following 
treatment with IL-6. This is in contrast to Kossakowska et al. (1999) who have shown 
that IL-6 could upregulate MMP-2 expression in various types of leukaemia cell lines. 
The combination of IL-6 and TPA treatment did not affect MMP-2 expression to the same 
extent as MMP-9 expression suggesting that these genes have different regulatory 
mechanisms. Treatment of the K562 cell line with IL-6 and TPA appeared to have little or 
no effect on TIMP-1 mRNA levels. However at the protein level TIMP-1 appeared to be 
enhanced by IL-6 and TPA which may suggest stabilisation of TIMP-1 mRNA. The 
expression of TIMP-1 could not be induced by IL-6/TPA treatment of the HL-60 cell line. 
TPA treatment appeared to inhibit the expression of TIMP-2 at the mRNA level in both 
the K562 and HL-60 cell line but this effect was not observed at the protein level.
In order to determine if the increase in matrilysin production after IL-6/TPA 
treatment would result in increased invasiveness we performed in vitro invasion assays. 
An increase in the in vitro invasiveness in the K562 cell line was observed but this may 
have been possibly due to enhanced MMP-9 expression. Treatment with IL-6 and TPA 
appeared to have no significant effect on the HL-60 rate of invasion
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5.8 C onclusion
In sum m ary the experim ents carried  out in this chapter dem onstrate the im portance 
o f  m atrilysin expression in leukaem ia cell invasion. W e have also shown that the 
expression o f  m atrilysin can be regulated by IL-6 and the phorbol ester TPA . Therefore 
aberrant expression o f  IL-6 or the IL-6 receptor by leukaem ia cell lines m ay result in the 
increased expression o f  m atrilysin w hich in turn m ay lead to a m ore aggressive 
phenotype. M atrilysin may be o f  use as a potential prognostic m arker for leukaem ia 
aggressiveness. Therefore, in conclusion we feel that based on the results obtained in this 
study further investigations into m atrilysin expression in additional leukaem ia cell lines 
and prim ary sam ples are warranted.
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Chapter 6 
Final Summary and Future Directions
6.1 Final Summary
Matrilysin is the smallest member of the MMP family and has one of the broadest 
substrate specificities with an ability to degrade collagen type IV, gelatin, laminin, 
fibronectin, entactin and tenascin. The matrilysin enzyme is secreted from the cell in a 
latent 28 kDa form which is subsequently proteolytically cleaved to produce the active 19 
kDa form.
The extracellular matrix can be viewed as a multifunctional dynamic meshwork 
of high molecular weight proteins which not only serves as an anchoring mechanism for 
various cell types but also in presenting the cells with an array of growth factors and other 
signalling molecules. During normal biological processes such as cell growth, wound 
healing and angiogenesis, the ECM must be remodelled to allow space for growing or 
advancing cells. This process involves the destruction of the ECM by a number of 
proteinases including the metalloproteinases which collectively are capable of degrading 
the entire ECM. The regulation of the MMPs must therefore be tightly controlled by the 
cells which secrete them as aberrant expression can lead to various disease processes. 
Increased MMP expression has been associated with cancer for many years and there are 
numerous reports linking the upregulation of MMPs with cancer invasion and metastasis 
(Chambers and Matrisian, 1997). In particular, matrilysin has been shown to be 
upregulated in several cancers, in particular those of a colon and breast origin and has 
been shown to correlate well with tumour aggressiveness (Wilson and Matrisian, 1996 and 
Rudolph-Owen et al., 1998). Matrilysin is unique amongst other MMPs as it has been 
shown to be exclusively expressed by the epithelial cells of colon and breast tumours. 
Other MMPs which have been shown to be associated with cancer progression, such as 
MMP-2 and MMP-9, are normally found in the stroma surrounding the tumour cells and 
are secreted predominantly by stromal and macrophage cells.
Recent studies have also shown that matrilysin plays an important role in the 
early tumourigenesis of both breast and colon cancers (Wilson et al., 1997 and Rudolph- 
Owen et al., 1998). With respect to colon tumourigenesis a series of elegant experiments 
were performed in the Matrisian laboratory (Vanderbilt University, Nashville, TN.)
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involving a mouse model of the human hereditary colon disease, familial adenomatous 
polyposis (FAP), in which there is a mutation in the APC  gene. This mouse model, 
known as the Min/f/cv‘ (Min'7') mouse for multiple intestinal neoplasia, was crossed with a 
matrilysin null mouse (Mat7') resulting in an APC and matrilysin deficient mouse (Min'7' 
/Mat'7'). The Min'7' mice develop numerous benign polyps in the intestine, in manner 
similar to that in FAP patients. Studies have shown that in the Min‘77M af7" mice there was 
a significant reduction in both size and number of the intestinal polyps which suggested 
that matrilysin played an important role in tumourigenesis (Wilson et al., 1997). 
Azoxymethone (AOM) treatment of mice simulates early colorectal tumour development 
whereby lesions known as aberrant crypt foci, which are similar to the first lesions 
observed in human colon tumour development, are formed. Again there is a reduction in 
the number of lesions formed when matrilysin null mice were examined which again 
suggests that matrilysin is involved in the early stages of colon tumour development (see 
Fingleton et al., 1999 for review). Matrilysin has also been shown to be involved in 
angiogenesis, apoptosis and the cleavage of a number of cell surface proteins, such as E- 
cadherin, which may have a potential role in tumourigenesis (Weisen and Werb, 2000, 
Powell et al., 1999 and Noe et al., 2001).
The association of matrilysin with enhanced tumour formation, growth and spread, 
have made it an exciting target for therapeutic drug development. Although many studies 
have investigated the expression of matrilysin in many systems, little is known about how 
matrilysin expression is regulated. In order to produce drugs which are effective in 
inhibiting matrilysin activity and have minimal side effects it is important to understand 
how this enzyme is regulated at the transcriptional and protein level.
Early studies investigating the regulation of matrilysin gene transcription 
observed that factors such as EGF and the phorbol ester, TPA, had positive regulatory 
effects on matrilysin gene transcription and suggested that the AP-1 and ETS transcription 
factor binding elements within the matrilysin promoter were important for this 
upregulation (Gaire et al., 1994). Analysis o f the matrilysin promoter using a 
transcription factor search engine revealed the presence of a number of potential 
transcription factor binding sites including an AP-1 site, three PEA3 sites, two of which
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have the potential to act as either a Kaiso (-168 PEA3) or a C/EBP binding site (-55 
PEA3) and two Tcf sites. Recent studies have shown that p-catenin, normally associated 
with E-cadherin at the adherens junctions acting as a cytoskeletal protein, can interact 
with the Tcf sites located within the matrilysin promoter and effect the transcription of 
matrilysin in conjunction with PEA3 and AP-1 bound factors (Crawford et al., 1999). In a 
normal cell, excess P-catenin is ‘mopped’ up by APC which in association with axin and 
GSK-3P targets p-catenin for ubiquitination. However as mentioned earlier, APC is 
commonly mutated in many colon cancers including those of a sporadic nature and this 
mutation prevents P-catenin from being degraded and allows it to translocate to the 
nucleus and assist in the transcription of several target genes including matrilysin. 
Although P-catenin transactivation of the matrilysin promoter is essential for transcription 
to take place it is not enough on its own to initiate matrilysin transcription which means 
that other factors must also be in place (Crawford et al., 2001).
In order to determine what these factors are we initially studied a panel of colon 
cell lines for their expression of matrilysin and found that with the exception o f SW480 
they all expressed matrilysin mRNA and protein. We then examined if growth factors 
such as EGF, IL-6, bFGF and IGF-I and IGF-II could upregulate matrilysin expression. 
Results showed that EGF, IL-6 and bFGF stimulated matrilysin transcription in many of 
the cell lines, in particular when the cytokines were treated in conjunction with each other 
or with the phorbol ester TPA which has been well documented as an upregulator of 
MMPs. Analysis using a matrilysin promoter reporter construct showed similar results 
and also showed that the transcription factor binding sites necessary for the stimulation of 
matrilysin gene transcription were located within the first 335 base pairs o f the matrilysin 
promoter. Therefore, the transcription factors being stimulated by the cytokines were 
binding within the first 335 base pairs of the matrilysin promoter which in turn indicated 
that the transcription factors were of an ETS and/or AP-1 origin.
Crawford et al., (2001) have shown that the ETS sub family o f PEA3 transcription 
factors, including, PEA3, ER81 and ERM bind preferentially to the ETS sites within the 
matrilysin promoter while other ETS family members such as Ets-1, Ets-2, Fli-1 and PU.l 
have little or no effect on matrilysin gene transcription. Interestingly, PEA3 protein has
218
been found to be expressed at higher levels in breast cancer than in normal tissue. This 
increase in PEA3 levels was almost always associated with an increase in the expression 
of the EGF receptor related Her2/Neu (O’Hagan and Hassell, 1998). In our preliminary 
studies we observed a consistent increase in matrilysin gene activity in all cell lines upon 
treatment with EGF with the exception of the SW480 cell line. We therefore suggested a 
potential model whereby EGF upregulated matrilysin by stimulating expression of the 
PEA3 sub family of transcription factors via the EGF receptor associated signalling 
cascades, for example RAS/MAPK. We initially examined the effect of EGF on AP-1, 
ETS and PEA3 artificial promoters which contained a number of transcription factor 
binding repeat motifs. Our results showed that EGF stimulated all three promoters but 
had a greater effect on the PEA3 promoter. The increases in ETS and AP-1 artificial 
promoter activity were expected as both these transcription factor families are targetted by 
the signalling pathways employed by the EGF receptor. Analysis of the nuclear proteins 
of treated cells also confirmed that there was not only an increase in PEA3 protein levels 
but also in PEA3 phosphorylation. These results suggested that PEA3 activity was 
increased via the phosphorylating signal cascades and the level of PEA3 protein was also 
increased suggesting a potential autoregulatory loop for PEA3. Our next step was to 
examine if the increase in PEA3 protein would lead to increased binding of an optimal 
PE A3 probe by using electrophoretic shift mobility assays (EMSA). Results indicated 
that this was indeed the case. Probes designed to mimic each of the PEA3 sites within the 
matrilysin promoter were then examined and it was found that the PEA3 bound to each of 
the probes with a similar intensity suggesting that all three sites were important for 
matrilysin gene transcription. This was also been confirmed via PEA3 site mutation 
analysis. Supershift assays revealed only partial shifting which implicated other members 
of the PEA3 sub family, ER-81 and ERM, in the regulation of the matrilysin gene. In 
addition, a recent paper has also shown that in many of the Min mice tumours, increased 
matrilysin levels were always accompanied with increased levels of the PEA3 family 
members (Crawford et al., 2001).
Several reports have also shown that EGF interacts with [3-catenin at the cell 
membrane and promotes the destabilisation of the E-cadherin/catenin complex. We 
therefore examined firstly if EGF was involved in the stimulation of PEA3 activity via (3-
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catenin. Analysis showed that p-catenin had little or no effect on PEA3 activity. 
Interestingly, EMSA analysis using Tcf probes with sequence similarity to those within 
the matrilysin promoter showed enhanced binding of p-catenin in EGF treated samples, in 
particular for the -109 Tcf site. This suggested that EGF through the destabilisation of the 
E-cadherin/catenin complex resulted in the release of P-catenin which, undegraded due to 
APC mutations, tranlocates to the nucleus and effects the transcription of matrilysin. As 
discussed earlier, matrilysin has been shown to be involved in early colorectal 
tumourigenesis and the mechanisms which ‘switch on’ the matrilysin gene in these early 
stages involves APC mutations. However, other aberrant regulatory mechanisms involved 
in matrilysin gene transcription such as, EGF receptor mutation or upregulation, may exist 
in cells where APC is not mutated. EGF or the EGF receptor has also been found to be 
upregulated in several cancers and through its stimulation and activation of PEA3 
transcription factors and release of p-catenin from the E-cadherin/catenin complex may 
not only serve to drive cell proliferation but also the production of matrilysin. Matrilysin, 
in turn may therefore activate other growth promoting factors that enhance tumour growth 
and invasion. In addition, factors such as bFGF and IL-6 were also shown to stimulate 
matrilysin activity and we expect that bFGF may act in a similar manner to that of EGF, 
i.e. via the upregulation of PEA3 and AP-1 transcription factors which in turn bind to the 
sites within the matrilysin promoter and effect its transcription. We expect that IL-6 may 
mediate its effects on matrilysin by the activation of the JAK/STAT pathway which in 
turn activates C/EBP binding proteins. These proteins may then cooperate with PEA3 and 
bind to the PE A3/C/EBP site within the matrilysin promoter and synergistically act in the 
activation of the matrilysin gene.
Several reports have investigated the expression of MMPs in leukaemias and 
these have mainly focussed on MMP-2 and MMP-9 (Janowska-Wieczorek et al, 1999 and 
Ries et al., 1999). The studies showed that in general, MMP-2 and MMP-9 expression 
was elevated and was associated with leukaemia aggressiveness. Matrilysin has been 
implicated in the growth and invasion and metastasis of several tumours but to date no 
reports have been published on its expression by leukaemias. We therefore analysed the 
expression of matrilysin in the K562 and HL-60 leukaemia cell lines and found that only 
the K562 cell line expressed matrilysin. In vitro invasion assays showed that the K562
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cell line was up to four times more invasive than the HL-60 cell line. Zymography 
analysis o f both cell lines revealed that MMP-2 and MMP-9 levels were similar and 
reverse zymography showed that the K562 cells expressed more TIMP-1 than the HL-60 
cells. These results suggested that matrilysin expression may lead to a more aggressive 
phenotype in the K562 cells and in vitro invasion experiments which incorporated a 
matrilysin blocking antibody proved this to be the case as there was a significant reduction 
in the K562 cell line invasion. Invasion was not completely inhibited which suggests that 
other MMPs such as MMP-2 and MMP-9 as well as cell adhesion molecules and other 
protease groups are involved in leukaemia invasion. We also examined the regulation of 
matrilysin in both cell lines and found that 1L-6 could stimulate matrilysin expression. 
Other reports have also linked increased IL-6 expression with MMPs and a poor prognosis 
(Kossakowska et ah, 1999). Our data shows that matrilysin plays an important role in 
leukaemia invasion and may be of potential use as a prognostic marker.
In conclusion our data suggests that EGF plays an important role in the regulation 
of matrilysin gene expression via a number of new mechanisms. These findings suggest 
possible new drug targets, such as transcription factor inhibition and tyrosine kinase 
inhibition, which will inhibit matrilysin expression and in turn should lead to decreased 
tumourigenesis and invasion and metastasis. Furthermore, we have shown that matrilysin 
plays an important role in leukaemia cell invasion and may therefore be of use as a 
potential prognostic marker.
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6.2 Future Directions
1) Data presented in chapter 3 consistently showed that EGF, IL-6 and bFGF stimulated 
matrilysin gene expression. However, the increase observed over the controls was 
typically only 0.5 to 1 fold. These increases were enhanced when cells were treated 
with a combination of cytokines, a result which was much more obvious with the 
matrilysin promoter-reporter construct. These studies were performed in colon cancer 
cell lines, the majority of which have mutations in signalling pathways such as Ras. 
This resulted in an increase of growth promoting transcription factors such as AP-1 
and ETS. Therefore the treatment of these cell lines with various cytokines may only 
augment the level of transcription factors required for matrilysin gene expression thus 
resulting in the low level responses observed in chapter 3 via RT-PCR, western blot 
and promoter-reporter studies. In order to confirm that cytokines such as EGF, IL-6 
and bFGF were having a direct effect on matrilysin gene transcription, we suggest that 
the matrilysin promoter should be studied in a cell line as close to ‘normal’ as 
possible. For example, Crawford et al. (2001) used a human embryonic kidney line 
(HEK293) which has low levels of the transcription factors thought to play an 
important role in matrilysin gene transcription such as PEA3, ETS and AP-1. 
Therefore treatment o f this cell line with EGF, IL-6 and bFGF should greatly enhance 
the expression of these transcription factors and subsequently matrilysin.
2) Chapter 4 showed that PEA3 transcription factors may be responsible for the increased 
expression of matrilysin following EGF treatment. In order to confirm this, supershift 
assays with PEA3 antibodies were performed. Results showed that only ‘partial’ 
supershifts were obtained which suggested that the assay required further optimisation 
or that other members of the PEA3 family such as ER-81 and ERM were involved. 
Optimisation of the supershift protocol and the generation of specific antibodies for 
ER-81 and ERM should help to clarify which of these transcription factors were 
responsible for the increase in matrilysin gene transcription following EGF treatment. 
The use of negative controls such as competition experiments with ‘cold’ unlabelled 
PEA3 probes and the use o f mutated probes would help to ensure that the binding of 
PEA3 proteins to PEA3 probes was specific. The relationship between EGF and the
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release o f P-catenin from the E-cadherin/catenin complex was also examined. Initial 
results showed that there was increased binding of P-catenin to TCF probes suggesting 
that EGF treatment may result in the release of p-catenin. Again these EMSA 
experiments should be repeated with the proper negative (mutated probes) and positive 
controls (recombinant PE A3 protein). Matrilysin has recently been shown to cleave 
E-cadherin at the cell surface which results in a more invasive phenotype (Noe et al.,
2001). We would therefore like to examine the relationship between matrilysin 
expression and E-cadherin, i.e. does overexpression o f matrilysin or the addition of 
exogenous matrilysin result in the cleavage of E-cadherin at the cell surface which in 
turn results in a destabilisation of the E-cadherin/catenin complex. The subsequent 
release of P-catenin should result in increased matrilysin expression. These 
experiments would show another mechanism whereby matrilysin can contribute to the 
invasive phenotype o f a cell.
3) Chapter 5 showed that the expression of matrilysin by K562 cells is associated with 
increased in vitro invasion. The involvement of matrilysin in leukaemia invasion 
could be confirmed by a number o f experiments including the stable transfection of 
the HL-60 cell line with a matrilysin construct and analysing if there is a resultant 
increase in cellular invasion. The expression of matrilysin in other leukaemic cell 
lines and primary samples should also be examined in order to determine if  there is a 
correlation between matrilysin expression and increased invasion. We would also like 
to further investigate the regulation o f matrilysin in leukaemia cell lines by IL-6 as 
increased IL-6 expression in NFIL samples has been associated with poor clinical 
outcome (Kossakowska et al., 1996). Results in chapter 3 also indicate that matrilysin 
expression can be directly regulated by IL-6. Interestingly several reports have shown 
that MMPs associate with cell adhesion molecules at the cell surface, for example 
MMP-9 and CD-44 (Yu and Stamenkovic, 1999). We hypothesise that matrilysin may 
associate with cell adhesion molecules on the cell surface such as CD-44 and this may 
offer a potential mechanism of how matrilysin can assist in the invasion of leukaemic 
cells.
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A ppendix  1
A) pHMATPro2.3-Luc plasmid containing 2.3kb of the human matrilysin promoter. The 
335 bp matrilysin promoter construct is similar in structure. Both constructs were 
developed by Howard C. Crawford, Vanderbilt University, Nashville ,TN.
B) The 2.3 kb and 335 bp human matrilysin promoter fragments were cloned into the 
pGL2-Basic vector (Promega).
262
C) The pGLa-Contro! plasmid (Promega) which was used as a positive control in transient 
transfection experiments.
D) T he pGL 2-Promoter (Promega) vector which was used to identify potential 
silencer/enhancer elements within the murine matrilysin gene.
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Hind III (1) ATG Kpn I (204)
E) The pCHl IO (Pharmacia) plasmici used in transfection optimisation studies
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F) The pRL-SV40 plasmid which was co-transfected with the matrilysin promoter 
reporter plasmids in order to normalise results.
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G) The pPCR Script plasmid which was used for cloning PCR products
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Matrilysin Promoter sequence
1 agctccagca tatttggagt gtttcccatg atgtattaga gtcaaaagcc atggtgttct
61 cccaagtaat gtataatata ataaaagaga cagacctatt acaaaatgaa taggcagtgc
121 agtgggatag aaaaagcact gagctactat ctgtgtgagc tgggagaagt ataataagtt
181 aaattatcat cttggcctca ctttcatttt tggtaagaat ggagtcattg ggctagaatc
241 tgtaggtaat ggattcttac tgctatacgt agaataacca ttttgtgtac taaggaccaa
301 tgcagcccta cctgtagctg ggcagcagcc agagtcagag tgattggaag aaaaaaattg
361 gatctccaag ttgaaggtct agccttggaa gaatctgtta ctataaaatg agaagcagaa
421 taagtaagcc agatgaagag ttaaacccgt gcttgtagat ttttgttggc ttggtatttt
481 tttgtgttta attcaagaag aattagaggc agtgttcccc attaagaaaa gacataaact
541 gattaaaagg agaccccaaa gaagggaatt atcactgctc tgctaaggga cgtggaaggt
601 gaggggacac agcacagttg tatatagagt ggccactaat ccagccacac agcagcattt
661 ccatctgcct cctgccatct ttcccctgta tggagaacca caggattttg gtgacgttct
721 atttcttgac tttggtgacg gttacagtat ttgcttaatt attatttcat tatttacatg
781 ttttgtgcac ttttccaaac cttttaattg ttaagaatat atggtaccat gtatttaaga
841 atacatggta ccatataata agaatatata tttaagaata tatattattc tttaagaata
901 tatggtacca taatgtcctg aatgatacct atgagagcag tcatttgact ttggcaaaaa
961 aatgaggttt ctcatggagt caatttatgc agcagacaga aaaaaaaatc ctttgaaaga
1021 caaatacatt gtgtgcttccjgccaataac gatgtaatac ttcctcgttt tagttaatga
1081 aaaataacac atactttcaa agttctgtag actctaaaaa gaaagaaaac actcaaatga
1141 gtcacctatt tccacattcg aggctgagaa gctatataaa tttctgcagt cactagcaga
1201 aaaca
G) The sequence of the matrilysin promoter (Genbank accession number L22525)with the 
PEA3 sites at-168, -144 and-55 outlined.
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